


**CUMULATIVE
SUPPLEMENT 3
MARCH 2016**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2016

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Cumulative Supplement 3

March 2016

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	vii
1.5 Availability of the Edition	viii
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend.....	x
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

36th EDITION

CUMULATIVE SUPPLEMENT 03
March 2016

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 36th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
 Office of Generic Drugs
 7620 Standish Place
 Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
BD RX INC (BD RX)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
CITRON PHARMA LLC (CITRON PHARMA LLC)	CASPER PHARMA LLC (CASPER PHARMA LLC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate

for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBVIE	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active

ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts,

esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2015</u>	<u>MAR 2016</u>	<u>JUN 2016</u>	<u>SEP 2016</u>	<u>DEC 2016</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	17151 2664 (15.5%)	17251 2693 (15.6%)			
MULTISOURCE	14487 (84.5%)	14558 (84.4%)			
THERAPEUTICALLY EQUIVALENT	14366 (83.8%)	14434 (83.7%)			
NOT THERAPEUTICALLY EQUIVALENT	121 (0.7%)	124 (0.7%)			
EXCEPTIONS ¹	73 (0.4%)	73 (0.4%)			
NEW MOLECULAR ENTITIES APPROVED	28	9			
NUMBER OF APPLICANTS	1011	1007			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >D>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE

	@ HIKMA MAPLE	EQ 500MG BASE/VIAL	A074885	001	Dec 19, 1997	Feb	DISC
	@	EQ 1GM BASE/VIAL	A074885	002	Dec 19, 1997	Feb	DISC
	ACYCLOVIR SODIUM						
	@ BEDFORD	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Feb	DISC
	@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb	DISC
AP	+	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb	CTEC
AP	HIKMA PHARMS LLC	EQ 500MG BASE/VIAL	A205771	001	Feb 29, 2016	Feb	NEWA
	+	EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Feb	CRLD
AP		EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Feb	NEWA

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

>D>	AN	HI TECH PHARMA	EQ 0.083% BASE	A075063	001	Feb 09, 1999	Mar	DISC
>A>		@	EQ 0.083% BASE	A075063	001	Feb 09, 1999	Mar	DISC
>D>	AN	LANDELA PHARM	EQ 0.083% BASE	A077569	001	Apr 04, 2006	Mar	DISC
>A>		@	EQ 0.083% BASE	A077569	001	Apr 04, 2006	Mar	DISC
>D>	AN	MYLAN SPECLT	EQ 0.083% BASE	A072652	001	Feb 21, 1992	Mar	DISC
>A>		@	EQ 0.083% BASE	A072652	001	Feb 21, 1992	Mar	DISC
>D>	AN	NEPHRON	EQ 0.083% BASE	A074880	001	Sep 17, 1997	Mar	CRLD
>A>	AN	+	EQ 0.083% BASE	A074880	001	Sep 17, 1997	Mar	CRLD
>D>	AN	TEVA PHARMS	EQ 0.083% BASE	A075343	001	Nov 09, 1999	Mar	DISC
>A>		@	EQ 0.083% BASE	A075343	001	Nov 09, 1999	Mar	DISC
>D>	AN	WATSON LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003	Mar	DISC
>A>		@	EQ 0.083% BASE	A076370	001	Nov 24, 2003	Mar	DISC

TABLET; ORAL

ALBUTEROL SULFATE

>D>	AB	MUTUAL PHARM	EQ 2MG BASE	A072637	002	Dec 05, 1989	Mar	CAHN
>D>	AB		EQ 4MG BASE	A072637	001	Dec 05, 1989	Mar	CAHN
>A>	AB	SUN PHARM INDS	EQ 2MG BASE	A072637	002	Dec 05, 1989	Mar	CAHN
>A>	AB		EQ 4MG BASE	A072637	001	Dec 05, 1989	Mar	CAHN

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

AB	UNICHEM LABS LTD	10MG	A203192	001	Jan 28, 2016	Jan	NEWA
----	------------------	------	---------	-----	--------------	-----	------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

>D>	AB	MUTUAL PHARM	300MG	A071450	001	Jan 09, 1987	Mar	CAHN
>A>	AB	SUN PHARM INDS	300MG	A071450	001	Jan 09, 1987	Mar	CAHN
		ZYLOPRIM						
AB	SEBELA IRELAND LTD	100MG	N016084	001			Jan	CAHN
AB	+	300MG	N016084	002			Jan	CAHN

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

AB	AJANTA PHARMA LTD	EQ 6.25MG BASE	A205523	001	Mar 03, 2016	Feb	NEWA
AB		EQ 12.5MG BASE	A205523	002	Mar 03, 2016	Feb	NEWA

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

LOTRONEX

AB	SEBELA IRELAND LTD	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Feb	CAHN
AB	+	EQ 1MG BASE	N021107	001	Feb 09, 2000	Feb	CAHN

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

	@ ACTAVIS LABS FL INC	0.5MG	A077198	001	May 13, 2010	Jan	DISC	
	@	1MG	A077198	002	May 13, 2010	Jan	DISC	
	@	2MG	A077198	003	May 13, 2010	Jan	DISC	
	@	3MG	A077198	004	May 13, 2010	Jan	DISC	
>D>	AB	COREPHARMA	0.5MG	A077996	001	Jan 31, 2007	Mar	DISC
>A>		@	0.5MG	A077996	001	Jan 31, 2007	Mar	DISC
>D>	AB		1MG	A077996	002	Jan 31, 2007	Mar	DISC

TABLET, EXTENDED RELEASE;ORAL
ALPRAZOLAM

>A>	@	1MG	A077996	002	Jan 31, 2007	Mar	DISC
>D>	AB	2MG	A077996	003	Jan 31, 2007	Mar	DISC
>A>	@	2MG	A077996	003	Jan 31, 2007	Mar	DISC
>D>	AB	3MG	A077996	004	Jan 31, 2007	Mar	DISC
>A>	@	3MG	A077996	004	Jan 31, 2007	Mar	DISC
	@ IMPAX LABS	0.5MG	A077968	004	May 24, 2007	Jan	DISC
	@	1MG	A077968	003	May 24, 2007	Jan	DISC
	@	2MG	A077968	002	May 24, 2007	Jan	DISC
	@	3MG	A077968	001	May 24, 2007	Jan	DISC

ALPROSTADIL

INJECTABLE; INJECTION
EDEX

>A>	@ AUXILIUM PHARMS INC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Mar	CAHN
>A>	AP	0.01MG/VIAL	N020649	002	Jun 12, 1997	Mar	CAHN
>A>	+	0.01MG/VIAL	N020649	005	Jul 30, 1998	Mar	CAHN
>A>	AP	0.02MG/VIAL	N020649	003	Jun 12, 1997	Mar	CAHN
>A>	+	0.02MG/VIAL	N020649	006	Jul 30, 1998	Mar	CAHN
>A>	AP	0.04MG/VIAL	N020649	004	Jun 12, 1997	Mar	CAHN
>A>	+	0.04MG/VIAL	N020649	007	Jul 30, 1998	Mar	CAHN
>D>	@ AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Mar	CAHN
>D>	AP	0.01MG/VIAL	N020649	002	Jun 12, 1997	Mar	CAHN
>D>	+	0.01MG/VIAL	N020649	005	Jul 30, 1998	Mar	CAHN
>D>	AP	0.02MG/VIAL	N020649	003	Jun 12, 1997	Mar	CAHN
>D>	+	0.02MG/VIAL	N020649	006	Jul 30, 1998	Mar	CAHN
>D>	AP	0.04MG/VIAL	N020649	004	Jun 12, 1997	Mar	CAHN
>D>	+	0.04MG/VIAL	N020649	007	Jul 30, 1998	Mar	CAHN

SUPPOSITORY; URETHRAL
MUSE

+	MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996	Jan	CRLD
+		0.25MG	N020700	002	Nov 19, 1996	Jan	CRLD
+		0.5MG	N020700	003	Nov 19, 1996	Jan	CRLD

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
AMANTADINE HYDROCHLORIDE

AB	BIONPHARMA INC	100MG	A078720	001	May 29, 2008	Jan	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER								
>A>	+	BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	002	Mar 26, 1997	Mar	CMS1
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER								
>D>	+	BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	002	Mar 26, 1997	Mar	CMS1
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER								
>A>	+	BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	005	Mar 26, 1997	Mar	CMS1
CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER								
>D>	+	BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	005	Mar 26, 1997	Mar	CMS1
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER								
>A>	+	BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	001	Mar 26, 1997	Mar	CMS1
CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER								
>D>	+	BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	001	Mar 26, 1997	Mar	CMS1
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER								
>A>	+	BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	009	Mar 26, 1997	Mar	CMS1
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER								
>D>	+	BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	009	Mar 26, 1997	Mar	CMS1

INJECTABLE; INJECTION

		CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER						
>A>	+	BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	011	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER						
>D>	+	BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	011	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER						
>A>	+	BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	012	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER						
>D>	+	BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	012	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER						
>A>	+	BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	008	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER						
>D>	+	BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	008	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER						
>A>	+	BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	016	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER						
>D>	+	BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	016	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER						
>A>	+	BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	017	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER						
>D>	+	BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	017	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER						
>A>	+	BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	018	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER						
>D>	+	BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	018	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER						
>A>	+	BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	019	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER						
>D>	+	BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	019	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER						
>A>	+	BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	021	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER						
>D>	+	BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	021	Mar 26, 1997	Mar	CMS1

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

>D>	AB	MUTUAL PHARM CO INC	10MG	A089399	002	Jul 14, 1987	Mar	CAHN
>D>	AB		25MG	A089399	001	Jul 14, 1987	Mar	CAHN
>D>	AB		50MG	A089399	003	Jul 14, 1987	Mar	CAHN
>D>	AB		75MG	A089399	004	Jul 14, 1987	Mar	CAHN
>D>	AB		100MG	A089399	005	Jul 14, 1987	Mar	CAHN
>D>	AB		150MG	A089399	006	Jul 14, 1987	Mar	CAHN
>D>	AB	SUN PHARM INDS INC	10MG	A040816	002	Jun 27, 2008	Mar	DISC
>A>	@		10MG	A040816	002	Jun 27, 2008	Mar	DISC

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

>A>	@	10MG	A089399	002	Jul 14, 1987	Mar	DISC
>A>	AB	10MG	A089399	002	Jul 14, 1987	Mar	CAHN
>D>	AB	25MG	A040816	001	Jun 27, 2008	Mar	DISC
>A>	@	25MG	A040816	001	Jun 27, 2008	Mar	DISC
>A>	@	25MG	A089399	001	Jul 14, 1987	Mar	DISC
>A>	AB	25MG	A089399	001	Jul 14, 1987	Mar	CAHN
>D>	AB	50MG	A040816	003	Jun 27, 2008	Mar	DISC
>A>	@	50MG	A040816	003	Jun 27, 2008	Mar	DISC
>A>	@	50MG	A089399	003	Jul 14, 1987	Mar	DISC
>A>	AB	50MG	A089399	003	Jul 14, 1987	Mar	CAHN
>D>	AB	75MG	A040816	004	Jun 27, 2008	Mar	DISC
>A>	@	75MG	A040816	004	Jun 27, 2008	Mar	DISC
>A>	@	75MG	A089399	004	Jul 14, 1987	Mar	DISC
>A>	AB	75MG	A089399	004	Jul 14, 1987	Mar	CAHN
>D>	AB	100MG	A040816	005	Jun 27, 2008	Mar	DISC
>A>	@	100MG	A040816	005	Jun 27, 2008	Mar	DISC
>A>	@	100MG	A089399	005	Jul 14, 1987	Mar	DISC
>A>	AB	100MG	A089399	005	Jul 14, 1987	Mar	CAHN
>D>	AB	150MG	A040816	006	Jun 27, 2008	Mar	DISC
>A>	@	150MG	A040816	006	Jun 27, 2008	Mar	DISC
>A>	@	150MG	A089399	006	Jul 14, 1987	Mar	DISC
>A>	AB	150MG	A089399	006	Jul 14, 1987	Mar	CAHN

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPFOXIDE

TABLET;ORAL

CHLORDIAZEPFOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

>D>	@	MUTUAL PHARM	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Mar	CAHN
>D>	@		EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Mar	CAHN
>A>	@	SUN PHARM INDS	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Mar	CAHN
>A>	@		EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Mar	CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

>D>	@	MUTUAL PHARM	10MG;2MG	A071077	001	Nov 12, 1986	Mar	CAHN
>D>	@		10MG;4MG	A071078	001	Nov 12, 1986	Mar	CAHN
>D>	@		25MG;2MG	A070297	001	Nov 12, 1986	Mar	CAHN
>D>	@		25MG;4MG	A071079	001	Nov 12, 1986	Mar	CAHN
>A>	@	SUN PHARM INDS	10MG;2MG	A071077	001	Nov 12, 1986	Mar	CAHN
>A>	@		10MG;4MG	A071078	001	Nov 12, 1986	Mar	CAHN
>A>	@		25MG;2MG	A070297	001	Nov 12, 1986	Mar	CAHN
>A>	@		25MG;4MG	A071079	001	Nov 12, 1986	Mar	CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB		INVAGEN PHARMS	EQ 2.5MG BASE	A206367	001	Dec 10, 2015	Feb	CAHN
AB			EQ 5MG BASE	A206367	002	Dec 10, 2015	Feb	CAHN
AB			EQ 10MG BASE	A206367	003	Dec 10, 2015	Feb	CAHN

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP		MA GENERAL HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A207025	001	Feb 03, 2016	Jan	NEWA
AP		MIDWEST MEDCL	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204457	001	Nov 18, 2015	Jan	NEWA

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

@	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Feb	DISC
@		500MG	A065016	002	Apr 08, 1999	Feb	DISC

TABLET;ORAL

AMOXICILLIN

@	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000	Feb	DISC
@		875MG	A065059	002	Nov 24, 2000	Feb	DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN

@	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999	Feb	DISC
@		250MG	A065021	002	Dec 23, 1999	Feb	DISC

TABLET, EXTENDED RELEASE;ORAL
MOXATAG

+ VERNALIS R AND D LTD 775MG N050813 001 Jan 23, 2008 Jan CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A201090	001	Dec 20, 2011	Feb	CDFR
AB		400MG/5ML;EQ 57MG BASE/5ML	A201090	002	Dec 20, 2011	Feb	CDFR
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A201091	001	Dec 20, 2011	Feb	CDFR
	@ SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Feb	DISC
	@	400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Feb	DISC
	@	600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Feb	DISC

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ SUN PHARM INDS LTD 875MG;EQ 125MG BASE A065102 001 Sep 17, 2002 Feb DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ SUN PHARM INDS LTD 200MG;EQ 28.5MG BASE A065161 001 Dec 03, 2003 Feb DISC
@ 400MG;EQ 57MG BASE A065161 002 Dec 03, 2003 Feb DISC

AUGMENTIN '125'

>D> AB DR REDDYS LABS INC 125MG;EQ 31.25MG BASE N050597 001 Jul 22, 1985 Mar CTEC
>A> 125MG;EQ 31.25MG BASE N050597 001 Jul 22, 1985 Mar CTEC

AUGMENTIN '250'

>D> AB DR REDDYS LABS INC 250MG;EQ 62.5MG BASE N050597 002 Jul 22, 1985 Mar CRLD
>A> + 250MG;EQ 62.5MG BASE N050597 002 Jul 22, 1985 Mar CRLD

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

ADZENYS XR-ODT

	NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jan	NEWA
		EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jan	NEWA
		EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jan	NEWA
		EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jan	NEWA
		EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jan	NEWA
		EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jan	NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A076852	001	Feb 16, 2016	Feb	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A076852	002	Feb 16, 2016	Feb	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A076852	003	Feb 16, 2016	Feb	NEWA
AB		5MG;5MG;5MG;5MG	A076852	004	Feb 16, 2016	Feb	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A076852	005	Feb 16, 2016	Feb	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A076852	006	Feb 16, 2016	Feb	NEWA
AB	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013	Feb	CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013	Feb	CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013	Feb	CTNA
AB		5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013	Feb	CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013	Feb	CTNA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013	Feb	CTNA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A206340	001	Feb 05, 2016	Jan	NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A206340	002	Feb 05, 2016	Jan	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206340	003	Feb 05, 2016	Jan	NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A206340	004	Feb 05, 2016	Jan	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206340	005	Feb 05, 2016	Jan	NEWA
AB		5MG;5MG;5MG;5MG	A206340	006	Feb 05, 2016	Jan	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206340	007	Feb 05, 2016	Jan	NEWA

ARIPIPIRAZOLE

SOLUTION;ORAL

ARIPIPIRAZOLE

AA + AMNEAL PHARMS 1MG/ML A203906 001 Aug 14, 2015 Feb CRLD

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 LYOPHILIZED

@	TELIGENT PHARMA INC	100MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15MG/VIAL; 5MCG/VIAL; 0.4MG/VIAL; 40MG/VIAL; 4MG/VIAL; 3.6MG/VIAL; 3MG/VIAL; 1MG/VIAL; 10MG/VIAL	N018933	002	Aug 08, 1985	Jan	CAHN
---	---------------------	---	---------	-----	--------------	-----	------

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

>A>	FOREST LABS LLC	EQ 2.5 BASE	N022117	003	Mar 12, 2015	Mar	NEWA
-----	-----------------	-------------	---------	-----	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

@	NOSTRUM LABS INC	325MG; 50MG; 40MG	A078149	001	Jun 13, 2007	Jan	CAHN
---	------------------	-------------------	---------	-----	--------------	-----	------

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB	INGENUS PHARMS NJ	325MG; 200MG	A040832	001	Jan 07, 2010	Jan	CAHN
----	-------------------	--------------	---------	-----	--------------	-----	------

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

>D>	@	INGENUS PHARMS NJ	325MG; 200MG; 16MG	A040860	001	Jan 07, 2010	Mar	CMFD
>A>	AB		325MG; 200MG; 16MG	A040860	001	Jan 07, 2010	Mar	CMFD
	@		325MG; 200MG; 16MG	A040860	001	Jan 07, 2010	Jan	CAHN
>D>	+	SANDOZ	325MG; 200MG; 16MG	A040118	001	Apr 16, 1996	Mar	CTEC
>A>	AB	+	325MG; 200MG; 16MG	A040118	001	Apr 16, 1996	Mar	CTEC
	+		325MG; 200MG; 16MG	A040118	001	Apr 16, 1996	Jan	CRLD
		SOMA COMPOUND W/ CODEINE						
	@	MEDA PHARMS	325MG; 200MG; 16MG	N012366	002	Jul 11, 1983	Jan	DISC

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

ASPIRIN AND DIPYRIDAMOLE

AB	AMNEAL PHARMS	25MG; 200MG	A206392	001	Mar 08, 2016	Feb	NEWA
----	---------------	-------------	---------	-----	--------------	-----	------

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

>D>	@	MUTUAL PHARM	325MG; 4.5MG; 0.38MG	A040260	001	Jul 17, 1998	Mar	CAHN
>D>	@		325MG; 4.5MG; 0.38MG	A087794	001	May 26, 1982	Mar	CAHN
>A>	@	SUN PHARM INDS	325MG; 4.5MG; 0.38MG	A040260	001	Jul 17, 1998	Mar	CAHN
>A>	@		325MG; 4.5MG; 0.38MG	A087794	001	May 26, 1982	Mar	CAHN

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	ALVOGEN MALTA	25MG	A073646	001	Jul 31, 1992	Jan	CAHN
AB		50MG	A072303	001	Jul 15, 1988	Jan	CAHN
AB		100MG	A072304	001	Jul 15, 1988	Jan	CAHN
	TENORMIN						
AB	ALVOGEN MALTA	25MG	N018240	004	Apr 09, 1990	Jan	CAHN
AB		50MG	N018240	001		Jan	CAHN
AB	+	100MG	N018240	002		Jan	CAHN

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB	ALVOGEN MALTA	50MG; 25MG	A072301	001	May 31, 1990	Jan	CAHN	
AB		100MG; 25MG	A072302	001	May 31, 1990	Jan	CAHN	
>D>	AB	MUTUAL PHARM	100MG; 25MG	A073582	001	Apr 29, 1993	Mar	CAHN
>A>	AB	SUN PHARM INDS	100MG; 25MG	A073582	001	Apr 29, 1993	Mar	CAHN
		TENORETIC 100						
AB	+	ALVOGEN MALTA	100MG; 25MG	N018760	001	Jun 08, 1984	Jan	CAHN

	TABLET;ORAL							
	TENORETIC 50							
AB	ALVOGEN MALTA	50MG;25MG	N018760	002	Jun 08, 1984		Jan	CAHN
	<u>ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE</u>							
	TABLET;ORAL							
	DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE							
>D>	@ MUTUAL PHARM	0.025MG;2.5MG	A085506	001			Mar	CAHN
>A>	@ SUN PHARM INDS	0.025MG;2.5MG	A085506	001			Mar	CAHN
	<u>AURANOFIN</u>							
	CAPSULE;ORAL							
	RIDAURA							
+	SEBELA IRELAND LTD	3MG	N018689	001	May 24, 1985		Jan	CAHN
	<u>AZATHIOPRINE</u>							
	TABLET;ORAL							
	IMURAN							
AB	@ SEBELA IRELAND LTD	25MG	N016324	002			Jan	CAHN
+		50MG	N016324	001			Jan	CAHN
	<u>AZATHIOPRINE SODIUM</u>							
	INJECTABLE;INJECTION							
	IMURAN							
	@ SEBELA IRELAND LTD	EQ 100MG BASE/VIAL	N017391	001			Jan	CAHN
	<u>AZILSARTAN KAMEDOXOMIL</u>							
	TABLET;ORAL							
	EDARBI							
+	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011		Jan	CAHN
		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011		Jan	CAHN
	<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE</u>							
	TABLET;ORAL							
	EDARBYCLOR							
+	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011		Jan	CAHN
		EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011		Jan	CAHN
	<u>AZTREONAM</u>							
	INJECTABLE;INJECTION							
	AZTREONAM							
>D>	AP	EUROHLTH INTL SARL	1GM/VIAL	A065286	001	Mar 23, 2011	Mar	DISC
>A>	@		1GM/VIAL	A065286	001	Mar 23, 2011	Mar	DISC
>D>	AP		2GM/VIAL	A065286	002	Mar 23, 2011	Mar	DISC
>A>	@		2GM/VIAL	A065286	002	Mar 23, 2011	Mar	DISC
	<u>BACLOFEN</u>							
	TABLET;ORAL							
	BACLOFEN							
AB	NORTHSTAR HLTHCARE	10MG	A078401	002	Sep 18, 2009		Jan	NEWA
	<u>BARIUM SULFATE</u>							
	FOR SUSPENSION;ORAL							
	E-Z-HD							
+	BRACCO	334GM/BOTTLE	N208036	001	Jan 11, 2016		Jan	NEWA
	SUSPENSION;ORAL							
	READI-CAT 2							
+	BRACCO	2% (9GM/450ML)	N208143	001	Jan 15, 2016		Jan	NEWA
	READI-CAT 2 SMOOTHIES							
	BRACCO	2% (9GM/450ML)	N208143	002	Jan 15, 2016		Jan	NEWA
	<u>BENAZEPRIL HYDROCHLORIDE</u>							
	TABLET;ORAL							
	BENAZEPRIL HYDROCHLORIDE							
	@ ACTAVIS LABS FL INC	5MG	A076267	001	Feb 11, 2004		Jan	DISC
	@	10MG	A076267	002	Feb 11, 2004		Jan	DISC
	@	20MG	A076267	003	Feb 11, 2004		Jan	DISC
	@	40MG	A076267	004	Feb 11, 2004		Jan	DISC

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@	ACTAVIS LABS FL INC	5MG;6.25MG	A076342	001	Feb 11, 2004	Jan	DISC
	@		10MG;12.5MG	A076342	002	Feb 11, 2004	Jan	DISC
	@		20MG;12.5MG	A076342	003	Feb 11, 2004	Jan	DISC
	@		20MG;25MG	A076342	004	Feb 11, 2004	Jan	DISC
>D>	AB	IVAX SUB TEVA PHARMS	5MG;6.25MG	A076348	001	Feb 11, 2004	Mar	DISC
>A>	@		5MG;6.25MG	A076348	001	Feb 11, 2004	Mar	DISC
>D>	AB		10MG;12.5MG	A076348	002	Feb 11, 2004	Mar	DISC
>A>	@		10MG;12.5MG	A076348	002	Feb 11, 2004	Mar	DISC
>D>	AB		20MG;12.5MG	A076348	003	Feb 11, 2004	Mar	DISC
>A>	@		20MG;12.5MG	A076348	003	Feb 11, 2004	Mar	DISC
>D>	AB		20MG;25MG	A076348	004	Feb 11, 2004	Mar	DISC
>A>	@		20MG;25MG	A076348	004	Feb 11, 2004	Mar	DISC
>D>	AB	SUN PHARM INDS LTD	5MG;6.25MG	A077483	001	Sep 08, 2005	Mar	DISC
>A>	@		5MG;6.25MG	A077483	001	Sep 08, 2005	Mar	DISC
>D>	AB		10MG;12.5MG	A077483	002	Sep 08, 2005	Mar	DISC
>A>	@		10MG;12.5MG	A077483	002	Sep 08, 2005	Mar	DISC
>D>	AB		20MG;12.5MG	A077483	003	Sep 08, 2005	Mar	DISC
>A>	@		20MG;12.5MG	A077483	003	Sep 08, 2005	Mar	DISC
>D>	AB		20MG;25MG	A077483	004	Sep 08, 2005	Mar	DISC
>A>	@		20MG;25MG	A077483	004	Sep 08, 2005	Mar	DISC

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

>A>	AP	GLENMARK PHARMS LTD	25MG/VIAL	A204771	001	Mar 24, 2016	Mar	NEWA
>A>	AP		100MG/VIAL	A204771	002	Mar 24, 2016	Mar	NEWA
>A>	AP	INNOPHARMA LICENSING	25MG/VIAL	A205476	001	Mar 24, 2016	Mar	NEWA
>A>	AP		100MG/VIAL	A205476	002	Mar 24, 2016	Mar	NEWA
		TREANDA						
>D>	+	CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Mar	CFTG
>A>	AP		25MG/VIAL	N022249	002	May 01, 2009	Mar	CFTG
>D>	+		100MG/VIAL	N022249	001	Mar 20, 2008	Mar	CFTG
>A>	AP		100MG/VIAL	N022249	001	Mar 20, 2008	Mar	CFTG

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA		BIONPHARMA INC	100MG	A081297	001	Jan 29, 1993	Jan	CAHN
AA			200MG	A081297	002	Oct 30, 2007	Jan	CAHN

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN PAK

	+	CUTANEA	5%;3%	N050769	001	Nov 27, 2000	Feb	CAHN
--	---	---------	-------	---------	-----	--------------	-----	------

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

>D>	AA	IMPAX LABS	50MG	A040845	001	Nov 18, 2008	Mar	DISC
>A>	@		50MG	A040845	001	Nov 18, 2008	Mar	DISC

BETAMETHASONE DIPROPIONATE

SPRAY; TOPICAL

SERNIVO

	+	PROMIUS PHARMA LLC	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Feb	NEWA
--	---	--------------------	---------------------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

>A>	AB	GLENMARK PHARMS	EQ 0.05% BASE;1%	A202894	001	Oct 30, 2015	Mar	CAHN
>D>	AB	GLENMARK PHARMS LTD	EQ 0.05% BASE;1%	A202894	001	Oct 30, 2015	Mar	CAHN

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT		TELIGENT PHARMA INC	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Jan	CAHN
----	--	---------------------	--------------	---------	-----	--------------	-----	------

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

>D>	AA	IMPAX LABS	5MG	A040739	001	Nov 01, 2006	Mar	DISC
>A>		@	5MG	A040739	001	Nov 01, 2006	Mar	DISC
>D>	AA		10MG	A040741	001	Nov 01, 2006	Mar	DISC
>A>		@	10MG	A040741	001	Nov 01, 2006	Mar	DISC
>D>	AA		25MG	A040740	001	Nov 01, 2006	Mar	DISC
>A>		@	25MG	A040740	001	Nov 01, 2006	Mar	DISC
>D>	AA		50MG	A040721	004	Nov 01, 2006	Mar	DISC
>A>		@	50MG	A040721	004	Nov 01, 2006	Mar	DISC

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HELIDAC

@	SEBELA IRELAND LTD	262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,500MG	N050719	001	Aug 15, 1996	Jan	CAHN
---	--------------------	---	---------	-----	--------------	-----	------

BRIVARACETAM

SOLUTION; INTRAVENOUS

BRIVIACT

+	UBC INC	50MG/5ML (10MG/ML)	N205837	001	Feb 18, 2016	Feb	NEWA
---	---------	--------------------	---------	-----	--------------	-----	------

SOLUTION; ORAL

BRIVIACT

+	UCB INC	10MG/ML	N205838	001	Feb 18, 2016	Feb	NEWA
---	---------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

BRIVIACT

	UCB INC	10MG	N205836	001	Feb 18, 2016	Feb	NEWA
		25MG	N205836	002	Feb 18, 2016	Feb	NEWA
		50MG	N205836	003	Feb 18, 2016	Feb	NEWA
		75MG	N205836	004	Feb 18, 2016	Feb	NEWA
+		100MG	N205836	005	Feb 18, 2016	Feb	NEWA

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

BROMOCRIPTINE MESYLATE

AB	+	MYLAN	EQ 5MG BASE	A077226	001	Apr 04, 2005	Jan	CRLD
		PARLODEL						
		@ US PHARMS HOLDINGS I	EQ 5MG BASE	N017962	002	Mar 01, 1982	Jan	DISC

TABLET; ORAL

BROMOCRIPTINE MESYLATE

AB	+	PADDOCK LLC	EQ 2.5MG BASE	A077646	001	Oct 01, 2008	Jan	CRLD
AB		SANDOZ INC	EQ 2.5MG BASE	A074631	001	Jan 13, 1998	Feb	CAHN
		PARLODEL						
		@ US PHARMS HOLDINGS I	EQ 2.5MG BASE	N017962	001		Jan	DISC

BUDESONIDE

CAPSULE; ORAL

BUDESONIDE

>A>	AB	ACTAVIS ELIZABETH	3MG	A206623	001	Apr 08, 2016	Mar	NEWA
		ENTOCORT EC						
AB	+	ELAN PHARMA INTL LTD	3MG	N021324	001	Oct 02, 2001	Jan	CAHN
		SUSPENSION; INHALATION						
		BUDESONIDE						
AN		TEVA PHARMS USA	1MG/2ML	A204548	001	Mar 08, 2016	Feb	NEWA

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 2MG BASE	A201760	001	Jan 29, 2016	Jan	NEWA
AB			EQ 8MG BASE	A201760	002	Jan 29, 2016	Jan	NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB1		INVAGEN PHARMS	100MG	A206674	001	Feb 09, 2016	Jan	NEWA
AB1			150MG	A206674	002	Feb 09, 2016	Jan	NEWA
AB1			200MG	A206674	003	Feb 09, 2016	Jan	NEWA
AB1		SCIEGEN PHARMS INC	100MG	A205794	001	Mar 01, 2016	Feb	NEWA
AB1			150MG	A205794	002	Mar 01, 2016	Feb	NEWA
AB1			200MG	A205794	003	Mar 01, 2016	Feb	NEWA

BUSULFANINJECTABLE; INJECTION
BUSULFAN

>A>	AP	LUITPOLD PHARMS INC	6MG/ML	A202259	001	Dec 22, 2015	Mar	CAHN
>D>	AP	PHARMAFORCE	6MG/ML	A202259	001	Dec 22, 2015	Mar	CAHN

BUTORPHANOL TARTRATEINJECTABLE; INJECTION
BUTORPHANOL TARTRATE

		@ CLARIS	2MG/ML	A075697	001	Oct 23, 2001	Jan	CAHN
		BUTORPHANOL TARTRATE PRESERVATIVE FREE						
>D>		@ APOTEX INC	1MG/ML	A075695	001	Oct 23, 2001	Mar	CAHN
>D>		@	2MG/ML	A075695	002	Oct 23, 2001	Mar	CAHN
>A>		@ CLARIS	1MG/ML	A075695	001	Oct 23, 2001	Mar	CAHN
>A>		@	2MG/ML	A075695	002	Oct 23, 2001	Mar	CAHN

CABERGOLINETABLET; ORAL
CABERGOLINE

>D>	AB	IMPAX LABS INC	0.5MG	A077843	001	Jul 03, 2007	Mar	DISC
>A>		@	0.5MG	A077843	001	Jul 03, 2007	Mar	DISC

CAFFEINE; ERGOTAMINE TARTRATESUPPOSITORY; RECTAL
MIGERGOT

		+ HORIZON PHARMA	100MG; 2MG	A086557	001	Oct 04, 1983	Jan	CAHN
--	--	------------------	------------	---------	-----	--------------	-----	------

CALCIPOTRIENECREAM; TOPICAL
CALCIPOTRIENE

>A>	AB	GLENMARK PHARMS	0.005%	A205772	001	Jun 09, 2015	Mar	CAHN
>D>	AB	GLENMARK PHARMS LTD	0.005%	A205772	001	Jun 09, 2015	Mar	CAHN

CALCITRIOLCAPSULE; ORAL
CALCITRIOL

AB		BIONPHARMA INC	0.25MCG	A091174	001	May 24, 2013	Jan	CAHN
AB			0.5MCG	A091174	002	May 24, 2013	Jan	CAHN

INJECTABLE; INJECTION
CALCITRIOL

		AKORN	0.001MG/ML	A078066	001	Jan 29, 2008	Feb	CTEC
		@ ROCKWELL MEDCL	0.001MG/ML	A076206	001	Sep 17, 2003	Feb	DISC

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

		DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER						
		@ FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	002		Feb	DISC
		DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER						
		@ FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	003		Feb	DISC
		DELFLX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER						
		@ FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	007	Jun 24, 1988	Feb	DISC
		DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER						
		@ FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	001		Feb	DISC
		DELFLX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER						
		@ FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	004	Jul 07, 1982	Feb	DISC
		DELFLX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER						
		@ FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	005	Jul 07, 1982	Feb	DISC
		DELFLX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER						
		@ FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	008	Jun 24, 1988	Feb	DISC
		DELFLX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER						
		@ FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	006	Jul 07, 1982	Feb	DISC
		DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER						
		BAXTER HLTHCARE	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	010	Nov 18, 1985	Feb	CTEC

SOLUTION;INTRAPERITONEAL

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	011	Nov 18, 1985	Feb	CTEC
-----------------	---	---------	-----	--------------	-----	------

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

>D>	AB	APOTEX	12.5MG	A074737	001	Oct 28, 1998	Mar	DISC
>A>		@	12.5MG	A074737	001	Oct 28, 1998	Mar	DISC
>D>	AB		25MG	A074737	002	Oct 28, 1998	Mar	DISC
>A>		@	25MG	A074737	002	Oct 28, 1998	Mar	DISC
>D>	AB		50MG	A074737	003	Oct 28, 1998	Mar	DISC
>A>		@	50MG	A074737	003	Oct 28, 1998	Mar	DISC
>D>	AB		100MG	A074737	004	Oct 28, 1998	Mar	DISC
>A>		@	100MG	A074737	004	Oct 28, 1998	Mar	DISC
		@ SANDOZ	12.5MG	A074363	001	Nov 09, 1995	Jan	DISC
		@	25MG	A074363	002	Nov 09, 1995	Jan	DISC
		@	50MG	A074363	003	Nov 09, 1995	Jan	DISC
		@	100MG	A074363	004	Nov 09, 1995	Jan	DISC
>D>	AB	STASON	12.5MG	A074677	004	May 30, 1997	Mar	DISC
>A>		@	12.5MG	A074677	004	May 30, 1997	Mar	DISC
>D>	AB		25MG	A074677	002	May 30, 1997	Mar	DISC
>A>		@	25MG	A074677	002	May 30, 1997	Mar	DISC
>D>	AB		50MG	A074677	001	May 30, 1997	Mar	DISC
>A>		@	50MG	A074677	001	May 30, 1997	Mar	DISC
>D>	AB		100MG	A074677	003	May 30, 1997	Mar	DISC
>A>		@	100MG	A074677	003	May 30, 1997	Mar	DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB	MYLAN IRELAND LTD	100MG	A076697	001	May 20, 2011	Jan	CAHN
AB		200MG	A076697	002	May 20, 2011	Jan	CAHN
AB		300MG	A076697	003	May 20, 2011	Jan	CAHN

CARBIDOPA

TABLET;ORAL

CARBIDOPA

AB	EDENBRIDGE PHARMS	25MG	A205304	001	Feb 17, 2016	Feb	NEWA
----	-------------------	------	---------	-----	--------------	-----	------

CARBOPLATIN

INJECTABLE;IV (INFUSION)

CARBOPLATIN

AP	SANDOZ INC	50MG/5ML (10MG/ML)	A078280	001	May 08, 2008	Feb	CAHN
AP		150MG/15ML (10MG/ML)	A078280	002	May 08, 2008	Feb	CAHN
AP		450MG/45ML (10MG/ML)	A078280	003	May 08, 2008	Feb	CAHN
>A>	SANJA PHARMS CO	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Mar	NEWA
>A>	AP	150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Mar	NEWA
>A>	AP	450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Mar	NEWA

CARFILZOMIB

POWDER;INTRAVENOUS

KYPROLIS

+	ONYX THERAP	60MG/VIAL	N202714	001	Jul 20, 2012	Feb	CAHN
---	-------------	-----------	---------	-----	--------------	-----	------

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

AA	INGENUS PHARMS NJ	350MG	A040823	001	Oct 22, 2008	Jan	CAHN
----	-------------------	-------	---------	-----	--------------	-----	------

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION;ORAL

CEFADROXIL

@	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Feb	DISC
@		EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Feb	DISC
@		EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Feb	DISC

<u>CEFAZOLIN SODIUM</u>							
INJECTABLE; INJECTION							
CEFAZOLIN SODIUM							
AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A201654	001	Feb 03, 2016	Jan	NEWA
<u>CEFEPIME HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
CEFEPIME HYDROCHLORIDE							
AP	QILU PHARM CO LTD	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan	NEWA
AP		EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan	NEWA
AP		EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan	NEWA
<u>CEFOTAXIME SODIUM</u>							
INJECTABLE; INJECTION							
CEFOTAXIME SODIUM							
AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016	Feb	NEWA
AP		EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016	Feb	NEWA
CLAFORAN							
AP	+ US PHARM HOLDINGS	EQ 500MG BASE/VIAL	N050547	001		Jan	CAHN
AP	+	EQ 1GM BASE/VIAL	N050547	002		Jan	CAHN
AP	+	EQ 2GM BASE/VIAL	N050547	003		Jan	CAHN
AP	+	EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan	CAHN
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER							
+	US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jan	CAHN
+		EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan	CAHN
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
@	US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan	CAHN
@		EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan	CAHN
<u>CEFOTETAN DISODIUM</u>							
INJECTABLE; INJECTION							
CEFOTAN							
@	TELGENT PHARMA INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	Jan	CAHN
AP		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb	CMFD
@		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Jan	CAHN
@		EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	Jan	CAHN
AP		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb	CMFD
@		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Jan	CAHN
@		EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Jan	CAHN
<u>CEFPODOXIME PROXETIL</u>							
FOR SUSPENSION; ORAL							
CEFPODOXIME PROXETIL							
@	SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Feb	DISC
@		EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Feb	DISC
TABLET; ORAL							
CEFPODOXIME PROXETIL							
@	SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Feb	DISC
@		EQ 200MG BASE	A065083	002	Aug 20, 2003	Feb	DISC
<u>CEFUROXIME AXETIL</u>							
FOR SUSPENSION; ORAL							
CEFTIN							
GLAXOSMITHKLINE		EQ 125MG BASE/5ML	N050672	001	Jun 30, 1994	Feb	CTEC
+		EQ 250MG BASE/5ML	N050672	002	Apr 29, 1997	Feb	CTEC
CEFUROXIME AXETIL							
@	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Feb	DISC
@		EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Feb	DISC
TABLET; ORAL							
CEFUROXIME AXETIL							
@	SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Feb	DISC
@		EQ 250MG BASE	A065118	002	Apr 25, 2003	Feb	DISC
@		EQ 500MG BASE	A065118	003	Apr 25, 2003	Feb	DISC
<u>CEFUROXIME SODIUM</u>							
INJECTABLE; INJECTION							
ZINACEF							
AP	+ IGI LABS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jan	CAHN
AP	+	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jan	CAHN

INJECTABLE; INJECTION

ZINACEF IN PLASTIC CONTAINER

	@ IGI LABS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jan CAHN
+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jan CAHN
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS						
ZINACEF						
AB	+ IGI LABS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jan CAHN

CELECOXIB

CAPSULE; ORAL

CELECOXIB

AB	AUROBINDO PHARMA LTD	50MG	A206827	001	Feb 01, 2016	Jan NEWA
AB		100MG	A206827	002	Feb 01, 2016	Jan NEWA
AB		200MG	A206827	003	Feb 01, 2016	Jan NEWA
AB		400MG	A206827	004	Feb 01, 2016	Jan NEWA
AB	MACLEODS PHARMS LTD	50MG	A204590	001	Mar 16, 2016	Feb NEWA
AB		100MG	A204590	002	Mar 16, 2016	Feb NEWA
AB		200MG	A204590	003	Mar 16, 2016	Feb NEWA
AB		400MG	A204590	004	Mar 16, 2016	Feb NEWA

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

	@ SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Feb DISC
	@	EQ 500MG BASE	A065007	002	Sep 16, 1999	Feb DISC
FOR SUSPENSION; ORAL						
KEFLEX						
>A>	@ PRAGMA PHARMS LLC	EQ 100MG BASE/ML	N050406	003		Mar CAHN
>A>	@	EQ 125MG BASE/5ML	N050406	001		Mar CAHN
>A>	@	EQ 250MG BASE/5ML	N050406	002		Mar CAHN
>D>	@ SHIONOGI INC	EQ 100MG BASE/ML	N050406	003		Mar CAHN
>D>	@	EQ 125MG BASE/5ML	N050406	001		Mar CAHN
>D>	@	EQ 250MG BASE/5ML	N050406	002		Mar CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

>A>	AA	NOSTRUM LABS INC	5MG/5ML	A090191	001	Nov 12, 2009	Mar CAHN
>D>	AA	SUN PHARM INDS INC	5MG/5ML	A090191	001	Nov 12, 2009	Mar CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

PERIOGARD

AT	COLGATE-PALMOLIVE CO	0.12%	A203212	001	Jan 28, 2016	Jan NEWA
----	----------------------	-------	---------	-----	--------------	----------

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

>D>	AA	IMPAX LABS	EQ 150MG BASE	A080880	001		Mar DISC
>A>		@	EQ 150MG BASE	A080880	001		Mar DISC
>D>	AA		EQ 300MG BASE	A040516	001	Aug 29, 2003	Mar DISC
>A>		@	EQ 300MG BASE	A040516	001	Aug 29, 2003	Mar DISC

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

CHLORPHENIRAMINE MALEATE

>A>		@ AUROLIFE PHARMA LLC	4MG	A080961	001		Mar CAHN
>D>		@ SANDOZ	4MG	A080961	001		Mar CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	MAYNE PHARMA INC	4MG/5ML; 5MG/5ML; 60MG/5ML	A205657	001	Aug 03, 2015	Feb CAHN
----	------------------	----------------------------	---------	-----	--------------	----------

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

>A>		@ AUROLIFE PHARMA LLC	100MG	A088725	001	Aug 31, 1984	Mar CAHN
>A>		@	250MG	A088726	001	Aug 31, 1984	Mar CAHN
>D>		@ SANDOZ	100MG	A088725	001	Aug 31, 1984	Mar CAHN
>D>		@	250MG	A088726	001	Aug 31, 1984	Mar CAHN

CHLOROTHALIDONE

TABLET; ORAL

CHLOROTHALIDONE

AB	MYLAN	25MG	A086831	002		Jan	CTEC
AB	SUN PHARM INDS	25MG	A089286	002	Jul 21, 1986	Jan	NEWA

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

@	AUROLIFE PHARMA LLC	250MG	A089852	001	May 04, 1988	Feb	CAHN
@		500MG	A089853	001	May 04, 1988	Feb	CAHN

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

+	TAKEDA GMBH	0.08MG/INH	N021658	002	Jan 10, 2008	Jan	CRLD
---	-------------	------------	---------	-----	--------------	-----	------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

@	ACTAVIS LABS FL INC	212.6MG;EQ 287.5MG BASE	A077417	001	Nov 30, 2010	Jan	DISC
@		425.2MG;EQ 574.9MG BASE	A077809	001	Nov 30, 2010	Jan	DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

>D>	@	MUTUAL PHARM	EQ 10MG BASE	A077052	001	Jul 03, 2006	Mar	CAHN
>D>	@		EQ 20MG BASE	A077052	002	Jul 03, 2006	Mar	CAHN
>D>	@		EQ 40MG BASE	A077052	003	Jul 03, 2006	Mar	CAHN
>A>	@	SUN PHARM INDS	EQ 10MG BASE	A077052	001	Jul 03, 2006	Mar	CAHN
>A>	@		EQ 20MG BASE	A077052	002	Jul 03, 2006	Mar	CAHN
>A>	@		EQ 40MG BASE	A077052	003	Jul 03, 2006	Mar	CAHN

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

AB	ALLIED PHARMA INC	500MG	A203243	001	Feb 29, 2016	Feb	NEWA
----	-------------------	-------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

BX	+	AQUA PHARMS LLC	1.2%;0.025%	N050803	001	Jul 16, 2010	Jan	CAHN
----	---	-----------------	-------------	---------	-----	--------------	-----	------

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

>D>	AB	FOUGERA PHARMS	0.05%	A074407	001	Feb 23, 1996	Mar	CRLD	
>A>	AB	+	0.05%	A074407	001	Feb 23, 1996	Mar	CRLD	
>D>		TEMOVATE							
>D>	AB	+	FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Mar	DISC
>A>		@	0.05%	N019323	001	Dec 27, 1985	Mar	DISC	

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

AB	+	MALLINCKRODT LLC	25MG	N019906	001	Dec 29, 1989	Jan	CRLD
AB			50MG	N019906	002	Dec 29, 1989	Jan	CRLD

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

@	AUROLIFE PHARMA LLC	0.1MG	A070887	001	Aug 31, 1988	Feb	CAHN
@		0.2MG	A070886	001	Aug 31, 1988	Feb	CAHN
@		0.3MG	A071294	001	Aug 31, 1988	Feb	CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

>D>	AB	MUTUAL PHARM	EQ 75MG BASE	A078133	001	Jun 10, 2013	Mar	CAHN
>A>	AB	SUN PHARM INDS	EQ 75MG BASE	A078133	001	Jun 10, 2013	Mar	CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC 7.5MG

A072220 001 Aug 26, 1988 Feb CAHN

@ 15MG

A072112 001 Aug 26, 1988 Feb CAHN

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

>A>	@	AUROLIFE PHARMA LLC	3.75MG	A072512	001	May 11, 1990	Mar	CAHN
-----	---	---------------------	--------	---------	-----	--------------	-----	------

>A>	@		7.5MG	A072513	001	May 11, 1990	Mar	CAHN
-----	---	--	-------	---------	-----	--------------	-----	------

	@		15MG	A072514	001	May 11, 1990	Feb	CAHN
--	---	--	------	---------	-----	--------------	-----	------

>D>	@	SANDOZ	3.75MG	A072512	001	May 11, 1990	Mar	CAHN
-----	---	--------	--------	---------	-----	--------------	-----	------

>D>	@		7.5MG	A072513	001	May 11, 1990	Mar	CAHN
-----	---	--	-------	---------	-----	--------------	-----	------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA		NOSTRUM LABS INC	10MG/5ML; 6.25MG/5ML	A090180	001	Mar 17, 2010	Feb	CAHN
----	--	------------------	----------------------	---------	-----	--------------	-----	------

COLCHICINE

CAPSULE; ORAL

MITIGARE

>D>		HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014	Mar	CRLD
-----	--	-------------------	-------	---------	-----	--------------	-----	------

>A>	+		0.6MG	N204820	001	Sep 26, 2014	Mar	CRLD
-----	---	--	-------	---------	-----	--------------	-----	------

COLCHICINE; PROBENECID

TABLET; ORAL

PROBENECID AND COLCHICINE

AB		INGENUS PHARMS NJ	0.5MG; 500MG	A040618	001	May 13, 2008	Jan	CAHN
----	--	-------------------	--------------	---------	-----	--------------	-----	------

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

+	ENDO PHARMS INC	EQ 3MG BASE/ML; 10MG/ML; EQ 3.3MG BASE/ML; 0.5MG/ML	N050356	001			Feb	CAHN
---	-----------------	--	---------	-----	--	--	-----	------

CORTICOTROPIN

INJECTABLE; INJECTION

PURIFIED CORTROPHIN GEL

@ ANI PHARMS 40 UNITS/ML

N008975 001 Feb CAHN

@ 80 UNITS/ML

N008975 002 Feb CAHN

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE; INJECTION

CORTROPHIN-ZINC

@ ANI PHARMS 40 UNITS/ML

N009854 001 Feb CAHN

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

>D>	AP	GAVIS PHARMS LLC	1MG/ML	A206503	001	Dec 11, 2015	Mar	CAHN
-----	----	------------------	--------	---------	-----	--------------	-----	------

>A>	AP	SOMERSET THERAPS LLC	1MG/ML	A206503	001	Dec 11, 2015	Mar	CAHN
-----	----	----------------------	--------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL

NASCOBAL

+	ENDO PHARMS INC	0.5MG/SPRAY	N021642	001	Jan 31, 2005	Feb	CAHN
---	-----------------	-------------	---------	-----	--------------	-----	------

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN (LYOPHILIZED)

>D>	AP	+	BAXTER HLTHCARE	500MG/VIAL	N012142	003		Mar	DISC
-----	----	---	-----------------	------------	---------	-----	--	-----	------

>A>		@		500MG/VIAL	N012142	003		Mar	DISC
-----	--	---	--	------------	---------	-----	--	-----	------

>D>	AP	+		1GM/VIAL	N012142	004	Aug 30, 1982	Mar	DISC
-----	----	---	--	----------	---------	-----	--------------	-----	------

>A>		@		1GM/VIAL	N012142	004	Aug 30, 1982	Mar	DISC
-----	--	---	--	----------	---------	-----	--------------	-----	------

>D>	AP	+		2GM/VIAL	N012142	005	Aug 30, 1982	Mar	DISC
-----	----	---	--	----------	---------	-----	--------------	-----	------

>A>		@		2GM/VIAL	N012142	005	Aug 30, 1982	Mar	DISC
-----	--	---	--	----------	---------	-----	--------------	-----	------

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA		INGENUS PHARMS NJ	4MG	A205087	001	Sep 23, 2015	Jan	CAHN
----	--	-------------------	-----	---------	-----	--------------	-----	------

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

>D>	AP	MYLAN LABS LTD	20MG/ML	A200915	001	Dec 13, 2011	Mar	CAHN
>D>	AP		20MG/ML	A200916	001	Dec 13, 2011	Mar	CAHN
>A>	AP	MYLAN PHARMS INC	20MG/ML	A200915	001	Dec 13, 2011	Mar	CAHN
>A>	AP		20MG/ML	A200916	001	Dec 13, 2011	Mar	CAHN

DACTINOMYCIN

INJECTABLE; INJECTION

DACTINOMYCIN

@ EUROHLTH INTL SARL 0.5MG/VIAL

A090304 001 Mar 16, 2010 Feb DISC

DALBAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)

DALVANCE

+ DURATA THERAPS INTL EQ 500MG BASE/VIAL

N021883 001 May 23, 2014 Jan CDFR

DANTROLENE SODIUM

INJECTABLE; INJECTION

DANTROLENE SODIUM

AP MYLAN INSTITUTIONAL 20MG/VIAL

A205239 001 Feb 18, 2016 Feb NEWA

DAPSONE

GEL; TOPICAL

ACZONE

+ ALLERGAN INC 7.5%

N207154 001 Feb 24, 2016 Feb NEWA

TABLET; ORAL

DAPSONE

>A>	AB	ALVOGEN	25MG	A205429	001	Jan 07, 2016	Mar	CAHN
>A>	AB		100MG	A205429	002	Jan 07, 2016	Mar	CAHN
>D>	AB	FERA PHARMS LLC	25MG	A205429	001	Jan 07, 2016	Mar	CAHN
>D>	AB		100MG	A205429	002	Jan 07, 2016	Mar	CAHN

DAPTOMYCIN

POWDER; INTRAVENOUS

CUBICIN

AP + CUBIST 500MG/VIAL

N021572 002 Sep 12, 2003 Jan CDFR

DAPTOMYCIN

AP HOSPIRA INC 500MG/VIAL

A202857 001 Sep 12, 2014 Jan CDFR

>A> AP TEVA PARENTERAL 500MG/VIAL

A091039 001 Mar 25, 2016 Mar NEWA

POWDER; IV (INFUSION)

CUBICIN

@ CUBIST 250MG/VIAL

N021572 001 Sep 12, 2003 Jan CDFR

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

ENABLEX

AB ALLERGAN PHARMS INTL EQ 7.5MG BASE

N021513 001 Dec 22, 2004 Jan CAHN

AB + EQ 15MG BASE

N021513 002 Dec 22, 2004 Jan CAHN

DEFERASIROX

TABLET, FOR SUSPENSION; ORAL

DEFERASIROX

AB ACTAVIS ELIZABETH 125MG

A203560 001 Jan 26, 2016 Jan NEWA

AB 250MG

A203560 002 Jan 26, 2016 Jan NEWA

AB 500MG

A203560 003 Jan 26, 2016 Jan NEWA

EXJADE

AB NOVARTIS 125MG

N021882 001 Nov 02, 2005 Jan CFTG

AB 250MG

N021882 002 Nov 02, 2005 Jan CFTG

AB + 500MG

N021882 003 Nov 02, 2005 Jan CFTG

>A>	<u>DEFIBROTIDE SODIUM</u>						
>A>	SOLUTION;IV (INFUSION)						
>A>	DEFITELIO						
>A>	+	GENTIUM SPA	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016	Mar NEWA
	<u>DEMECLOCYCLINE HYDROCHLORIDE</u>						
	TABLET;ORAL						
	DEMECLOCYCLINE HYDROCHLORIDE						
>D>	AB	IMPAX LABS	150MG	A065094	001	Mar 22, 2004	Mar DISC
>A>		@	150MG	A065094	001	Mar 22, 2004	Mar DISC
>D>	AB		300MG	A065094	002	Mar 22, 2004	Mar DISC
>A>		@	300MG	A065094	002	Mar 22, 2004	Mar DISC
	<u>DESIPRAMINE HYDROCHLORIDE</u>						
	TABLET;ORAL						
	DESIPRAMINE HYDROCHLORIDE						
>A>	AB	AMNEAL PHARMS CO	10MG	A208105	001	Mar 17, 2016	Mar NEWA
>A>	AB		25MG	A208105	002	Mar 17, 2016	Mar NEWA
>A>	AB		50MG	A208105	003	Mar 17, 2016	Mar NEWA
>A>	AB		75MG	A208105	004	Mar 17, 2016	Mar NEWA
>A>	AB		100MG	A208105	005	Mar 17, 2016	Mar NEWA
>A>	AB		150MG	A208105	006	Mar 17, 2016	Mar NEWA
	NORPRAMIN						
	AB	US PHARM HOLDINGS	10MG	N014399	007	Feb 11, 1982	Jan CAHN
	AB		25MG	N014399	001		Jan CAHN
	AB		50MG	N014399	003		Jan CAHN
	AB		75MG	N014399	004		Jan CAHN
	AB	+	100MG	N014399	005		Jan CAHN
	AB		150MG	N014399	006		Jan CAHN
	<u>DESONIDE</u>						
	CREAM;TOPICAL						
	DESONIDE						
AB		G AND W LABS INC	0.05%	A074027	001	Sep 28, 1992	Jan CAHN
	<u>DESOXIMETASONE</u>						
	OINTMENT;TOPICAL						
	DESOXIMETASONE						
AB		TELIGENT PHARMA INC	0.25%	A208101	001	Feb 25, 2016	Feb NEWA
	<u>DESVENLAFAXINE SUCCINATE</u>						
	TABLET, EXTENDED RELEASE;ORAL						
	DESVENLAFAXINE SUCCINATE						
AB		ROXANE	EQ 50MG BASE	A204082	001	Feb 16, 2016	Feb NEWA
AB			EQ 100MG BASE	A204083	001	Feb 16, 2016	Feb NEWA
	<u>DEXAMETHASONE</u>						
	TABLET;ORAL						
	DEXAMETHASONE						
>D>		@ MUTUAL PHARM	0.25MG	A084013	001		Mar CAHN
>D>		@	0.25MG	A084764	001		Mar CAHN
>D>		@	0.5MG	A084084	001		Mar CAHN
>D>		@	0.5MG	A084766	001		Mar CAHN
>D>		@	0.75MG	A084081	001		Mar CAHN
>D>		@	0.75MG	A084765	001		Mar CAHN
>D>		@	1.5MG	A084086	001		Mar CAHN
>D>		@	1.5MG	A084763	001		Mar CAHN
>A>		@ SUN PHARM INDS	0.25MG	A084013	001		Mar CAHN
>A>		@	0.25MG	A084764	001		Mar CAHN
>A>		@	0.5MG	A084084	001		Mar CAHN
>A>		@	0.5MG	A084766	001		Mar CAHN
>A>		@	0.75MG	A084081	001		Mar CAHN
>A>		@	0.75MG	A084765	001		Mar CAHN
>A>		@	1.5MG	A084086	001		Mar CAHN
>A>		@	1.5MG	A084763	001		Mar CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
 >D> DEXAMETHASONE SODIUM PHOSPHATE
 >D> AP + FRESENIUS KABI USA EQ 10MG PHOSPHATE/ML A040491 001 Apr 11, 2003 Mar CTNA
 >A> DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE
 >A> AP + FRESENIUS KABI USA EQ 10MG PHOSPHATE/ML A040491 001 Apr 11, 2003 Mar CTNA

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE; ORAL
 DEXILANT SOLUTAB
 + TAKEDA PHARMS USA 30MG N208056 001 Jan 26, 2016 Jan NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
 DEXMEDETOMIDINE HYDROCHLORIDE
 AP ACCORD HLTHCARE INC EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A204023 001 Feb 09, 2016 Jan NEWA
 >A> AP AUROBINDO PHARMA LTD EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A205867 001 Mar 17, 2016 Mar NEWA
 PRECEDEX
 + HOSPIRA EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) N021038 004 Nov 14, 2014 Feb CRLD

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL
 DEXMETHYLPHENIDATE HYDROCHLORIDE
 AB SUN PHARM INDS 2.5MG A201231 001 Sep 24, 2015 Feb CAHN
 AB 5MG A201231 002 Sep 24, 2015 Feb CAHN
 AB 10MG A201231 003 Sep 24, 2015 Feb CAHN

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION
 TOTECT
 >D> + BIOCDEX INC EQ 500MG BASE/VIAL N022025 001 Sep 06, 2007 Mar CAHN
 >A> + CLINIGEN HLTHCARE EQ 500MG BASE/VIAL N022025 001 Sep 06, 2007 Mar CAHN

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
 DEXTROAMPHETAMINE SULFATE
 AB MYLAN PHARMS INC 5MG A206735 001 Jan 27, 2016 Jan NEWA
 AB 10MG A206735 002 Jan 27, 2016 Jan NEWA
 AB 15MG A206735 003 Jan 27, 2016 Jan NEWA
 TABLET; ORAL
 DEXTROAMPHETAMINE SULFATE
 >A> AA NESHER PHARMS 5MG A206588 001 Mar 28, 2016 Mar NEWA
 >A> AA 10MG A206588 002 Mar 28, 2016 Mar NEWA
 AA NOVEL LABS INC 5MG A204330 001 Mar 16, 2016 Feb NEWA
 AA 10MG A204330 002 Mar 16, 2016 Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE
 @ ANI PHARMS 15MG/5ML; 6.25MG/5ML N011265 002 Apr 02, 1984 Feb CMS1

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
 DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER
 BAXTER HLTHCARE 5GM/100ML; 31MG/100ML; 141MG/100ML; 20MG/100ML; 12MG/100ML; 260MG/100ML N017484 001 Feb CMS1

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
 DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER
 @ BAXTER HLTHCARE 5GM/100ML; 205MG/100ML; 100MG/100ML; 120MG/100ML; 220MG/100ML N018840 001 Jun 29, 1983 Feb CMS1

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

@ EUROHLTH INTL SARL 5MG/ML

A070313 001 Dec 16, 1985 Jan CAHN

TABLET; ORAL

DIAZEPAM

DAVA PHARMS INC 2MG

A070228 002 Sep 26, 1985 Jan NEWA

5MG

A070228 003 Sep 26, 1985 Jan NEWA

DICLOFENAC POTASSIUM

CAPSULE; ORAL

DICLOFENAC POTASSIUM

AB BIONPHARMA INC 25MG

A204648 001 Feb 23, 2016 Feb NEWA

ZIPSOR

AB + DEPOMED INC 25MG

N022202 001 Jun 16, 2009 Feb CFTG

TABLET; ORAL

CATAFLAM

>D> AB + NOVARTIS 50MG

N020142 002 Nov 24, 1993 Mar DISC

>A> @ 50MG

N020142 002 Nov 24, 1993 Mar DISC

DICLOFENAC POTASSIUM

>D> AB MYLAN 50MG

A075463 001 Jul 26, 1999 Mar CRLD

>A> AB + 50MG

A075463 001 Jul 26, 1999 Mar CRLD

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

>A> AB AMNEAL PHARMS 1%

A208077 001 Mar 18, 2016 Mar NEWA

VOLTAREN

>D> + GLAXOSMITHKLINE CONS 1%

N022122 001 Oct 17, 2007 Mar CFTG

>A> AB + 1%

N022122 001 Oct 17, 2007 Mar CFTG

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

AT RISING PHARMS INC 0.1%

A078553 001 Dec 28, 2007 Jan CAHN

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

AB + ACTAVIS ELIZABETH 100MG

A075910 001 Jan 07, 2002 Feb CRLD

VOLTAREN-XR

@ NOVARTIS 100MG

N020254 001 Mar 08, 1996 Feb DISC

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

>D> AB EAGLE PHARMS 50MG; 0.2MG

A200540 001 Mar 14, 2014 Mar CAHN

>D> AB 75MG; 0.2MG

A200540 002 Mar 14, 2014 Mar CAHN

>A> AB EXELA PHARMA SCS LLC 50MG; 0.2MG

A200540 001 Mar 14, 2014 Mar CAHN

>A> AB 75MG; 0.2MG

A200540 002 Mar 14, 2014 Mar CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HYDROCHLORIDE

>D> @ MUTUAL PHARM 10MG

A084505 001 Oct 21, 1986 Mar CAHN

>A> @ SUN PHARM INDS 10MG

A084505 001 Oct 21, 1986 Mar CAHN

INJECTABLE; INJECTION

DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)

>A> AP EUROHLTH INTL SARL 10MG/ML

A040465 001 Jun 30, 2003 Mar CMS1

DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE)

>D> AP EUROHLTH INTL SARL 10MG/ML

A040465 001 Jun 30, 2003 Mar CMS1

SYRUP; ORAL

BENTYL

@ APTALIS PHARMA US 10MG/5ML

N007961 002 Oct 15, 1984 Jan DISC

DICYCLOMINE HYDROCHLORIDE

+ MIKART 10MG/5ML

A040169 001 Mar 24, 2005 Jan CRLD

TABLET; ORAL

DICYCLOMINE HYDROCHLORIDE

>D> @ MUTUAL PHARM 20MG

A084600 001 Jul 29, 1985 Mar CAHN

>A> @ SUN PHARM INDS 20MG

A084600 001 Jul 29, 1985 Mar CAHN

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

>D>	AA	COREPHARMA	25MG	A040828	001	Nov 05, 2008	Mar	DISC
>A>		@	25MG	A040828	001	Nov 05, 2008	Mar	DISC
		TENUATE						
>D>	AA	+ ACTAVIS LABS UT INC	25MG	N011722	002		Mar	CAHN
>A>	AA	+ ALLERGAN SALES LLC	25MG	N011722	002		Mar	CAHN
		TABLET, EXTENDED RELEASE; ORAL						
		TENUATE DOSPAN						
>D>	AB	+ ACTAVIS LABS UT INC	75MG	N012546	001		Mar	CAHN
>A>	AB	+ ALLERGAN SALES LLC	75MG	N012546	001		Mar	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

		@ ACTAVIS LABS FL INC	120MG	A074852	001	Oct 10, 1997	Jan	DISC
		@	180MG	A074852	002	Oct 10, 1997	Jan	DISC
		@	240MG	A074852	003	Oct 10, 1997	Jan	DISC
AB3		VALEANT PHARMS NORTH	120MG	A075116	001	Dec 23, 1999	Jan	CAHN
AB3			180MG	A075116	002	Dec 23, 1999	Jan	CAHN
AB3			240MG	A075116	003	Dec 23, 1999	Jan	CAHN
AB3			300MG	A075116	004	Dec 23, 1999	Jan	CAHN

DINOPROSTONEINSERT, EXTENDED RELEASE; VAGINAL
CERVIDIL

+ FERRING PHARMS INC 10MG

N020411 001 Mar 30, 1995 Jan CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

		@ HIKMA PHARMS	50MG	A083567	001		Feb	CAHN
>D>		@ MUTUAL PHARM	25MG	A089488	001	Jan 02, 1987	Mar	CAHN
>A>		@ SUN PHARM INDS	25MG	A089488	001	Jan 02, 1987	Mar	CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

		@ AUROLIFE PHARMA LLC	EQ 100MG BASE	A070470	001	Dec 10, 1985	Feb	CAHN
		@	EQ 150MG BASE	A070471	001	Dec 10, 1985	Feb	CAHN
>D>		@ MUTUAL PHARM	EQ 100MG BASE	A070351	001	Dec 17, 1985	Mar	CAHN
>D>		@	EQ 150MG BASE	A070352	001	Dec 17, 1985	Mar	CAHN
>A>		@ SUN PHARM INDS	EQ 100MG BASE	A070351	001	Dec 17, 1985	Mar	CAHN
>A>		@	EQ 150MG BASE	A070352	001	Dec 17, 1985	Mar	CAHN

DISULFIRAM

TABLET; ORAL

DISULFIRAM

AB		ALVOGEN MALTA	250MG	A091681	001	Aug 08, 2013	Jan	CAHN
----	--	---------------	-------	---------	-----	--------------	-----	------

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

@ IMPAX LABS EQ 250MG VALPROIC ACID
 @ EQ 500MG VALPROIC ACID

A078791 001 May 06, 2009 Feb DISC
 A078791 002 Aug 04, 2009 Feb DISC

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

@ TELIGENT PHARMA INC EQ 12.5MG BASE/ML

A074098 001 Feb 21, 1995 Jan CAHN

DOCETAXEL

SOLUTION; IV (INFUSION)

DOCETAXEL

EAGLE PHARMS 20MG/ML (20MG/ML)
 80MG/4ML (20MG/ML)
 160MG/8ML (20MG/ML)

N205934 001 Dec 22, 2015 Jan CAHN
 N205934 002 Dec 22, 2015 Jan CAHN
 N205934 003 Dec 22, 2015 Jan CAHN

DOLASETRON MESYLATEINJECTABLE; INJECTION
ANZEMET

+	US PHARM HOLDINGS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997	Jan	CAHN
+		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997	Jan	CAHN
+		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001	Jan	CAHN

TABLET; ORAL
ANZEMET

	US PHARM HOLDINGS	50MG	N020623	001	Sep 11, 1997	Jan	CAHN
+		100MG	N020623	002	Sep 11, 1997	Jan	CAHN

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	DEXCEL PHARMA	23MG	A203713	001	Feb 19, 2016	Feb	NEWA	
>A>	AB	INDICUS PHARMA	23MG	A203419	001	Apr 12, 2016	Mar	NEWA
AB	OSMOTICA PHARM CORP	23MG	A203114	001	Jan 26, 2016	Jan	NEWA	

TABLET, ORALLY DISINTEGRATING; ORAL
DONEPEZIL HYDROCHLORIDE

>D>	@	MUTUAL PHARM	5MG	A077975	002	Dec 11, 2009	Mar	CAHN
>D>	@		10MG	A077975	001	Dec 11, 2009	Mar	CAHN
>A>	@	SUN PHARM INDS	5MG	A077975	002	Dec 11, 2009	Mar	CAHN
>A>	@		10MG	A077975	001	Dec 11, 2009	Mar	CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

>A>	@	IDT AUSTRALIA LTD	EQ 1MG BASE	A075432	001	Oct 18, 2000	Mar	CAHN
>A>	@		EQ 2MG BASE	A075432	002	Oct 18, 2000	Mar	CAHN
>A>	@		EQ 4MG BASE	A075432	003	Oct 18, 2000	Mar	CAHN
>A>	@		EQ 8MG BASE	A075432	004	Oct 18, 2000	Mar	CAHN
>D>	@	SANDOZ	EQ 1MG BASE	A075432	001	Oct 18, 2000	Mar	CAHN
>D>	@		EQ 2MG BASE	A075432	002	Oct 18, 2000	Mar	CAHN
>D>	@		EQ 4MG BASE	A075432	003	Oct 18, 2000	Mar	CAHN
>D>	@		EQ 8MG BASE	A075432	004	Oct 18, 2000	Mar	CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

>D>	@	MUTUAL PHARM	EQ 50MG BASE	A071653	001	Feb 18, 1988	Mar	CAHN
>D>	@		EQ 75MG BASE	A071654	001	Feb 18, 1988	Mar	CAHN
>D>	@		EQ 100MG BASE	A071521	001	Feb 18, 1988	Mar	CAHN
>A>	@	SUN PHARM INDS	EQ 50MG BASE	A071653	001	Feb 18, 1988	Mar	CAHN
>A>	@		EQ 75MG BASE	A071654	001	Feb 18, 1988	Mar	CAHN
>A>	@		EQ 100MG BASE	A071521	001	Feb 18, 1988	Mar	CAHN

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 3MG BASE	A202337	001	Jan 20, 2016	Jan	NEWA
AB		EQ 6MG BASE	A202337	002	Jan 20, 2016	Jan	NEWA

DOXERCALCIFEROL

INJECTABLE; INJECTION

DOXERCALCIFEROL

>A>	AP	AKORN INC	2MCG/ML (2MCG/ML)	A203929	002	Mar 28, 2016	Mar	NEWA
		HECTOROL						
>D>		GENZYME CORP	2MCG/ML (2MCG/ML)	N021027	002	Apr 06, 2000	Mar	CFTG
>A>	AP		2MCG/ML (2MCG/ML)	N021027	002	Apr 06, 2000	Mar	CFTG

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

>A>	AB	G AND W LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	Mar	CAHN
>A>	AB		EQ 75MG BASE	A204446	002	May 28, 2015	Mar	CAHN
>A>	AB		EQ 100MG BASE	A204446	003	May 28, 2015	Mar	CAHN
>D>	AB	NOVEL LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	Mar	CAHN
>D>	AB		EQ 75MG BASE	A204446	002	May 28, 2015	Mar	CAHN
>D>	AB		EQ 100MG BASE	A204446	003	May 28, 2015	Mar	CAHN
	AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A205115	001	Feb 18, 2016	Feb	NEWA
	AB		EQ 75MG BASE	A205115	002	Feb 18, 2016	Feb	NEWA
	AB		EQ 100MG BASE	A205115	003	Feb 18, 2016	Feb	NEWA

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

>D>	AB	MUTUAL PHARM	EQ 100MG BASE	A 062676	001	Jul 10, 1986	Mar CAHN
>A>	AB	SUN PHARM INDS	EQ 100MG BASE	A 062676	001	Jul 10, 1986	Mar CAHN

TABLET;ORAL

DOXYCYCLINE HYCLATE

>D>	AB	COREPHARMA	EQ 20MG BASE	A 065182	001	May 13, 2005	Mar DISC
>A>		@	EQ 20MG BASE	A 065182	001	May 13, 2005	Mar DISC
>D>	AB	MUTUAL PHARM	EQ 100MG BASE	A 062677	001	Jul 10, 1986	Mar CAHN
>D>	AB	MUTUAL PHARMA	EQ 20MG BASE	A 065134	001	May 13, 2005	Mar CAHN
>A>	AB	SUN PHARM INDS	EQ 20MG BASE	A 065134	001	May 13, 2005	Mar CAHN
>A>	AB		EQ 100MG BASE	A 062677	001	Jul 10, 1986	Mar CAHN
>D>	AB	VINTAGE PHARMS	EQ 100MG BASE	A 062538	001	Apr 07, 1986	Mar DISC
>A>		@	EQ 100MG BASE	A 062538	001	Apr 07, 1986	Mar DISC

TABLET, DELAYED RELEASE;ORAL

DOXYCYCLINE HYCLATE

>D>	AB	IMPAX LABS INC	EQ 75MG BASE	A 090505	001	Dec 28, 2010	Mar DISC
>A>		@	EQ 75MG BASE	A 090505	001	Dec 28, 2010	Mar DISC
>D>	AB		EQ 100MG BASE	A 090505	002	Dec 28, 2010	Mar DISC
>A>		@	EQ 100MG BASE	A 090505	002	Dec 28, 2010	Mar DISC

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

MELAMISA

	AB	NOVAST LABS LTD	3MG;0.02MG	A 202016	001	Jan 26, 2016	Jan NEWA
--	----	-----------------	------------	----------	-----	--------------	----------

TABLET;ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

>A>	AB	GLENMARK PHARMS LTD	3MG;0.03MG	A 204848	001	Mar 25, 2016	Mar NEWA
-----	----	---------------------	------------	----------	-----	--------------	----------

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

	AB	BIONPHARMA INC	0.5MG	A 200899	001	Nov 20, 2015	Jan CAHN
	AB	INTERGEL PHARMS INC	0.5MG	A 206373	001	Mar 17, 2016	Feb NEWA
>D>	AB	STRIDES ARCOLAB LTD	0.5MG	A 204262	001	Nov 20, 2015	Mar CAHN
>A>	AB	STRIDES PHARMA	0.5MG	A 204262	001	Nov 20, 2015	Mar CAHN

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

TENSILON

@ TELIGENT PHARMA INC 10MG/ML

N 007959 001 Jan CAHN

TENSILON PRESERVATIVE FREE

@ TELIGENT PHARMA INC 10MG/ML

N 007959 002 Jan CAHN

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ

	AB	MYLAN LABS LTD	600MG	A 091471	001	Feb 17, 2016	Feb NEWA
--	----	----------------	-------	----------	-----	--------------	----------

SUSTIVA

	AB	+ BRISTOL MYERS SQUIBB	600MG	N 021360	002	Feb 01, 2002	Feb CFTG
--	----	------------------------	-------	----------	-----	--------------	----------

ELBASVIR; GRAZOPREVIR

TABLET;ORAL

ZEPATIER

		+ MERCK SHARP DOHME	50MG;100MG	N 208261	001	Jan 28, 2016	Jan NEWA
--	--	---------------------	------------	----------	-----	--------------	----------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

>A>							
>A>							
>A>							
>A>		+ GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N 208351	001	Mar 01, 2016	Mar NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TRUVADA

>A>		GILEAD	100MG;150MG	N 021752	002	Mar 10, 2016	Mar NEWA
>A>			133MG;200MG	N 021752	003	Mar 10, 2016	Mar NEWA
>A>			167MG;250MG	N 021752	004	Mar 10, 2016	Mar NEWA

EPINASTINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
EPINASTINE HYDROCHLORIDE

>D>	AT	GAVIS PHARMS LLC	0.05%	A090951	001	Oct 31, 2011	Mar	CAHN
>A>	AT	SOMERSET THERAPS LLC	0.05%	A090951	001	Oct 31, 2011	Mar	CAHN

EPINEPHRINEINJECTABLE;INJECTION
SUS-PHRINE SULFITE FREE

>A>	@	FOREST LABS	1.5MG/AMP	N007942	003	Feb 05, 1999	Mar	CMS1
>A>	@		5MG/ML	N007942	001		Mar	CMS1
>D>	@	FOREST LABS	1.5MG/AMP	N007942	003	Feb 05, 1999	Mar	CMS1
>D>	@		5MG/ML	N007942	001		Mar	CMS1

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
AUVI-Q

>A>	BX	+ KALEO INC	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012	Mar	CAHN
>A>	BX		EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012	Mar	CAHN
>D>	BX	+ SANOFI AVENTIS US	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012	Mar	CAHN
>D>	BX		EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012	Mar	CAHN

EPINEPHRINE HYDROCHLORIDESOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE

		BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Feb	CDFR
--	--	--------------------	---------------------------------	---------	-----	--------------	-----	------

ERGOCALCIFEROLCAPSULE;ORAL
DRISDOL

AA	+	US PHARM HOLDINGS	50,000 IU	N003444	001		Jan	CAHN
AA		BIONPHARMA INC	50,000 IU	A080704	001		Jan	CAHN

ERGOLOID MESYLATESTABLET;ORAL
ERGOLOID MESYLATES

>D>	AB	MUTUAL PHARM	1MG	A081113	001	Oct 31, 1991	Mar	CAHN
>A>	AB	SUN PHARM INDS	1MG	A081113	001	Oct 31, 1991	Mar	CAHN

ERYTHROMYCINSOLUTION;TOPICAL
C-SOLVE-2

	@	FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985	Feb	DISC
	@	HI TECH PHARMA	2%	A064101	001	Oct 22, 1996	Feb	DISC
AT	+	FOUGERA PHARMS	2%	A064187	001	Sep 30, 1997	Jan	CRLD
AT		PERRIGO NEW YORK	2%	A063038	001	Jan 11, 1991	Jan	CRLD

ESCITALOPRAM OXALATESOLUTION;ORAL
ESCITALOPRAM OXALATE

>A>	AA	MACLEODS PHARMS LTD	EQ 5MG BASE/5ML	A202754	001	Mar 31, 2016	Mar	NEWA
-----	----	---------------------	-----------------	---------	-----	--------------	-----	------

ESTRADIOLFILM, EXTENDED RELEASE;TRANSDERMAL
ALORA

>D>	BX	ACTAVIS LABS UT INC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar	CAHN
>D>	BX		0.05MG/24HR	N020655	001	Dec 20, 1996	Mar	CAHN
>D>	BX		0.075MG/24HR	N020655	002	Dec 20, 1996	Mar	CAHN
>D>	BX		0.1MG/24HR	N020655	003	Dec 20, 1996	Mar	CAHN
>A>	BX	ALLERGAN SALES LLC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar	CAHN
>A>	BX		0.05MG/24HR	N020655	001	Dec 20, 1996	Mar	CAHN
>A>	BX		0.075MG/24HR	N020655	002	Dec 20, 1996	Mar	CAHN
>A>	BX		0.1MG/24HR	N020655	003	Dec 20, 1996	Mar	CAHN

ESTRADIOL ACETATEINSERT, EXTENDED RELEASE;VAGINAL
FEMRING

	ALLERGAN PHARMS INTL	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	Jan	CAHN
+		EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	Jan	CAHN

TABLET;ORAL

FEMTRACE

	ALLERGAN PHARMS INTL	0.45MG	N021633	001	Aug 20, 2004	Jan	CAHN
		0.9MG	N021633	002	Aug 20, 2004	Jan	CAHN
+		1.8MG	N021633	003	Aug 20, 2004	Jan	CAHN

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

AB	JAI PHARMA LTD	0.05MG;1MG	A204704	001	Feb 09, 2016	Jan	NEWA
AB	+ WATSON LABS	0.05MG;1MG	A072723	001	Dec 30, 1991	Jan	CTEC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

>A>	FAYOSIM						
>A> AB	LUPIN LTD	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	A205943	001	Mar 29, 2016	Mar	NEWA
>D>	+ TEVA BRANDED PHARM	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061	001	Mar 28, 2013	Mar	CFTG
>A> AB	+	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061	001	Mar 28, 2013	Mar	CFTG

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

NORINYL 1+35 21-DAY

>D> AB	ACTAVIS LABS UT INC	0.035MG;1MG	N017565	001		Mar	CAHN
>A> AB	ALLERGAN SALES LLC	0.035MG;1MG	N017565	001		Mar	CAHN

TABLET;ORAL-28

BREVICON 28-DAY

>D> AB	ACTAVIS LABS UT INC	0.035MG;0.5MG	N017743	001		Mar	CAHN
>A> AB	ALLERGAN SALES LLC	0.035MG;0.5MG	N017743	001		Mar	CAHN
>D> AB	ACTAVIS LABS UT INC	0.035MG;1MG	N017565	002		Mar	CAHN
>A> AB	ALLERGAN SALES LLC	0.035MG;1MG	N017565	002		Mar	CAHN

TABLET, CHEWABLE;ORAL

FEMCON FE

AB	+ ALLERGAN PHARMS INTL	0.035MG;0.4MG	N021490	001	Nov 14, 2003	Jan	CAHN
AB	+ ALLERGAN PHARMS INTL	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jan	CAHN
>A> AB	LUPIN LTD	0.035MG;0.4MG	A091332	001	Mar 23, 2016	Mar	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

FEMHRT

AB	ALLERGAN PHARMS INTL	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Jan	CAHN
	@	0.005MG;1MG	N021065	002	Oct 15, 1999	Jan	CAHN

LO LOESTRIN FE

+	ALLERGAN PHARMS INTL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	Jan	CAHN
---	----------------------	-----------------------	---------	-----	--------------	-----	------

TABLET;ORAL-21

ESTROSTEP 21

AB	@ ALLERGAN PHARMS INTL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	001	Oct 09, 1996	Jan	CAHN
AB	GLENMARK PHARMS LTD	0.02MG;1MG	A206969	001	Jan 20, 2016	Jan	NEWA

TABLET;ORAL-28

ESTROSTEP FE

AB	+ ALLERGAN PHARMS INTL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	002	Oct 09, 1996	Jan	CAHN
----	------------------------	-----------------------------------	---------	-----	--------------	-----	------

TABLET, CHEWABLE;ORAL

MINASTRIN 24 FE

+	ALLERGAN PHARMS INTL	0.02MG;1MG	N203667	001	May 08, 2013	Jan	CAHN
---	----------------------	------------	---------	-----	--------------	-----	------

TABLET, CHEWABLE, TABLET;ORAL

LO MINASTRIN FE

+	ALLERGAN PHARMS INTL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jan	CAHN
---	----------------------	-------------------------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	GLENMARK PHARMS LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A204057	001	Feb 23, 2016	Feb	NEWA
AB	JAI PHARMA LTD	0.035MG, 0.035MG, 0.035MG;0.18MG, 0.215MG, 0.25MG	A201897	001	Jan 27, 2016	Jan	NEWA
AB		0.035MG;0.25MG	A201896	001	Jan 27, 2016	Jan	NEWA

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

AB	BIONPHARMA INC	250MG	A040430	001	Oct 28, 2002	Jan	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

ETODOLAC

CAPSULE;ORAL

ETODOLAC

@ LEHIGH VALLEY

300MG

A074929 001 Jan 30, 1998 Feb CAHN

ETOMIDATE

INJECTABLE;INJECTION

ETOMIDATE

AP	HIKMA FARMACEUTICA	2MG/ML	A202354	001	Feb 25, 2016	Feb	NEWA
----	--------------------	--------	---------	-----	--------------	-----	------

EXEMESTANE

TABLET;ORAL

EXEMESTANE

AB	ALVOGEN MALTA	25MG	A200898	001	Jul 28, 2014	Jan	CAHN
----	---------------	------	---------	-----	--------------	-----	------

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

BYDUREON PEN

+ ASTRAZENECA AB

2MG

N022200 002 Feb 28, 2014 Feb NEWA

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

>D>	@ MUTUAL PHARM	20MG	A075639	002	Dec 12, 2001	Mar	CAHN
>D>	@	40MG	A075639	001	Dec 12, 2001	Mar	CAHN
>A>	@ SUN PHARM INDS	20MG	A075639	002	Dec 12, 2001	Mar	CAHN
>A>	@	40MG	A075639	001	Dec 12, 2001	Mar	CAHN

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

>D>	AB	MUTUAL PHARM	2.5MG	A075896	001	Nov 02, 2004	Mar	CAHN
>D>	AB		5MG	A075896	002	Nov 02, 2004	Mar	CAHN
>D>	AB		10MG	A075896	003	Nov 02, 2004	Mar	CAHN
>A>	AB	SUN PHARM INDS	2.5MG	A075896	001	Nov 02, 2004	Mar	CAHN
>A>	AB		5MG	A075896	002	Nov 02, 2004	Mar	CAHN
>A>	AB		10MG	A075896	003	Nov 02, 2004	Mar	CAHN

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

>A>	@ AUROLIFE PHARMA LLC	EQ 200MG BASE	A072394	001	Oct 17, 1988	Mar	CAHN
	@	EQ 300MG BASE	A072395	001	Oct 17, 1988	Feb	CAHN
>D>	@ SANDOZ	EQ 200MG BASE	A072394	001	Oct 17, 1988	Mar	CAHN

TABLET;ORAL

FENOPROFEN CALCIUM

>D>	@ AUROLIFE PHARMA LLC	EQ 600MG BASE	A072396	001	Oct 17, 1988	Feb	CAHN
>D>	@ MUTUAL PHARM	EQ 600MG BASE	A072902	001	Dec 21, 1990	Mar	CAHN
>A>	@ SUN PHARM INDS	EQ 600MG BASE	A072902	001	Dec 21, 1990	Mar	CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-12

AB	AVEVA	12.5MCG/HR	A077449	005	Sep 11, 2015	Jan	NEWA
----	-------	------------	---------	-----	--------------	-----	------

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

@ ALKEM LABS LTD 4MG A204827 001 Dec 10, 2015 Jan DISC
@ 8MG A204827 002 Dec 10, 2015 Jan DISC

>D> FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

>D> FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D> AB BARR 60MG;120MG A076236 001 Apr 14, 2005 Mar DISC
>A> @ 60MG;120MG A076236 001 Apr 14, 2005 Mar DISC
>D> AB IMPAX PHARMS 60MG;120MG A076298 001 Nov 12, 2010 Mar DISC
>A> @ 60MG;120MG A076298 001 Nov 12, 2010 Mar DISC

FLAVOXATE HYDROCHLORIDE

TABLET;ORAL

FLAVOXATE HYDROCHLORIDE

>D> AB IMPAX PHARMS 100MG A076234 001 Aug 28, 2003 Mar DISC
>A> @ 100MG A076234 001 Aug 28, 2003 Mar DISC

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

@ SUN PHARM INDS LTD 50MG/5ML A076332 001 Jul 29, 2004 Feb DISC
@ 200MG/5ML A076332 002 Jul 29, 2004 Feb DISC

INJECTABLE;INJECTION

FLUCANAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D> AP ACS DOBFAR INFO SA 200MG/100ML (2MG/ML) A079104 001 Jul 30, 2009 Mar CMS1
>D> AP 400MG/200ML (2MG/ML) A079104 002 Jul 30, 2009 Mar CMS1
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%
@ TEVA PHARMS USA 200MG/100ML (2MG/ML) A076653 001 Jul 29, 2004 Jan DISC
@ 400MG/200ML (2MG/ML) A076653 002 Jul 29, 2004 Jan DISC
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
>A> AP ACS DOBFAR INFO SA 200MG/100ML (2MG/ML) A079104 001 Jul 30, 2009 Mar CMS1
>A> AP 400MG/200ML (2MG/ML) A079104 002 Jul 30, 2009 Mar CMS1

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

>A> AP KREITCHMAN PET CTR 10-100mCi/ML A203942 001 Apr 11, 2016 Mar NEWA
>D> QUEEN HAMAMATSU PET 10-100mCi/ML A203771 001 Aug 31, 2015 Mar CTEC
>A> AP + 10-100mCi/ML A203771 001 Aug 31, 2015 Mar CTEC
AP ZEVACOR PHARMA INC 20-300mCi/ML A203591 001 Aug 31, 2015 Feb CAHN

FLUOROURACIL

INJECTABLE;INJECTION

FLUOROURACIL

AP SAGENT PHARMS 2.5GM/50ML (50MG/ML) A203609 001 Feb 17, 2016 Feb NEWA
AP 5GM/100ML (50MG/ML) A203609 002 Feb 17, 2016 Feb NEWA
@ SPECTRUM PHARMS 500MG/10ML (50MG/ML) N012209 001 Jan CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE

>D> @ MUTUAL PHARMA EQ 10MG BASE A075787 001 Jan 29, 2002 Mar CAHN
>D> @ EQ 20MG BASE A075787 002 Jan 29, 2002 Mar CAHN
>A> @ SUN PHARM INDS EQ 10MG BASE A075787 001 Jan 29, 2002 Mar CAHN
>A> @ EQ 20MG BASE A075787 002 Jan 29, 2002 Mar CAHN

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

>D> EDMONT PHARMS LLC EQ 60MG BASE N202133 001 Oct 06, 2011 Mar CRLD
>A> + EQ 60MG BASE N202133 001 Oct 06, 2011 Mar CRLD
SARAFEM
AB1 ALLERGAN PHARMS INTL EQ 10MG BASE N021860 001 May 19, 2006 Jan CAHN
AB1 EQ 15MG BASE N021860 002 May 19, 2006 Jan CAHN
AB1 + EQ 20MG BASE N021860 003 May 19, 2006 Jan CAHN

FLURANDRENOLIDECREAM; TOPICAL
CORDRAN SP

>D>	+	AQUA PHARMS	0.05%		N012806	002			Mar	CFTG
>A>	AT	+	0.05%		N012806	002			Mar	CFTG
>A>		FLURANDRENOLIDE								
>A>	AT	TELIGENT PHARMA INC	0.05%		A205342	001	Apr 13, 2016		Mar	NEWA

FLURANDRENOLIDE; NEOMYCIN SULFATECREAM; TOPICAL
CORDRAN N

>A>		@ LILLY	0.05%;EQ 3.5MG BASE/GM		N050346	001			Mar	CMS1
>D>		CORDRAN-N								
>D>		@ LILLY	0.05%;EQ 3.5MG BASE/GM		N050346	001			Mar	CMS1

OINTMENT; TOPICAL
CORDRAN N

>A>		@ LILLY	0.05%;EQ 3.5MG BASE/GM		N050345	001			Mar	CMS1
>D>		CORDRAN-N								
>D>		@ LILLY	0.05%;EQ 3.5MG BASE/GM		N050345	001			Mar	CMS1

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

		@ AUROLIFE PHARMA LLC	15MG		A071716	001	Jul 31, 1991		Feb	CAHN
		@	30MG		A071717	001	Jul 31, 1991		Feb	CAHN
>D>		@ MUTUAL PHARM	15MG		A070454	001	Aug 04, 1986		Mar	CAHN
>D>		@	30MG		A070455	001	Aug 04, 1986		Mar	CAHN
>A>		@ SUN PHARM INDS	15MG		A070454	001	Aug 04, 1986		Mar	CAHN
>A>		@	30MG		A070455	001	Aug 04, 1986		Mar	CAHN

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

		@ AUROLIFE PHARMA LLC	50MG		A074448	001	Jul 28, 1995		Feb	CAHN
		@	100MG		A074448	002	Jul 28, 1995		Feb	CAHN

FLUTICASONE FUROATEPOWDER; INHALATION
ARNUITY ELLIPTA

>D>		GLAXOSMITHKLINE	0.1MG/INH		N205625	001	Aug 20, 2014		Mar	CRLD
>A>		+	0.1MG/INH		N205625	001	Aug 20, 2014		Mar	CRLD

FLUTICASONE FUROATE; VILANTEROL TRIFENATATEPOWDER; INHALATION
BREQ ELLIPTA

>D>		GLAXO GRP LTD	0.2MG/INH;EQ 0.025MG BASE/INH		N204275	002	Apr 30, 2015		Mar	CRLD
>A>		+	0.2MG/INH;EQ 0.025MG BASE/INH		N204275	002	Apr 30, 2015		Mar	CRLD

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE; ORAL

FLUVASTATIN SODIUM

AB		TEVA PHARMS USA	80MG		A079011	001	Jan 27, 2016		Jan	NEWA
----	--	-----------------	------	--	---------	-----	--------------	--	-----	------

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

>D>		@ MUTUAL PHARM	25MG		A076125	001	Apr 29, 2002		Mar	CAHN
>D>		@	50MG		A076125	002	Apr 29, 2002		Mar	CAHN
>D>		@	100MG		A076125	003	Apr 29, 2002		Mar	CAHN
		@ NOSTRUM LABS INC	25MG		A075900	001	Feb 23, 2006		Feb	CAHN
		@	50MG		A075900	002	Feb 23, 2006		Feb	CAHN
		@	100MG		A075900	003	Feb 23, 2006		Feb	CAHN
>A>		@ SUN PHARM INDS	25MG		A076125	001	Apr 29, 2002		Mar	CAHN
>A>		@	50MG		A076125	002	Apr 29, 2002		Mar	CAHN
>A>		@	100MG		A076125	003	Apr 29, 2002		Mar	CAHN

FOLIC ACID

TABLET;ORAL

FOLIC ACID

>D>	@ MUTUAL PHARM	1MG	A040582	001	Jul 18, 2005	Mar	CAHN
>A>	@ SUN PHARM INDS	1MG	A040582	001	Jul 18, 2005	Mar	CAHN

FOSINOPRIL SODIUM

TABLET;ORAL

FOSINOPRIL SODIUM

	@ ACTAVIS LABS FL INC	10MG	A076620	001	Oct 15, 2004	Jan	DISC
	@	20MG	A076620	002	Oct 15, 2004	Jan	DISC
	@	40MG	A076620	003	Oct 15, 2004	Jan	DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

	@ ACTAVIS LABS FL INC	10MG;12.5MG	A076608	001	Dec 03, 2004	Jan	DISC
	@	20MG;12.5MG	A076608	002	Dec 03, 2004	Jan	DISC
	@ SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004	Feb	DISC
	@	20MG;12.5MG	A076739	002	Dec 17, 2004	Feb	DISC

FROVATRIPTAN SUCCINATE

TABLET;ORAL

FROVATRIPTAN SUCCINATE

AB	GLENMARK PHARMS LTD	EQ 2.5MG BASE	A204730	001	Mar 11, 2016	Feb	NEWA
----	---------------------	---------------	---------	-----	--------------	-----	------

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

	@ EUROHLTH INTL SARL	10MG/ML	A071439	001	Sep 14, 1990	Jan	CAHN
	@ LUITPOLD	10MG/ML	N018579	001	Nov 30, 1983	Feb	DISC

TABLET;ORAL

FUROSEMIDE

>D>	@ MUTUAL PHARM	20MG	A070043	001	Sep 26, 1985	Mar	CAHN
>A>	@ SUN PHARM INDS	20MG	A070043	001	Sep 26, 1985	Mar	CAHN
	LASIX						
AB	US PHARM HOLDINGS	20MG	N016273	002		Jan	CAHN
AB		40MG	N016273	001		Jan	CAHN
AB	+	80MG	N016273	003		Jan	CAHN

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

>D>	@ MUTUAL PHARM	100MG	A076537	001	Jun 30, 2005	Mar	CAHN
>D>	@	300MG	A076537	002	Jun 30, 2005	Mar	CAHN
>D>	@	400MG	A076537	003	Jun 30, 2005	Mar	CAHN
AB	SCIEGEN PHARMS INC	100MG	A204989	001	Feb 18, 2016	Feb	NEWA
AB		300MG	A204989	002	Feb 18, 2016	Feb	NEWA
AB		400MG	A204989	003	Feb 18, 2016	Feb	NEWA
>A>	@ SUN PHARM INDS	100MG	A076537	001	Jun 30, 2005	Mar	CAHN
>A>	@	300MG	A076537	002	Jun 30, 2005	Mar	CAHN
>A>	@	400MG	A076537	003	Jun 30, 2005	Mar	CAHN

SOLUTION;ORAL

GABAPENTIN

AA	TRIS PHARMA INC	250MG/5ML	A091286	001	Mar 14, 2016	Feb	NEWA
----	-----------------	-----------	---------	-----	--------------	-----	------

TABLET;ORAL

GABAPENTIN

AB	SCIEGEN PHARMS INC	600MG	A205101	001	Feb 04, 2016	Jan	NEWA
AB		800MG	A205101	002	Feb 04, 2016	Jan	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

GALANTAMINE HYDROBROMIDE

	@ IMPAX LABS	EQ 8MG BASE	A078484	001	May 27, 2009	Feb	DISC
	@	EQ 16MG BASE	A078484	002	May 27, 2009	Feb	DISC
	@	EQ 24MG BASE	A078484	003	May 27, 2009	Feb	DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

>A>		GEMCITABINE HYDROCHLORIDE					
>A>	AP	ACTAVIS INC	200MG/5.26ML (38MG/ML)	A204549	001	Apr 11, 2016	Mar NEWA
>A>	AP		1GM/26.3ML (38MG/ML)	A204549	002	Apr 11, 2016	Mar NEWA
>A>	AP		2GM/52.6ML (38MG/ML)	A204549	003	Apr 11, 2016	Mar NEWA
>D>	+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Mar CFTG
>A>	AP	+	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Mar CFTG
>D>	+		1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Mar CFTG
>A>	AP	+	1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Mar CFTG
>D>	+		2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Mar CFTG
>A>	AP	+	2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Mar CFTG

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

@	ACTAVIS LABS FL INC	1MG	A076995	001	Apr 27, 2010	Jan DISC
@		2MG	A076995	002	Apr 27, 2010	Jan DISC
@		4MG	A076995	003	Apr 27, 2010	Jan DISC

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

>A>		ROSIGLITAZONE MALEATE AND GLIMEPIRIDE					
>A>	+	TEVA PHARMS USA	1MG; 4MG	A078709	001	Apr 01, 2016	Mar NEWA
>A>			2MG; 4MG	A078709	002	Apr 01, 2016	Mar NEWA
>A>			2MG; 8MG	A078709	004	Apr 01, 2016	Mar NEWA
>A>			4MG; 4MG	A078709	003	Apr 01, 2016	Mar NEWA
>A>			4MG; 8MG	A078709	005	Apr 01, 2016	Mar NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

@	COREPHARMA	1.25MG; 250MG	A076731	001	Nov 19, 2004	Jan DISC
@		2.5MG; 500MG	A076731	002	Nov 19, 2004	Jan DISC
@		5MG; 500MG	A076731	003	Nov 19, 2004	Jan DISC
AB	ZYDUS PHARMS USA INC	1.25MG; 250MG	A206748	001	Feb 29, 2016	Feb NEWA
AB		2.5MG; 500MG	A206748	002	Feb 29, 2016	Feb NEWA
AB		5MG; 500MG	A206748	003	Feb 29, 2016	Feb NEWA

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

AP	+	HIKMA FARMACEUTICA	0.2MG/ML	A090963	001	Sep 21, 2011	Feb CRLD
		ROBINUL					
	@	EUROHLTH INTL SARL	0.2MG/ML	N017558	001		Feb DISC

TABLET; ORAL

GLYCOPYRROLATE

AA		RISING PHARMS INC	1MG	A040821	001	Dec 29, 2008	Jan CAHN
AA			2MG	A040821	002	Dec 29, 2008	Jan CAHN
		ROBINUL					
AA	+	CASPER PHARMA LLC	1MG	N012827	001		Jan CAHN
		ROBINUL FORTE					
AA	+	CASPER PHARMA LLC	2MG	N012827	002		Jan CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP		BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan CAHN
AP		HIKMA FARMACEUTICA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078629	001	Dec 23, 2009	Jan CMS1
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078629	002	Dec 23, 2009	Jan CMS1

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

AP		BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN
----	--	----------------	---------------------------------	---------	-----	--------------	----------

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

>D>	AB	COREPHARMA	EQ 1MG BASE	A078260	001	Dec 31, 2007	Mar DISC
>A>	@		EQ 1MG BASE	A078260	001	Dec 31, 2007	Mar DISC

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
GUANFACINE HYDROCHLORIDE

>D>	AB	IMPAX LABS INC	EQ 1MG BASE	A202238	001	Oct 20, 2015	Mar	DISC
>A>		@	EQ 1MG BASE	A202238	001	Oct 20, 2015	Mar	DISC
>D>	AB		EQ 2MG BASE	A202238	002	Oct 20, 2015	Mar	DISC
>A>		@	EQ 2MG BASE	A202238	002	Oct 20, 2015	Mar	DISC
>D>	AB		EQ 3MG BASE	A202238	003	Oct 20, 2015	Mar	DISC
>A>		@	EQ 3MG BASE	A202238	003	Oct 20, 2015	Mar	DISC
>D>	AB		EQ 4MG BASE	A202238	004	Oct 20, 2015	Mar	DISC
>A>		@	EQ 4MG BASE	A202238	004	Oct 20, 2015	Mar	DISC

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

>D>		@	CYCLE PHARMS LTD	2MG	A071130	001	Feb 17, 1987	Jan	CAHN
>A>		@	MUTUAL PHARM	10MG	A071173	001	Jan 07, 1988	Mar	CAHN
>D>		@	SUN PHARM INDS	10MG	A071173	001	Jan 07, 1988	Mar	CAHN
>A>		@	VINTAGE	0.5MG	A071235	002	Nov 03, 1986	Jan	CMS1
		@		1MG	A071235	003	Nov 03, 1986	Jan	CMS1
		@		5MG	A071235	004	Nov 03, 1986	Jan	CMS1
		@		10MG	A071235	005	Jul 20, 1987	Jan	CMS1

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET;ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

		@	ACTAVIS ELIZABETH	1.5MG;5MG	A040295	001	Dec 01, 2000	Jan	CMS1
--	--	---	-------------------	-----------	---------	-----	--------------	-----	------

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

>D>		@	MUTUAL PHARM	10MG	A089359	001	Jul 25, 1986	Mar	CAHN
>D>		@		25MG	A089258	001	May 05, 1986	Mar	CAHN
>D>		@		50MG	A089259	001	May 05, 1986	Mar	CAHN
>A>		@	SUN PHARM INDS	10MG	A089359	001	Jul 25, 1986	Mar	CAHN
>A>		@		25MG	A089258	001	May 05, 1986	Mar	CAHN
>A>		@		50MG	A089259	001	May 05, 1986	Mar	CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDRALAZINE AND HYDROCHLOROTHIAZIDE

		@	WATSON LABS	25MG;15MG	A085827	001		Feb	CMS1
--	--	---	-------------	-----------	---------	-----	--	-----	------

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL

RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>D>		@	MUTUAL PHARM	25MG;15MG;0.1MG	A088570	001	Apr 10, 1984	Mar	CAHN
>A>		@	SUN PHARM INDS	25MG;15MG;0.1MG	A088570	001	Apr 10, 1984	Mar	CAHN

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE

		@	AUROLIFE PHARMA LLC	25MG	A083899	001		Feb	CAHN
		@		50MG	A085219	001		Feb	CAHN
		@	ORETIC						
		@	ABBVIE	50MG	N011971	002		Jan	DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

>A>	AB	AUROBINDO PHARMA LTD	25MG;300MG	A203630	003	Mar 31, 2016	Mar	NEWA
	AB	INTL SPECLT CHEMS	12.5MG;150MG	A203036	001	Jan 15, 2016	Jan	NEWA
	AB		12.5MG;300MG	A203036	002	Jan 15, 2016	Jan	NEWA
>D>			25MG;300MG	A203036	003	Jan 15, 2016	Mar	CTEC
>A>	AB		25MG;300MG	A203036	003	Jan 15, 2016	Mar	CTEC
			25MG;300MG	A203036	003	Jan 15, 2016	Jan	NEWA

HYDROCHLOROTHIAZIDE; LISINAPRILTABLET; ORAL
ZESTORETIC

AB		ALVOGEN MALTA	12.5MG;10MG	N019888	003	Nov 18, 1993	Jan	CAHN
AB	+		12.5MG;20MG	N019888	001	Sep 20, 1990	Jan	CAHN
AB	+		25MG;20MG	N019888	002	Jul 20, 1989	Jan	CAHN

HYDROCHLOROTHIAZIDE; SPIRONOLACTONETABLET; ORAL
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

>D>	AB	MUTUAL PHARM	25MG;25MG	A089534	001	Jul 02, 1987	Mar	CAHN
>A>	AB	SUN PHARM INDS	25MG;25MG	A089534	001	Jul 02, 1987	Mar	CAHN

HYDROCHLOROTHIAZIDE; VALSARTANTABLET; ORAL
VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		PRINSTON INC	12.5MG;80MG	A206083	001	Feb 08, 2016	Jan	NEWA
AB			12.5MG;160MG	A206083	002	Feb 08, 2016	Jan	NEWA
AB			12.5MG;320MG	A206083	003	Feb 08, 2016	Jan	NEWA
AB			25MG;160MG	A206083	004	Feb 08, 2016	Jan	NEWA
AB			25MG;320MG	A206083	005	Feb 08, 2016	Jan	NEWA

HYDROCODONE BITARTRATE; IBUPROFENTABLET; ORAL
HYDROCODONE BITARTRATE AND IBUPROFEN
@ ACTAVIS LABS FL INC 5MG;200MG

A077454	001	Jun 23, 2010	Jan	DISC
---------	-----	--------------	-----	------

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATESUSPENSION/DROPS; OTIC
PEDIOTIC

@ MONARCH PHARMS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A062822	001	Sep 29, 1987	Jan	DISC
---------	-----	--------------	-----	------

HYDROXOCOBALAMININJECTABLE; INJECTION
CYANOKIT@ SERB SA 2.5GM/VIAL (5GM/KIT)
+ 5GM/VIAL (5GM/KIT)

N022041	002	Dec 15, 2006	Jan	CAHN
N022041	001	Apr 08, 2011	Jan	CAHN

HYDROXYCHLOROQUINE SULFATETABLET; ORAL
HYDROXYCHLOROQUINE SULFATE

AB		WATSON LABS	200MG	A040133	001	Nov 30, 1995	Feb	CMFD
----	--	-------------	-------	---------	-----	--------------	-----	------

HYDROXYPROGESTERONE CAPROATEINJECTABLE; INJECTION
HYDROXYPROGESTERONE CAPROATE

+ ASPEN GLOBAL INC 250MG/ML

A200271	001	Aug 24, 2015	Jan	CAHN
---------	-----	--------------	-----	------

SOLUTION; INTRAMUSCULAR
MAKENA

+ LUMARA HEALTH INC 250MG/ML (250MG/ML)

N021945	002	Feb 19, 2016	Feb	NEWA
---------	-----	--------------	-----	------

HYDROXYZINE HYDROCHLORIDETABLET; ORAL
HYDROXYZINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 10MG

@ 25MG

@ 50MG

>D>		@ MUTUAL PHARM	10MG	A087869	001	Dec 20, 1982	Feb	CAHN
>D>		@	25MG	A087870	001	Dec 20, 1982	Feb	CAHN
>D>		@	50MG	A087871	001	Dec 20, 1982	Feb	CAHN
>D>		@	10MG	A089381	001	May 19, 1986	Mar	CAHN
>D>		@	25MG	A089382	001	May 19, 1986	Mar	CAHN
>D>		@	50MG	A089383	001	May 19, 1986	Mar	CAHN
>D>		@	100MG	A087862	001	Apr 18, 1983	Mar	CAHN
>A>		@ SUN PHARM INDS	10MG	A089381	001	May 19, 1986	Mar	CAHN
>A>		@	25MG	A089382	001	May 19, 1986	Mar	CAHN
>A>		@	50MG	A089383	001	May 19, 1986	Mar	CAHN
>A>		@	100MG	A087862	001	Apr 18, 1983	Mar	CAHN

IBANDRONATE SODIUMINJECTABLE; INTRAVENOUS
IBANDRONATE SODIUM

AP	ACCORD HLTHCARE	EQ 3MG BASE/3ML	A206058	001	Feb 05, 2016	Jan	NEWA
	TABLET; ORAL						
	IBANDRONATE SODIUM						
AB	AUROBINDO PHARMA LTD	EQ 150MG BASE	A204502	001	Mar 11, 2016	Feb	NEWA
>D>	MUTUAL PHARM CO INC	EQ 150MG BASE	A078996	001	Aug 15, 2012	Mar	CAHN
>A>	SUN PHARM INDS	EQ 150MG BASE	A078996	001	Aug 15, 2012	Mar	CAHN

IBUPROFENTABLET; ORAL
IBUPROFEN

	@ AUROLIFE PHARMA LLC	300MG	A070734	001	Jun 12, 1986	Feb	CAHN
	@	400MG	A070735	001	Jun 12, 1986	Feb	CAHN
	@	600MG	A070736	001	Jun 12, 1986	Feb	CAHN
>A>	@	800MG	A071938	001	Jan 14, 1988	Mar	CAHN
>D>	@ MUTUAL PHARM	400MG	A070079	001	Jul 24, 1985	Mar	CAHN
>D>	@	600MG	A070080	001	Jul 24, 1985	Mar	CAHN
>D>	@	800MG	A071448	001	Feb 18, 1987	Mar	CAHN
>D>	@ SANDOZ	800MG	A071938	001	Jan 14, 1988	Mar	CAHN
>A>	@ SUN PHARM INDS	400MG	A070079	001	Jul 24, 1985	Mar	CAHN
>A>	@	600MG	A070080	001	Jul 24, 1985	Mar	CAHN
>A>	@	800MG	A071448	001	Feb 18, 1987	Mar	CAHN

IBUPROFEN LYSINEINJECTABLE; INTRAVENOUS
IBUPROFEN LYSINE

>A>	NEOPROFEN							
>A>	AP	EXELA PHARMA SCIENCE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016	Mar	NEWA
>D>	+	RECORDATI RARE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006	Mar	CFTG
>A>	AP	+	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006	Mar	CFTG

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

>D>	AB	MUTUAL PHARM	10MG	A081048	001	Jun 05, 1990	Mar	CAHN
>D>	AB		25MG	A081049	001	Jun 05, 1990	Mar	CAHN
>D>	AB		50MG	A081050	001	Jun 05, 1990	Mar	CAHN
>A>	AB	SUN PHARM INDS	10MG	A081048	001	Jun 05, 1990	Mar	CAHN
>A>	AB		25MG	A081049	001	Jun 05, 1990	Mar	CAHN
>A>	AB		50MG	A081050	001	Jun 05, 1990	Mar	CAHN

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

AB	+	ROXANE	EQ 75MG HCL	A091099	001	Apr 16, 2010	Feb	CRLD
		TOFRANIL-PM						
	@	MALLINCKRODT INC	EQ 75MG HCL	N017090	001		Feb	DISC
	@		EQ 100MG HCL	N017090	004		Feb	DISC
	@		EQ 125MG HCL	N017090	003		Feb	DISC
	@		EQ 150MG HCL	N017090	002		Feb	DISC

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION

INDIUM IN 111 CHLORIDE

+	MALLINKRODT NUCLEAR	5mCi/0.5ML	N019841	001	Sep 27, 1994	Jan	CAHN
---	---------------------	------------	---------	-----	--------------	-----	------

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION

INDIUM IN 111 OXYQUINOLINE

>A>	+	GE HEALTHCARE	1mCi/ML	N019044	001	Dec 24, 1985	Mar	CMS1
>D>	+	GE HEALTHCARE	1mCi/ML	N019044	001	Dec 24, 1985	Mar	CMS1

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

OCTREOSCAN

+	MALLINKRODT NUCLEAR	3mCi/ML	N020314	001	Jun 02, 1994	Jan	CAHN
---	---------------------	---------	---------	-----	--------------	-----	------

INDOCYANINE GREEN

	INJECTABLE; INJECTION						
	INDOCYANINE GREEN						
AP	DIAGNOSTIC GREEN	25MG/VIAL	A040811	001	Nov 21, 2007	Jan	CAHN

INSULIN DETEMIR RECOMBINANT

	INJECTABLE; SUBCUTANEOUS						
	LEVEMIR FLEXPEN						
	@ NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	002	Jun 16, 2005	Feb	DISC

INSULIN HUMAN

	SOLUTION; SUBCUTANEOUS						
	HUMULIN R						
+	LILLY	10000 UNITS/20ML (500 UNITS/ML)	N018780	004	Mar 31, 1994	Jan	CAIN
	HUMULIN R KWIKPEN						
+	LILLY	1500 UNITS/3ML (500 UNITS/ML)	N018780	002	Dec 29, 2015	Jan	NEWA

INSULIN RECOMBINANT HUMAN

	POWDER; INHALATION						
	AFREZZA						
>A>	MANNKIND	4 UNITS/INH	N022472	001	Jun 27, 2014	Mar	CAHN
>A>	+	8 UNITS/INH	N022472	002	Jun 27, 2014	Mar	CAHN
>A>		12 UNITS/INH	N022472	003	Apr 17, 2015	Mar	CAHN
>D>	SANOFI AVENTIS	4 UNITS/INH	N022472	001	Jun 27, 2014	Mar	CAHN
>D>	+	8 UNITS/INH	N022472	002	Jun 27, 2014	Mar	CAHN
>D>		12 UNITS/INH	N022472	003	Apr 17, 2015	Mar	CAHN

IRINOTECAN HYDROCHLORIDE

	INJECTABLE; INJECTION						
	IRINOTECAN HYDROCHLORIDE						
AP	SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009	Jan	CAHN
AP		100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009	Jan	CAHN

ISONIAZID

	TABLET; ORAL						
	ISONIAZID						
>D>	@ MUTUAL PHARM	100MG	A080136	001		Mar	CAHN
>D>	@	300MG	A083633	001		Mar	CAHN
>A>	@ SUN PHARM INDS	100MG	A080136	001		Mar	CAHN
>A>	@	300MG	A083633	001		Mar	CAHN

ISOSORBIDE DINITRATE

	CAPSULE, EXTENDED RELEASE; ORAL						
	DILATRATE-SR						
>A>	+ AUXILIUM PHARMS INC	40MG	N019790	001	Sep 02, 1988	Mar	CAHN
>D>	+ AUXILIUM PHARMS LLC	40MG	N019790	001	Sep 02, 1988	Mar	CAHN
	TABLET; ORAL						
	ISOSORBIDE DINITRATE						
>D>	@ MUTUAL PHARM	5MG	A086166	002	Sep 19, 1986	Mar	CAHN
>A>	@ SUN PHARM INDS	5MG	A086166	002	Sep 19, 1986	Mar	CAHN
	TABLET, EXTENDED RELEASE; ORAL						
	ISOSORBIDE DINITRATE						
>D> AB	COREPHARMA	40MG	A040723	001	Mar 17, 2008	Mar	DISC
>A>	@	40MG	A040723	001	Mar 17, 2008	Mar	DISC
>D> AB	+ SUN PHARM INDS INC	40MG	A040009	001	Dec 30, 1998	Mar	CTEC
>A>	+	40MG	A040009	001	Dec 30, 1998	Mar	CTEC

ISOSULFAN BLUE

	INJECTABLE; INJECTION						
	ISOSULFAN BLUE						
AP	AUROBINDO PHARMA LTD	1%	A206831	001	Feb 02, 2016	Jan	NEWA
AP	+ MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010	Jan	CTEC

KETOCONAZOLE

	TABLET; ORAL						
	KETOCONAZOLE						
	@ SUN PHARM INDS	200MG	A075314	001	Jun 15, 1999	Jan	CAHN

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

@ AUROLIFE PHARMA LLC	50MG	A074024	001	Dec 29, 1995	Feb	CAHN
@	75MG	A074024	002	Dec 29, 1995	Feb	CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

AP	SAGENT STRIDES	5MG/ML	A079134	001	Feb 03, 2010	Jan	CTNA
	TRANDATE						
	@ SEBELA IRELAND LTD	5MG/ML	N019425	001	Dec 31, 1985	Jan	CAHN

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	NOSTRUM LABS INC	100MG	A075215	001	Jul 29, 1999	Jan	CAHN
AB		200MG	A075215	002	Jul 29, 1999	Jan	CAHN
AB		300MG	A075215	003	Jul 29, 1999	Jan	CAHN

LAMIVUDINE

TABLET; ORAL

LAMIVUDINE

AB	MYLAN PHARMS INC	150MG	A204528	001	Mar 04, 2016	Feb	NEWA
AB		300MG	A204528	002	Mar 04, 2016	Feb	NEWA

LAMOTRIGINE

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

AB	+ GLAXOSMITHKLINE LLC	200MG	N022115	004	May 29, 2009	Jan	CRLD
----	-----------------------	-------	---------	-----	--------------	-----	------

LETROZOLE

TABLET; ORAL

LETROZOLE

AB	KREMERS URBAN PHARMS	2.5MG	A091098	001	Jun 03, 2011	Jan	CAHN
----	----------------------	-------	---------	-----	--------------	-----	------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

>A>	AN	RITEDOSE CORP	EQ 0.0103% BASE	A203653	001	Mar 22, 2016	Mar	NEWA
>A>	AN		EQ 0.021% BASE	A203653	002	Mar 22, 2016	Mar	NEWA
>A>	AN		EQ 0.042% BASE	A203653	003	Mar 22, 2016	Mar	NEWA

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP	AUROBINDO PHARMA LTD	500MG/5ML (100MG/ML)	A204312	001	Feb 01, 2016	Jan	NEWA
----	----------------------	----------------------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

AB	INTELLIPHARMACEUTICS	500MG	A204511	001	Feb 23, 2016	Feb	NEWA	
AB		750MG	A204511	002	Feb 23, 2016	Feb	NEWA	
>D>	AB	MUTUAL PHARM CO INC	500MG	A091285	001	Sep 12, 2011	Mar	CAHN
>D>	AB		750MG	A091285	002	Sep 12, 2011	Mar	CAHN
>A>	AB	SUN PHARM INDS	500MG	A091285	001	Sep 12, 2011	Mar	CAHN
>A>	AB		750MG	A091285	002	Sep 12, 2011	Mar	CAHN

TABLET, FOR SUSPENSION; ORAL

SPRITAM

		APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015	Feb	CDFR
			500MG	N207958	002	Jul 31, 2015	Feb	CDFR
			750MG	N207958	003	Jul 31, 2015	Feb	CDFR
>D>			1GM	N207958	004	Jul 31, 2015	Mar	CRLD
>A>	+		1GM	N207958	004	Jul 31, 2015	Mar	CRLD
			1GM	N207958	004	Jul 31, 2015	Feb	CDFR

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	AUROBINDO PHARMA LTD	EQ 250MG/50ML (EQ 5MG/ML)	A206919	001	Feb 10, 2016	Jan	NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A206919	002	Feb 10, 2016	Jan	NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A206919	003	Feb 10, 2016	Jan	NEWA

SOLUTION/DROPS;OPHTHALMIC
LEVOFLOXACIN

AT	+	RISING PHARMS INC	0.5%		A077700	001	Dec 20, 2010	Jan	CAHN
----	---	-------------------	------	--	---------	-----	--------------	-----	------

LIDOCAINEOINTMENT;TOPICAL
LIDOCAINE

AT		TELIGENT PHARMA INC	5%		A205318	001	Feb 01, 2016	Jan	NEWA
----	--	---------------------	----	--	---------	-----	--------------	-----	------

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

@	HOSPIRA	400MG/100ML			N018388	002		Feb	DISC
---	---------	-------------	--	--	---------	-----	--	-----	------

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

@	HOSPIRA	800MG/100ML			N018388	003	Nov 05, 1982	Feb	DISC
---	---------	-------------	--	--	---------	-----	--------------	-----	------

JELLY;TOPICAL

ANESTACON

@	BIONPHARMA INC	2%			A080429	001		Jan	CAHN
---	----------------	----	--	--	---------	-----	--	-----	------

LINEZOLID

SOLUTION;IV (INFUSION)

LINEZOLID

AP		FRESENIUS KABI USA	600MG/300ML (2MG/ML)		A204764	001	Mar 15, 2016	Feb	NEWA
----	--	--------------------	----------------------	--	---------	-----	--------------	-----	------

TABLET;ORAL

LINEZOLID

AB		GATE PHARMS	600MG		A091210	001	Feb 05, 2016	Jan	NEWA
>A>	AB	GLENMARK PHARMS	600MG		A078987	001	Dec 21, 2015	Mar	CAHN
>D>	AB	GLENMARK PHARMS LTD	600MG		A078987	001	Dec 21, 2015	Mar	CAHN

LIOTHYRONINE SODIUM

TABLET;ORAL

LIOTHYRONINE SODIUM

>D>	AB	COASTAL PHARMS	EQ 0.005MG BASE		A090097	001	Mar 20, 2009	Mar	CAHN
>D>	AB		EQ 0.025MG BASE		A090097	002	Mar 20, 2009	Mar	CAHN
>D>	AB		EQ 0.05MG BASE		A090097	003	Mar 20, 2009	Mar	CAHN
>A>	AB	MAYNE PHARMA INC	EQ 0.005MG BASE		A090097	001	Mar 20, 2009	Mar	CAHN
>A>	AB		EQ 0.025MG BASE		A090097	002	Mar 20, 2009	Mar	CAHN
>A>	AB		EQ 0.05MG BASE		A090097	003	Mar 20, 2009	Mar	CAHN

LISINOPRIL

TABLET;ORAL

ZESTRIL

AB		ALVOGEN MALTA	2.5MG		N019777	005	Apr 29, 1993	Jan	CAHN
AB			5MG		N019777	001	May 19, 1988	Jan	CAHN
AB			10MG		N019777	002	May 19, 1988	Jan	CAHN
AB			20MG		N019777	003	May 19, 1988	Jan	CAHN
AB			30MG		N019777	006	Jan 20, 1999	Jan	CAHN
AB	+		40MG		N019777	004	May 19, 1988	Jan	CAHN

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

AB		DELCOR ASSET CORP	150MG		A076243	002	Feb 24, 2003	Feb	CAHN
AB			300MG		A076243	001	Jun 27, 2002	Feb	CAHN
AB			600MG		A078763	001	Apr 15, 2008	Feb	CAHN
AB		HIKMA PHARMS	600MG		A078763	001	Apr 15, 2008	Jan	CMFD

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

AEGERION EQ 20MG BASE

N203858	003	Dec 21, 2012	Jan	CRLD
---------	-----	--------------	-----	------

+ EQ 60MG BASE

N203858	006	Apr 23, 2015	Jan	CRLD
---------	-----	--------------	-----	------

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

IMODIUM

@ J AND J CONSUMER INC 2MG

N017694	001		Feb	DISC
---------	-----	--	-----	------

LOPERAMIDE HYDROCHLORIDE

AB	+	MYLAN	2MG		A072741	001	Sep 18, 1991	Feb	CRLD
----	---	-------	-----	--	---------	-----	--------------	-----	------

LOVASTATINTABLET; ORAL
LOVASTATIN

>D>	AB	MUTUAL PHARM	10MG	A 077520	001	Apr 14, 2006	Mar	CAHN
>D>	AB		20MG	A 077520	002	Apr 14, 2006	Mar	CAHN
>D>	AB		40MG	A 077520	003	Apr 14, 2006	Mar	CAHN
>A>	AB	SUN PHARM INDS	10MG	A 077520	001	Apr 14, 2006	Mar	CAHN
>A>	AB		20MG	A 077520	002	Apr 14, 2006	Mar	CAHN
>A>	AB		40MG	A 077520	003	Apr 14, 2006	Mar	CAHN

LOXAPINEPOWDER; INHALATION
ADASUVE

+	ALEXZA PHARMS	10MG	N 022549	001	Dec 21, 2012	Feb	CAHN
---	---------------	------	----------	-----	--------------	-----	------

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	1GM/100ML	A 206486	001	Mar 07, 2016	Feb	NEWA
AP	+	HOSPIRA	1GM/100ML	N 020488	001	Jul 11, 1995	Feb	CFTG
AP		HQ SPCLT PHARMA	1GM/100ML	A 207349	001	Mar 02, 2016	Feb	NEWA
MAGNESIUM SULFATE IN PLASTIC CONTAINER								
AP		FRESENIUS KABI USA	4GM/100ML (40MG/ML)	A 206485	001	Mar 15, 2016	Feb	NEWA
AP			4GM/50ML (80MG/ML)	A 206485	002	Mar 15, 2016	Feb	NEWA
>A>	AP		2GM/50ML (40MG/ML)	A 206485	003	Mar 15, 2016	Mar	NEWA
>A>	AP		20GM/500ML (40MG/ML)	A 206485	004	Mar 15, 2016	Mar	NEWA
>A>	AP		40GM/1000ML (40MG/ML)	A 206485	005	Mar 15, 2016	Mar	NEWA
>D>		HOSPIRA	2GM/50ML (40MG/ML)	N 020309	003	Jan 26, 2007	Mar	CFTG
>A>	AP		2GM/50ML (40MG/ML)	N 020309	003	Jan 26, 2007	Mar	CFTG
	AP	+	4GM/100ML (40MG/ML)	N 020309	001	Jun 24, 1994	Feb	CFTG
	AP	+	4GM/50ML (80MG/ML)	N 020309	002	Jun 24, 1994	Feb	CFTG
>D>			20GM/500ML (40MG/ML)	N 020309	004	Jan 18, 1995	Mar	CFTG
>A>	AP		20GM/500ML (40MG/ML)	N 020309	004	Jan 18, 1995	Mar	CFTG
>D>			40GM/1000ML (40MG/ML)	N 020309	005	Jan 18, 1995	Mar	CFTG
>A>	AP		40GM/1000ML (40MG/ML)	N 020309	005	Jan 18, 1995	Mar	CFTG
SOLUTION; INTRAMUSCULAR, INTRAVENOUS								
MAGNESIUM SULFATE								
	+	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N 019316	003	Jan 29, 2016	Jan	NEWA
	+		25GM/50ML (500MG/ML)	N 019316	004	Jan 29, 2016	Jan	NEWA

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

@	RISING PHARMS INC	12.5MG	A 040179	001	Jan 30, 1997	Jan	CAHN
@		25MG	A 040179	002	Jan 30, 1997	Jan	CAHN

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE ES

AB	+	ENDO PHARMS INC	125MG/ML	N 021778	001	Jul 05, 2005	Feb	CAHN
----	---	-----------------	----------	----------	-----	--------------	-----	------

MELOXICAM

TABLET; ORAL

MELOXICAM

@	SUN PHARM INDS	7.5MG	A 077935	001	Jul 19, 2006	Jan	CAHN
@		15MG	A 077935	002	Jul 19, 2006	Jan	CAHN

MELPHALAN

TABLET; ORAL

ALKERAN

+	APOTEX INC	2MG	N 014691	002		Jan	CAHN
---	------------	-----	----------	-----	--	-----	------

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

AP	+	APOTEX INC	EQ 50MG BASE/VIAL	N 020207	001	Nov 18, 1992	Jan	CAHN
----	---	------------	-------------------	----------	-----	--------------	-----	------

POWDER; IV (INFUSION)

>A>		EVOMELA						
>A>		SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N 207155	001	Mar 10, 2016	Mar	NEWA

MEPERIDINE HYDROCHLORIDE

	INJECTABLE; INJECTION						
	DEMEROL						
	@ US PHARM HOLDINGS	25MG/ML	N005010	007		Jan	CAHN
	@	50MG/ML	N005010	002		Jan	CAHN
	@	75MG/ML	N005010	009		Jan	CAHN
	@	100MG/ML	N005010	003		Jan	CAHN
	SYRUP; ORAL						
	DEMEROL						
	@ US PHARM HOLDINGS	50MG/5ML	N005010	005		Jan	CAHN
	TABLET; ORAL						
	DEMEROL						
AA	+ US PHARM HOLDINGS	50MG	N005010	001		Jan	CAHN
AA	+	100MG	N005010	004		Jan	CAHN

MEPROBAMATE

	TABLET; ORAL						
	MEPROBAMATE						
	@ AUROLIFE PHARMA LLC	400MG	A080655	001		Feb	CAHN

MERCAPTOPURINE

	TABLET; ORAL						
	PURINETHOL						
	@ STASON PHARMS	50MG	N009053	002		Jan	CAHN

MEROPENEM

	INJECTABLE; INJECTION						
	MEROPENEM						
>A>	AP	AMNEAL PHARMS	500MG/VIAL	A205883	001	Apr 12, 2016	Mar NEWA
>A>	AP		1GM/VIAL	A205883	002	Apr 12, 2016	Mar NEWA

MESALAMINE

	CAPSULE, DELAYED RELEASE; ORAL						
	DELZICOL						
	+ ALLERGAN PHARMS INTL	400MG	N204412	001	Feb 01, 2013	Jan	CAHN
	TABLET, DELAYED RELEASE; ORAL						
	ASACOL						
	@ ALLERGAN PHARMS INTL	400MG	N019651	001	Jan 31, 1992	Jan	CAHN
	ASACOL HD						
	+ ALLERGAN PHARMS INTL	800MG	N021830	001	May 29, 2008	Jan	CAHN

METFORMIN HYDROCHLORIDE

	TABLET; ORAL						
	METFORMIN HYDROCHLORIDE						
>D>	AB	MUTUAL PHARMA	500MG	A076038	001	Feb 21, 2002	Mar CAHN
>D>	AB		850MG	A076038	002	Feb 21, 2002	Mar CAHN
>D>	AB		1GM	A076038	003	Feb 21, 2002	Mar CAHN
>A>	AB	SUN PHARM INDS	500MG	A076038	001	Feb 21, 2002	Mar CAHN
>A>	AB		850MG	A076038	002	Feb 21, 2002	Mar CAHN
>A>	AB		1GM	A076038	003	Feb 21, 2002	Mar CAHN
	TABLET, EXTENDED RELEASE; ORAL						
	GLUMETZA						
AB3		SANTARUS INC	500MG	N021748	001	Jun 03, 2005	Jan CTEC
AB3	+		1GM	N021748	002	Jun 03, 2005	Jan CTEC
	METFORMIN HYDROCHLORIDE						
>D>	AB1	IMPAX LABS	500MG	A076249	001	Jul 30, 2004	Mar DISC
>A>		@	500MG	A076249	001	Jul 30, 2004	Mar DISC
>D>	AB		750MG	A076985	001	Sep 13, 2005	Mar DISC
>A>		@	750MG	A076985	001	Sep 13, 2005	Mar DISC
>D>		@ MUTUAL PHARM	500MG	A077124	001	Dec 21, 2005	Mar CAHN
>A>		@ SUN PHARM INDS	500MG	A077124	001	Dec 21, 2005	Mar CAHN

METHENAMINE HIPPURATE

	TABLET; ORAL						
	HIPREX						
AB	+ US PHARM HOLDINGS	1GM	N017681	001		Jan	CAHN

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	RISING PHARMS INC	5MG	A202068	001	Mar 07, 2012	Jan	CAHN
AB		10MG	A202068	002	Mar 07, 2012	Jan	CAHN

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

>D>	@ MUTUAL PHARM	500MG	A084488	001		Mar	CAHN
>D>	@	750MG	A084486	001		Mar	CAHN
	@ SANDOZ	500MG	A084616	001		Feb	DISC
	@	750MG	A084615	001		Feb	DISC
>A>	@ SUN PHARM INDS	500MG	A084488	001		Mar	CAHN
>A>	@	750MG	A084486	001		Mar	CAHN
	ROBAXIN						
>A> AA	+ AUXILIUM PHARMS INC	500MG	N011011	004		Mar	CAHN
>D> AA	+ AUXILIUM PHARMS LLC	500MG	N011011	004		Mar	CAHN
	ROBAXIN-750						
>A> AA	+ AUXILIUM PHARMS INC	750MG	N011011	006		Mar	CAHN
>D> AA	+ AUXILIUM PHARMS LLC	750MG	N011011	006		Mar	CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	SANDOZ INC	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A090039	001	Mar 31, 2009	Jan	CAHN
AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A090039	002	Mar 31, 2009	Jan	CAHN
AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A090029	001	Mar 31, 2009	Jan	CAHN

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHERGINE

	@ EDISON THERAPS LLC	0.2MG	N006035	003		Jan	DISC
	METHYLERGONOVINE MALEATE						
	+ NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011	Jan	CRLD

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	NOSTRUM LABS INC	5MG/5ML	A201466	001	Nov 12, 2013	Feb	CAHN
AA		10MG/5ML	A201466	002	Nov 12, 2013	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	TEDOR PHARMA INC	10MG	A204772	001	Feb 29, 2016	Feb	NEWA
AB		20MG	A204772	002	Feb 29, 2016	Feb	NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP	HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	A202691	001	Feb 16, 2016	Feb	NEWA
AP		EQ 1GM BASE/VIAL	A202691	002	Feb 16, 2016	Feb	NEWA
AP	SAGENT PHARMS	EQ 40MG BASE/VIAL	A040888	001	Jul 18, 2011	Jan	CAHN
AP		EQ 125MG BASE/VIAL	A040888	002	Jul 18, 2011	Jan	CAHN
AP		EQ 500MG BASE/VIAL	A040888	003	Jul 18, 2011	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A040888	004	Jul 18, 2011	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A040888	005	Jul 18, 2011	Jan	CAHN

METHYLTESTOSTERONE

TABLET; ORAL

METHYLTESTOSTERONE

>D> BP	IMPAX LABS	25MG	A084310	001		Mar	DISC
>A>	@	25MG	A084310	001		Mar	DISC

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

>D> AB	MUTUAL PHARM	EQ 5MG BASE	A071536	002	Jan 16, 1997	Mar	CAHN
>D>	@	EQ 10MG BASE	A071536	001	Apr 28, 1993	Mar	CAHN
>A> AB	SUN PHARM INDS	EQ 5MG BASE	A071536	002	Jan 16, 1997	Mar	CAHN
>A>	@	EQ 10MG BASE	A071536	001	Apr 28, 1993	Mar	CAHN

METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE

>D>	AB	MUTUAL PHARM	25MG	A 073654	002	Jul 15, 2009	Mar	CAHN
>D>	AB		100MG	A 073654	001	Dec 21, 1993	Mar	CAHN
>A>	AB	SUN PHARM INDS	25MG	A 073654	002	Jul 15, 2009	Mar	CAHN
>A>	AB		100MG	A 073654	001	Dec 21, 1993	Mar	CAHN

METRONIDAZOLE

TABLET;ORAL

METRONIDAZOLE

AB		NOSTRUM LABS INC	250MG	A 070772	001	Jul 16, 1986	Jan	CAHN
AB			500MG	A 070773	001	Jul 16, 1986	Jan	CAHN

MICONAZOLE

TABLET;BUCCAL

ORAVIG

+		MIDATECH PHARMA US	50MG	N 022404	001	Apr 16, 2010	Jan	CAHN
---	--	--------------------	------	----------	-----	--------------	-----	------

MIGLITOL

TABLET;ORAL

GLYSET

AB	+	PHARMACIA AND UPJOHN	25MG	N 020682	001	Dec 18, 1996	Feb	CRLD
AB			100MG	N 020682	003	Dec 18, 1996	Feb	CRLD

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

MILNACIPRAN HYDROCHLORIDE

@		LIBERTY PHARMA INC	12.5MG	A 205071	001	Jan 27, 2016	Jan	DISC
			12.5MG	A 205071	001	Jan 27, 2016	Jan	NEWA
@			25MG	A 205071	002	Jan 27, 2016	Jan	DISC
			25MG	A 205071	002	Jan 27, 2016	Jan	NEWA
@			50MG	A 205071	003	Jan 27, 2016	Jan	DISC
			50MG	A 205071	003	Jan 27, 2016	Jan	NEWA
@			100MG	A 205071	004	Jan 27, 2016	Jan	DISC
			100MG	A 205071	004	Jan 27, 2016	Jan	NEWA

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE IN DEXTROSE 5%

>D>	AP	APOTEX INC	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A 077151	002	Jul 20, 2005	Mar	CAHN
>A>	AP	CLARIS	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A 077151	002	Jul 20, 2005	Mar	CAHN
>D>		MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
		@ APOTEX INC	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A 077151	001	Jul 20, 2005	Mar	CAHN
>A>		@ CLARIS	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A 077151	001	Jul 20, 2005	Mar	CAHN

MINOCYCLINE HYDROCHLORIDE

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

AB		SUN PHARM INDS	EQ 50MG BASE	A 090217	001	Jan 29, 2016	Jan	NEWA
AB			EQ 75MG BASE	A 090217	002	Jan 29, 2016	Jan	NEWA
AB			EQ 100MG BASE	A 090217	003	Jan 29, 2016	Jan	NEWA

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

>D>	AB	IMPAX LABS INC	EQ 45MG BASE	A 090024	001	Feb 03, 2009	Mar	DISC
>A>		@	EQ 45MG BASE	A 090024	001	Feb 03, 2009	Mar	DISC
>D>	AB		EQ 90MG BASE	A 090024	002	Feb 03, 2009	Mar	DISC
>A>		@	EQ 90MG BASE	A 090024	002	Feb 03, 2009	Mar	DISC
>D>	AB		EQ 135MG BASE	A 090024	003	Feb 03, 2009	Mar	DISC
>A>		@	EQ 135MG BASE	A 090024	003	Feb 03, 2009	Mar	DISC

MINOXIDIL

TABLET;ORAL

MINOXIDIL

>D>	AB	MUTUAL PHARM	10MG	A 072709	001	Dec 14, 1995	Mar	CAHN
>A>	AB	SUN PHARM INDS	10MG	A 072709	001	Dec 14, 1995	Mar	CAHN

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

@ ACTAVIS LABS FL INC 15MG
 @ 30MG
 @ 45MG

A076336 001 Jun 20, 2003 Jan DISC
 A076336 002 Jun 20, 2003 Jan DISC
 A076336 003 Jun 20, 2003 Jan DISC

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

AP EUROHLTH INTL SARL 5MG/VIAL
 AP 20MG/VIAL

A064180 001 Dec 23, 1999 Jan CAHN
 A064180 002 Dec 23, 1999 Jan CAHN

MODAFINIL

TABLET; ORAL

MODAFINIL

AB WATSON LABS INC 100MG
 AB 200MG

A076715 001 Nov 01, 2012 Jan CAHN
 A076715 002 Nov 01, 2012 Jan CAHN

MOMETASONE FUROATE

SPRAY, METERED; NASAL

MOMETASONE FUROATE

>A>
 >A> AB APOTEX INC EQ 0.05MG BASE/SPRAY
 NASONEX
 >A> AB + MERCK SHARP DOHME EQ 0.05MG BASE/SPRAY

A091161 001 Mar 22, 2016 Mar NEWA
 N020762 001 Oct 01, 1997 Mar CFTG

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL

NASONEX

>D> + MERCK SHARP DOHME EQ 0.05MG BASE/SPRAY

N020762 001 Oct 01, 1997 Mar CFTG

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

AB + ACTAVIS LABS UT INC 10MG
 AB 20MG
 AB 30MG
 AB 40MG
 AB 50MG
 AB 60MG
 AB 70MG
 AB 80MG
 AB + 100MG
 + 200MG

N020616 008 Apr 20, 2007 Feb CTEC
 N020616 001 Jul 03, 1996 Feb CTEC
 N020616 004 Mar 09, 2001 Feb CTEC
 N020616 009 Jul 09, 2012 Feb CTEC
 N020616 002 Jul 03, 1996 Feb CTEC
 N020616 005 Mar 09, 2001 Feb CTEC
 N020616 010 Jul 09, 2012 Feb CTEC
 N020616 006 Oct 27, 2006 Feb CTEC
 N020616 003 Jul 03, 1996 Feb CTEC
 N020616 007 Feb 27, 2007 Feb CTEC

MORPHINE SULFATE

>A> AB IMPAX LABS INC 20MG
 >A> AB 30MG
 >A> AB 50MG
 >A> AB 60MG
 >A> AB 80MG
 >A> AB 100MG
 AB PAR PHARM INC 20MG
 AB 30MG
 AB 50MG
 AB 60MG
 AB 80MG
 AB 100MG
 AB TEVA PHARMS USA 20MG
 AB 30MG
 AB 40MG
 AB 50MG
 AB 60MG
 AB 70MG
 AB 80MG
 AB 100MG
 AB UPSHER SMITH 10MG
 AB 20MG
 AB 30MG
 AB 50MG
 AB 60MG
 AB 80MG
 AB 100MG

A200411 001 Apr 12, 2016 Mar NEWA
 A200411 002 Apr 12, 2016 Mar NEWA
 A200411 003 Apr 12, 2016 Mar NEWA
 A200411 004 Apr 12, 2016 Mar NEWA
 A200411 005 Apr 12, 2016 Mar NEWA
 A200411 006 Apr 12, 2016 Mar NEWA
 A200812 001 Nov 10, 2011 Feb CTEC
 A200812 002 Nov 10, 2011 Feb CTEC
 A200812 003 Nov 10, 2011 Feb CTEC
 A200812 004 Nov 10, 2011 Feb CTEC
 A200812 005 Nov 10, 2011 Feb CTEC
 A200812 006 Nov 10, 2011 Feb CTEC
 A202718 001 Dec 29, 2014 Feb CTEC
 A202718 002 Dec 29, 2014 Feb CTEC
 A202718 007 Jun 03, 2015 Feb CTEC
 A202718 003 Dec 29, 2014 Feb CTEC
 A202718 004 Dec 29, 2014 Feb CTEC
 A202718 008 Jun 03, 2015 Feb CTEC
 A202718 005 Dec 29, 2014 Feb CTEC
 A202718 006 Dec 29, 2014 Feb CTEC
 A202104 001 Jun 03, 2013 Feb CTEC
 A202104 002 Jun 03, 2013 Feb CTEC
 A202104 003 Jun 03, 2013 Feb CTEC
 A202104 004 Jun 03, 2013 Feb CTEC
 A202104 005 Jun 03, 2013 Feb CTEC
 A202104 006 Jun 03, 2013 Feb CTEC
 A202104 007 Jun 03, 2013 Feb CTEC

SOLUTION;ORAL

MORPHINE SULFATE

>A>	AA	NOSTRUM LABS INC	10MG/5ML	A201011	001	Feb 05, 2014	Mar	CAHN
>A>	AA		20MG/5ML	A201011	002	Feb 05, 2014	Mar	CAHN
>D>	AA	SUN PHARM INDS INC	10MG/5ML	A201011	001	Feb 05, 2014	Mar	CAHN
>D>	AA		20MG/5ML	A201011	002	Feb 05, 2014	Mar	CAHN

MOXIFLOXACIN HYDROCHLORIDE

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB		CROSSMEDIKA SA	EQ 400MG BASE	A205348	001	Jan 14, 2016	Jan	NEWA
----	--	----------------	---------------	---------	-----	--------------	-----	------

NALIDIXIC ACID

TABLET;ORAL

NALIDIXIC ACID

>D>		@ MUTUAL PHARM	250MG	A070270	001	Jun 29, 1988	Mar	CAHN
>D>		@	1GM	A070272	001	Jun 29, 1988	Mar	CAHN
>A>		@ SUN PHARM INDS	250MG	A070270	001	Jun 29, 1988	Mar	CAHN
>A>		@	1GM	A070272	001	Jun 29, 1988	Mar	CAHN

NAPROXEN

TABLET;ORAL

NAPROSYN

AB		ATNAHS PHARMA US	250MG	N017581	002		Feb	CAHN
AB			375MG	N017581	003		Feb	CAHN
AB	+		500MG	N017581	004	Apr 15, 1982	Feb	CAHN

NAPROXEN

		@ SANDOZ	250MG	A074140	001	Dec 21, 1993	Feb	DISC
		@	375MG	A074140	002	Dec 21, 1993	Feb	DISC
		@	500MG	A074140	003	Dec 21, 1993	Feb	DISC

TABLET, DELAYED RELEASE;ORAL

EC-NAPROSYN

AB	+	ATNAHS PHARMA US	375MG	N020067	002	Oct 14, 1994	Feb	CAHN
AB	+		500MG	N020067	003	Oct 14, 1994	Feb	CAHN

NAPROXEN

		@ SANDOZ	375MG	A075061	001	Feb 18, 1998	Feb	DISC
		@	500MG	A075061	002	Feb 18, 1998	Feb	DISC

NAPROXEN SODIUM

TABLET;ORAL

ANAPROX

AB		ATNAHS PHARMA US	EQ 250MG BASE	N018164	001		Feb	CAHN
AB	+	ATNAHS PHARMA US	EQ 500MG BASE	N018164	003	Sep 30, 1987	Feb	CAHN

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

		@ SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003	Feb	DISC
		@	100MG	A076409	002	Sep 16, 2003	Feb	DISC
		@	150MG	A076409	003	Sep 16, 2003	Feb	DISC
		@	200MG	A076409	004	Sep 16, 2003	Feb	DISC
		@	250MG	A076409	005	Sep 16, 2003	Feb	DISC

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

>D>		@ CATALENT	10MG	A073250	001	Oct 08, 1991	Mar	CAHN
>D>		@	20MG	A074045	001	Apr 30, 1992	Mar	CAHN
>A>		@ VALIDUS PHARMS	10MG	A073250	001	Oct 08, 1991	Mar	CAHN
>A>		@	20MG	A074045	001	Apr 30, 1992	Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL

ADALAT CC

AB1		ALVOGEN	30MG	N020198	001	Apr 21, 1993	Feb	CAHN
AB1	+		60MG	N020198	002	Apr 21, 1993	Feb	CAHN
AB1	+		90MG	N020198	003	Apr 21, 1993	Feb	CAHN

NIFEDIPINE

AB1		VALEANT PHARMS NORTH	30MG	A075269	001	Dec 04, 2000	Jan	CAHN
AB1			60MG	A075269	002	Dec 04, 2000	Jan	CAHN
AB1			90MG	A076070	001	Aug 16, 2002	Jan	CAHN

NIMODIPINE

	CAPSULE;ORAL						
	NIMODIPINE						
AB	+	BIONPHARMA INC	30MG	A076740	001	Jan 17, 2008	Jan CAHN

NITRIC OXIDE

	GAS;INHALATION						
	INOMAX						
	+	MALLINCKRODT HOSP	800PPM	N020845	003	Dec 23, 1999	Jan CAHN

NITROFURANTOIN

	SUSPENSION;ORAL						
	NITROFURANTOIN						
AB		NOSTRUM LABS INC	25MG/5ML	A201355	001	Aug 14, 2013	Feb CAHN

NITROFURANTOIN, MACROCRYSTALLINE

	CAPSULE;ORAL						
	NITROFURANTOIN						
AB		SUN PHARM INDS	25MG	A201722	001	Feb 16, 2016	Feb NEWA
AB			50MG	A201722	002	Feb 16, 2016	Feb NEWA
AB			100MG	A201722	003	Feb 16, 2016	Feb NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

	CAPSULE;ORAL						
	MACROBID						
AB	+	ALVOGEN MALTA	75MG;25MG	N020064	001	Dec 24, 1991	Jan CAHN

NIZATIDINE

	SOLUTION;ORAL						
	AXID						
	@	BRAINTREE	15MG/ML	N021494	001	May 25, 2004	Feb DISC
	NIZATIDINE						
	+	AMNEAL PHARMS	15MG/ML	A090576	001	Nov 18, 2009	Feb CRLD

NOREPINEPHRINE BITARTRATE

	INJECTABLE;INJECTION						
	NOREPINEPHRINE BITARTRATE						
AP		CLARIS	EQ 1MG BASE/ML	A040859	001	Mar 27, 2012	Jan CAHN

NORETHINDRONE

	TABLET;ORAL-28						
	NOR-QD						
AB1	+	ALLERGAN PHARMS INTL	0.35MG	N017060	001		Jan CAHN

NORTRIPTYLINE HYDROCHLORIDE

	CAPSULE;ORAL						
	NORTRIPTYLINE HYDROCHLORIDE						
	@	AUROLIFE PHARMA LLC	EQ 10MG BASE	A074835	001	Jun 30, 1997	Feb CAHN
	@		EQ 25MG BASE	A074835	002	Jun 30, 1997	Feb CAHN
	@		EQ 50MG BASE	A074835	003	Jun 30, 1997	Feb CAHN
	@		EQ 75MG BASE	A074835	004	Jun 30, 1997	Feb CAHN

NYSTATIN

	TABLET;ORAL						
	NYSTATIN						
>D>	AA	MUTUAL PHARM	500,000 UNITS	A062838	001	Dec 22, 1988	Mar CAHN
>A>	AA	SUN PHARM INDS	500,000 UNITS	A062838	001	Dec 22, 1988	Mar CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

	CREAM;TOPICAL						
	NYSTATIN TRIAMCINOLONE ACETONIDE						
>A>	@	PHARMADERM	100,000 UNITS/GM;0.1%	A062596	001	Oct 08, 1985	Mar CMS1
>D>	@	PHARMADERM	100,000 UNITS/GM;0.1%	A062596	001	Oct 08, 1985	Mar CMS1

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

@	WOCKHARDT USA	EQ 0.2MG BASE/ML	A 090986	001	May 11, 2011	Jan	DISC
@		EQ 1MG BASE/ML	A 090986	002	May 11, 2011	Jan	DISC
OCTREOTIDE ACETATE (PRESERVATIVE FREE)							
@	WOCKHARDT USA	EQ 0.05MG BASE/ML	A 090985	001	May 11, 2011	Jan	DISC
@		EQ 0.1MG BASE/ML	A 090985	002	May 11, 2011	Jan	DISC
@		EQ 0.5MG BASE/ML	A 090985	003	May 11, 2011	Jan	DISC
OCTREOTIDE ACETATE PRESERVATIVE FREE							
@	WOCKHARDT USA	EQ 0.05MG BASE/ML	A 090985	001	May 11, 2011	Feb	CMS1
@		EQ 0.1MG BASE/ML	A 090985	002	May 11, 2011	Feb	CMS1
@		EQ 0.5MG BASE/ML	A 090985	003	May 11, 2011	Feb	CMS1

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

>A>	AT	ALVOGEN	0.3%	A 076830	001	Aug 31, 2004	Mar	CAHN
>D>	AT	FERA PHARMS	0.3%	A 076830	001	Aug 31, 2004	Mar	CAHN

SOLUTION/DROPS; OTIC

FLOXIN OTIC

@	DAIICHI	0.3%	N 020799	001	Dec 16, 1997	Feb	DISC	
OFLOXACIN								
>A>	AT	ALVOGEN	0.3%	A 090395	001	Aug 11, 2009	Mar	CAHN
	AT	+ BAUSCH AND LOMB	0.3%	A 076128	001	Mar 17, 2008	Feb	CRLD
>D>	AT	FERA PHARMS	0.3%	A 090395	001	Aug 11, 2009	Mar	CAHN

OLANZAPINE

TABLET; ORAL

OLANZAPINE

AB	INVAGEN PHARMS	2.5MG	A 203333	001	Mar 15, 2016	Feb	NEWA
AB		5MG	A 203333	002	Mar 15, 2016	Feb	NEWA
AB		7.5MG	A 203333	003	Mar 15, 2016	Feb	NEWA
AB		10MG	A 203333	004	Mar 15, 2016	Feb	NEWA
AB		15MG	A 203333	005	Mar 15, 2016	Feb	NEWA
AB		20MG	A 203333	006	Mar 15, 2016	Feb	NEWA
AB	QILU PHARM CO LTD	2.5MG	A 204319	001	Jan 27, 2016	Jan	NEWA
AB		5MG	A 204319	002	Jan 27, 2016	Jan	NEWA
AB		7.5MG	A 204319	003	Jan 27, 2016	Jan	NEWA
AB		10MG	A 204319	004	Jan 27, 2016	Jan	NEWA
AB		15MG	A 204319	005	Jan 27, 2016	Jan	NEWA
AB		20MG	A 204319	006	Jan 27, 2016	Jan	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB	INVAGEN PHARMS	5MG	A 203456	001	Mar 16, 2016	Feb	NEWA
AB		10MG	A 203456	002	Mar 16, 2016	Feb	NEWA
AB		15MG	A 203456	003	Mar 16, 2016	Feb	NEWA
AB		20MG	A 203456	004	Mar 16, 2016	Feb	NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

>D>	AT	NOVEL LABS INC	EQ 0.1% BASE	A 206306	001	Dec 07, 2015	Mar	CAHN
>A>	AT	SOMERSET THERAPS LLC	EQ 0.1% BASE	A 206306	001	Dec 07, 2015	Mar	CAHN

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

OMEGA-3-ACID ETHYL ESTERS

AB	AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A 204940	001	Nov 27, 2015	Jan	CMS1	
>D>		OMTRYG						
>D>	+	TRYGG	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N 204977	001	Apr 23, 2014	Mar	CAIN

>A>	<u>OMEGA-3-ACID ETHYL ESTERS TYPE A</u>				
>A>	CAPSULE;ORAL				
>A>	OMTRYG				
>A>	+	TRYGG	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001 Apr 23, 2014 Mar CAIN
<u>OMEPRAZOLE</u>					
CAPSULE, DELAYED REL PELLETS;ORAL					
OMEPRAZOLE					
>D>	AB	SANDOZ	20MG	A075757	002 Jan 28, 2003 Mar CRLD
>A>	AB	+	20MG	A075757	002 Jan 28, 2003 Mar CRLD
>D>	AB		40MG	A076515	001 Jan 21, 2009 Mar CRLD
>A>	AB	+	40MG	A076515	001 Jan 21, 2009 Mar CRLD
<u>ONDANSETRON HYDROCHLORIDE</u>					
INJECTABLE;INJECTION					
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP		ACCORD HLTHCARE	EQ 2MG BASE/ML	A206845	001 Mar 10, 2016 Feb NEWA
<u>OXALIPLATIN</u>					
INJECTABLE;IV (INFUSION)					
OXALIPLATIN					
AP		SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001 Aug 07, 2009 Jan CAHN
AP			100MG/20ML (5MG/ML)	A078812	002 Aug 07, 2009 Jan CAHN
<u>OXAZEPAM</u>					
CAPSULE;ORAL					
OXAZEPAM					
>D>		@ MUTUAL PHARM	10MG	A071026	002 Aug 10, 1987 Mar CAHN
>D>		@	15MG	A071026	003 Aug 10, 1987 Mar CAHN
>D>		@	30MG	A071026	001 Aug 10, 1987 Mar CAHN
>A>		@ SUN PHARM INDS	10MG	A071026	002 Aug 10, 1987 Mar CAHN
>A>		@	15MG	A071026	003 Aug 10, 1987 Mar CAHN
>A>		@	30MG	A071026	001 Aug 10, 1987 Mar CAHN
<u>OXICONAZOLE NITRATE</u>					
CREAM;TOPICAL					
OXICONAZOLE NITRATE					
AB		TARO	EQ 1% BASE	A205076	001 Mar 07, 2016 Feb NEWA
AB	+	FOUGERA PHARMS	EQ 1% BASE	N019828	001 Dec 30, 1988 Feb CFTG
<u>OXYBUTYNIN CHLORIDE</u>					
TABLET, EXTENDED RELEASE;ORAL					
OXYBUTYNIN CHLORIDE					
AB		ACCORD HLTHCARE	5MG	A207138	001 Feb 29, 2016 Feb NEWA
AB			10MG	A207138	002 Feb 29, 2016 Feb NEWA
AB			15MG	A207138	003 Feb 29, 2016 Feb NEWA
<u>OXYCODONE HYDROCHLORIDE</u>					
CAPSULE;ORAL					
OXYCODONE HYDROCHLORIDE					
>A>	AB	ANI PHARMS INC	5MG	A205177	001 Mar 31, 2016 Mar NEWA
TABLET;ORAL					
OXYCODONE HYDROCHLORIDE					
AB		ALVOGEN MALTA	5MG	A202116	001 Dec 30, 2011 Jan CAHN
AB			15MG	A202116	002 Dec 30, 2011 Jan CAHN
AB			30MG	A202116	003 Dec 30, 2011 Jan CAHN
>A>	AB	KEN LIFESCIENCE	5MG	A207119	001 Apr 12, 2016 Mar NEWA
>A>	AB		10MG	A207119	002 Apr 12, 2016 Mar NEWA
>A>	AB		15MG	A207119	003 Apr 12, 2016 Mar NEWA
>A>	AB		20MG	A207119	004 Apr 12, 2016 Mar NEWA
>A>	AB		30MG	A207119	005 Apr 12, 2016 Mar NEWA
<u>PACLITAXEL</u>					
INJECTABLE;INJECTION					
PACLITAXEL					
AP		SANDOZ INC	6MG/ML	A078167	001 Dec 26, 2007 Jan CAHN

PALIPERIDONE PALMITATESUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
INVEGA SUSTENNA

>D>	+	JANSSEN PHARMS	117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Mar	CRLD
>A>			117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Mar	CRLD
>D>			156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Mar	CRLD
>A>	+		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Mar	CRLD

PALONOSETRON HYDROCHLORIDESOLUTION; INTRAVENOUS
PALONOSETRON HYDROCHLORIDE

>A>		DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Mar	NEWA
>A>			EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Mar	NEWA

PAMIDRONATE DISODIUMINJECTABLE; INJECTION
PAMIDRONATE DISODIUM

AP		SAGENT PHARMS	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	Jan	CAHN
AP			90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	Jan	CAHN

PANTOPRAZOLE SODIUMINJECTABLE; IV (INFUSION)
PANTOPRAZOLE SODIUM

>A>	AP	AUROBINDO PHARMA LTD	EQ 40MG BASE/VIAL	A205675	001	Mar 30, 2016	Mar	NEWA
			TABLET, DELAYED RELEASE; ORAL					
			PANTOPRAZOLE SODIUM					
	AB	AMNEAL PHARMS	EQ 20MG BASE	A205119	001	Jan 26, 2016	Jan	NEWA
	AB		EQ 40MG BASE	A205119	002	Jan 26, 2016	Jan	NEWA

PARICALCITOLCAPSULE; ORAL
PARICALCITOL

	AB	BIONPHARMA INC	1MCG	A202539	001	Mar 27, 2014	Jan	CAHN
	AB		2MCG	A202539	002	Mar 27, 2014	Jan	CAHN
	AB		4MCG	A202539	003	Mar 27, 2014	Jan	CAHN
	AB	LOTUS PHARM CO LTD	1MCG	A206710	001	Feb 24, 2016	Feb	NEWA
	AB		2MCG	A206710	002	Feb 24, 2016	Feb	NEWA
	AB		4MCG	A206710	003	Feb 24, 2016	Feb	NEWA

SOLUTION; INTRAVENOUS
PARICALCITOL

	AP	ACCORD HLTHCARE	0.002MG/ML (0.002MG/ML)	N207174	001	Feb 04, 2016	Feb	NEWA
	AP		0.005MG/ML (0.005MG/ML)	N207174	002	Feb 04, 2016	Feb	NEWA
	AP		0.01MG/2ML (0.005MG/ML)	N207174	003	Feb 04, 2016	Feb	NEWA

PENBUTOLOL SULFATETABLET; ORAL
LEVATOL

>A>	@	AUXILIUM PHARMS INC	10MG	N018976	001	Dec 30, 1987	Mar	CAHN
>A>	@		20MG	N018976	004	Jan 05, 1989	Mar	CAHN
>D>	@	AUXILIUM PHARMS LLC	10MG	N018976	001	Dec 30, 1987	Mar	CAHN
>D>	@		20MG	N018976	004	Jan 05, 1989	Mar	CAHN

PENTETATE CALCIUM TRISODIUMSOLUTION; INHALATION, INTRAVENOUS
PENTETATE CALCIUM TRISODIUM

@	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Feb	CAHN
---	--------------------	------------------------------------	---------	-----	--------------	-----	------

PENTETATE ZINC TRISODIUMSOLUTION; INHALATION, INTRAVENOUS
PENTETATE ZINC TRISODIUM

@	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004	Feb	CAHN
---	--------------------	------------------------------------	---------	-----	--------------	-----	------

PENTOXIFYLLINETABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

>D>	AB	APOTEX	400MG	A075191	001	Jun 09, 1999	Mar	CRLD
>A>	AB	+	400MG	A075191	001	Jun 09, 1999	Mar	CRLD
>D>	AB	IMPAX LABS	400MG	A075093	001	Aug 10, 1999	Mar	DISC
>A>		@	400MG	A075093	001	Aug 10, 1999	Mar	DISC

TABLET, EXTENDED RELEASE;ORAL

PENTOXIFYLLINE

>D>	AB	PLIVA	400MG	A074874	001	May 25, 1999	Mar	DISC
>A>		@	400MG	A074874	001	May 25, 1999	Mar	DISC
		TRENTAL						
		@ US PHARM HOLDINGS	400MG	N018631	001	Aug 30, 1984	Jan	CAHN

PERPHENAZINE

TABLET;ORAL

PERPHENAZINE

AB		WILSHIRE PHARMS INC	2MG	A205973	001	Dec 17, 2015	Jan	CAHN
AB			4MG	A205973	002	Dec 17, 2015	Jan	CAHN
AB			8MG	A205973	003	Dec 17, 2015	Jan	CAHN
AB			16MG	A205973	004	Dec 17, 2015	Jan	CAHN

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE

		@ ABLE	200MG,N/A,N/A;N/A,800MG,160MG	N021105	001	Jun 26, 2001	Jan	CMS1
--	--	--------	-------------------------------	---------	-----	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

>D>	AA	MUTUAL PHARM	30MG	A040525	001	Oct 23, 2003	Mar	CAHN
>A>	AA	SUN PHARM INDS	30MG	A040525	001	Oct 23, 2003	Mar	CAHN

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE

	AA	INGENUS PHARMS NJ	37.5MG	A091451	001	Sep 21, 2012	Jan	CAHN
>D>	AA	MUTUAL PHARM	37.5MG	A040526	001	Oct 23, 2003	Mar	CAHN
>A>	AA	SUN PHARM INDS	37.5MG	A040526	001	Oct 23, 2003	Mar	CAHN

PHENYL BUTAZONE

CAPSULE;ORAL

PHENYL BUTAZONE

>D>		@ MUTUAL PHARM	100MG	A088994	001	Dec 04, 1985	Mar	CAHN
>A>		@ SUN PHARM INDS	100MG	A088994	001	Dec 04, 1985	Mar	CAHN

TABLET;ORAL

PHENYL BUTAZONE

>D>		@ MUTUAL PHARM	100MG	A088863	001	Dec 04, 1985	Mar	CAHN
>A>		@ SUN PHARM INDS	100MG	A088863	001	Dec 04, 1985	Mar	CAHN

PHYTONADIONE

INJECTABLE;INJECTION

AQUAMEPHYTON

		@ TELIGENT PHARMA INC	1MG/0.5ML	N012223	002		Jan	CAHN
		@	10MG/ML	N012223	001		Jan	CAHN

PINDOLOL

TABLET;ORAL

PINDOLOL

>D>	AB	MUTUAL PHARM	5MG	A074063	001	Jan 27, 1994	Mar	CAHN
>D>	AB		10MG	A074063	002	Jan 27, 1994	Mar	CAHN
>A>	AB	SUN PHARM INDS	5MG	A074063	001	Jan 27, 1994	Mar	CAHN
>A>	AB		10MG	A074063	002	Jan 27, 1994	Mar	CAHN

PIROXICAM

CAPSULE;ORAL

PIROXICAM

>D>		@ MUTUAL PHARM	20MG	A073536	001	Mar 12, 1993	Mar	CAHN
	AB	MYLAN PHARMS INC	20MG	A074118	001	Jun 15, 1993	Jan	CAHN
>A>		@ SUN PHARM INDS	20MG	A073536	001	Mar 12, 1993	Mar	CAHN

PODOFILOX

GEL;TOPICAL

CONDYLOX

>D>		+ ACTAVIS LABS UT INC	0.5%	N020529	001	Mar 13, 1997	Mar	CAHN
>A>		+ ALLERGAN SALES LLC	0.5%	N020529	001	Mar 13, 1997	Mar	CAHN

SOLUTION;TOPICAL

CONDYLOX

>D>	AT	+ ACTAVIS LABS UT INC	0.5%	N019795	001	Dec 13, 1990	Mar	CAHN
>A>	AT	+ ALLERGAN SALES LLC	0.5%	N019795	001	Dec 13, 1990	Mar	CAHN

POLYMYXIN B SULFATEINJECTABLE; INJECTION
POLYMYXIN B SULFATE

>A>	AP	AUROBINDO PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A206589	001	Apr 04, 2016	Mar	NEWA
-----	----	----------------------	----------------------------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

	AB	GLENMARK PHARMS LTD	10MEQ	A202868	001	Jan 19, 2016	Jan	NEWA
>A>	AB	KREMERS URBAN PHARMS	8MEQ	A204210	001	Mar 28, 2016	Mar	NEWA
>A>	AB		10MEQ	A204210	002	Mar 28, 2016	Mar	NEWA
	AB	TRIS PHARMA INC	8MEQ	A201944	001	Mar 04, 2016	Feb	NEWA
	AB		10MEQ	A201944	002	Mar 04, 2016	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

	AB1	NOVEL LABS INC	10MEQ	A206347	001	Jan 21, 2016	Jan	NEWA
	AB1		20MEQ	A206347	002	Jan 21, 2016	Jan	NEWA

PRAVASTATIN SODIUMTABLET; ORAL
PRAVASTATIN SODIUM

>A>	AB	CIPLA LTD	80MG	A077904	004	Mar 22, 2016	Mar	NEWA
>D>	AB	MYLAN	10MG	A077013	001	Oct 23, 2006	Mar	DISC
>A>		@	10MG	A077013	001	Oct 23, 2006	Mar	DISC
>D>	AB		20MG	A077013	002	Oct 23, 2006	Mar	DISC
>A>		@	20MG	A077013	002	Oct 23, 2006	Mar	DISC
>D>	AB		40MG	A077013	003	Oct 23, 2006	Mar	DISC
>A>		@	40MG	A077013	003	Oct 23, 2006	Mar	DISC
>D>	AB		80MG	A077013	004	Dec 28, 2007	Mar	DISC
>A>		@	80MG	A077013	004	Dec 28, 2007	Mar	DISC

PREDNISOLONETABLET; ORAL
PREDNISOLONE

	@	AUROLIFE PHARMA LLC	5MG	A084773	001		Feb	CAHN
--	---	---------------------	-----	---------	-----	--	-----	------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

>D>		ORAPRED						
>D>	AA	+ CONCORDIA PHARMS INC	EQ 15MG BASE/5ML	A075117	001	Dec 14, 2000	Mar	DISC
>A>		@	EQ 15MG BASE/5ML	A075117	001	Dec 14, 2000	Mar	DISC
		PREDNISOLONE SODIUM PHOSPHATE						
>D>	AA	WOCKHARDT	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Mar	CRLD
>A>	AA	+	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Mar	CRLD

PREDNISONTABLET; ORAL
PREDNISON

>A>	@	AUROLIFE PHARMA LLC	5MG	A084774	001		Mar	CAHN
>A>	@		10MG	A089983	001	Jan 12, 1989	Mar	CAHN
>A>	@		20MG	A085813	001		Mar	CAHN
>A>	@		50MG	A089984	001	Jan 12, 1989	Mar	CAHN
>A>	AB	DELCOR ASSET CORP	5MG	A080292	001		Mar	CAHN
>A>	AB		10MG	A088832	001	Dec 04, 1985	Mar	CAHN
>A>	AB		20MG	A083677	001		Mar	CAHN
>D>	AB	HIKMA PHARMS	5MG	A080292	001		Mar	CAHN
>D>	AB		10MG	A088832	001	Dec 04, 1985	Mar	CAHN
>D>	AB		20MG	A083677	001		Mar	CAHN
>D>	AB	MUTUAL PHARM	20MG	A089247	001	Dec 04, 1985	Mar	CAHN
>D>	@	SANDOZ	5MG	A084774	001		Mar	CAHN
>D>	@		10MG	A089983	001	Jan 12, 1989	Mar	CAHN
>D>	@		20MG	A085813	001		Mar	CAHN
>D>	@		50MG	A089984	001	Jan 12, 1989	Mar	CAHN
>A>	AB	SUN PHARM INDS	20MG	A089247	001	Dec 04, 1985	Mar	CAHN

PRIMIDONETABLET; ORAL
PRIMIDONE

>D>	AB	IMPAX LABS	50MG	A040717	001	Feb 12, 2008	Mar	DISC
>A>		@	50MG	A040717	001	Feb 12, 2008	Mar	DISC
>D>	AB		250MG	A040717	002	Feb 12, 2008	Mar	DISC

TABLET;ORAL

PRIMIDONE

>A>	@	250MG	A 040717	002	Feb 12, 2008	Mar	DISC
>D>	AB	MUTUAL PHARM	50MG	A 040626	001	Sep 29, 2005	Mar CAHN
>D>	AB		250MG	A 040626	002	Sep 29, 2005	Mar CAHN
>A>	AB	SUN PHARM INDS	50MG	A 040626	001	Sep 29, 2005	Mar CAHN
>A>	AB		250MG	A 040626	002	Sep 29, 2005	Mar CAHN

PROGESTERONE

CAPSULE;ORAL

PROGESTERONE

AB		BIONPHARMA INC	100MG	A 200900	001	Aug 16, 2013	Jan CAHN
AB			200MG	A 200900	002	Aug 16, 2013	Jan CAHN

PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE

AA		NOSTRUM LABS INC	6.25MG/5ML	A 040891	001	Mar 13, 2009	Feb CAHN
----	--	------------------	------------	----------	-----	--------------	----------

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

>D>	AB	IMPAX LABS	12.5MG	A 040724	001	Feb 12, 2008	Mar DISC
>A>	@		12.5MG	A 040724	001	Feb 12, 2008	Mar DISC
>D>	AB		25MG	A 040724	002	Feb 12, 2008	Mar DISC
>A>	@		25MG	A 040724	002	Feb 12, 2008	Mar DISC
>D>	AB		50MG	A 040791	001	May 20, 2008	Mar DISC
>A>	@		50MG	A 040791	001	May 20, 2008	Mar DISC
>D>	@	MUTUAL PHARM	12.5MG	A 084555	001		Mar CAHN
>D>	@		25MG	A 084554	001		Mar CAHN
>A>	@	SUN PHARM INDS	12.5MG	A 084555	001		Mar CAHN
>A>	@		25MG	A 084554	001		Mar CAHN
>A>	@		50MG	A 084557	001		Jan CAHN

PROPAFENONE HYDROCHLORIDE

TABLET;ORAL

PROPAFENONE HYDROCHLORIDE

>D>	AB	MUTUAL PHARM	150MG	A 075998	001	Nov 29, 2001	Mar CAHN
>D>	AB		225MG	A 075998	002	Nov 29, 2001	Mar CAHN
>D>	AB		300MG	A 075998	003	Nov 29, 2001	Mar CAHN
>A>	AB	SUN PHARM INDS	150MG	A 075998	001	Nov 29, 2001	Mar CAHN
>A>	AB		225MG	A 075998	002	Nov 29, 2001	Mar CAHN
>A>	AB		300MG	A 075998	003	Nov 29, 2001	Mar CAHN

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPRANOLOL HYDROCHLORIDE

>D>	AB	UPSHER SMITH	60MG	A 078311	001	Mar 06, 2009	Mar CTEC
>A>	BX		60MG	A 078311	001	Mar 06, 2009	Mar CTEC
>D>	AB		80MG	A 078311	002	Mar 06, 2009	Mar CTEC
>A>	BX		80MG	A 078311	002	Mar 06, 2009	Mar CTEC
>D>	AB		120MG	A 078311	003	Mar 06, 2009	Mar CTEC
>A>	BX		120MG	A 078311	003	Mar 06, 2009	Mar CTEC
>D>	AB		160MG	A 078311	004	Mar 06, 2009	Mar CTEC
>A>	BX		160MG	A 078311	004	Mar 06, 2009	Mar CTEC

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

>D>	AP	SANDOZ	1MG/ML	A 076400	001	Feb 26, 2003	Mar DISC
>A>	@		1MG/ML	A 076400	001	Feb 26, 2003	Mar DISC

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

>D>	@	MUTUAL PHARM	80MG	A 070322	001	Aug 04, 1986	Mar CAHN
>A>	@	SUN PHARM INDS	80MG	A 070322	001	Aug 04, 1986	Mar CAHN

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

>D>	@	MUTUAL PHARM	50MG	A 083982	001		Mar CAHN
>A>	@	SUN PHARM INDS	50MG	A 083982	001		Mar CAHN

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE;ORAL
PYRIDOSTIGMINE BROMIDE

AB	ALVOGEN MALTA	180MG	A204737	001	Jun 26, 2015	Jan	CAHN
----	---------------	-------	---------	-----	--------------	-----	------

QUAZEPAM

TABLET;ORAL
DORAL

>A>	@ CUTIS HEALTH LLC	7.5MG	N018708	003	Feb 26, 1987	Mar	CAHN
>A>	@	15MG	N018708	001	Dec 27, 1985	Mar	CAHN
>D>	@ SCIECURE PHARMA INC	7.5MG	N018708	003	Feb 26, 1987	Mar	CAHN
>D>	@	15MG	N018708	001	Dec 27, 1985	Mar	CAHN

QUETIAPINE FUMARATE

TABLET;ORAL
QUETIAPINE FUMARATE

AB	UNICHEM LABS LTD	EQ 25MG BASE	A202674	001	Mar 08, 2016	Feb	NEWA
AB		EQ 50MG BASE	A202674	002	Mar 08, 2016	Feb	NEWA
AB		EQ 100MG BASE	A202674	003	Mar 08, 2016	Feb	NEWA
AB		EQ 200MG BASE	A202674	004	Mar 08, 2016	Feb	NEWA
AB		EQ 300MG BASE	A202674	005	Mar 08, 2016	Feb	NEWA
AB		EQ 400MG BASE	A202674	006	Mar 08, 2016	Feb	NEWA

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL
QUINAPRIL HYDROCHLORIDE

@	ACTAVIS LABS FL INC	EQ 5MG BASE	A076049	001	Jan 14, 2005	Jan	DISC
@		EQ 10MG BASE	A076049	002	Jan 14, 2005	Jan	DISC
@		EQ 20MG BASE	A076049	003	Jan 14, 2005	Jan	DISC
@		EQ 40MG BASE	A076049	004	Jan 14, 2005	Jan	DISC

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL
QUINIDINE GLUCONATE

>A>	@ AUROLIFE PHARMA LLC	324MG	A089894	001	Dec 15, 1988	Mar	CAHN
>D> BX	+ MUTUAL PHARM	324MG	A089338	001	Feb 11, 1987	Mar	CAHN
>D>	@ SANDOZ	324MG	A089894	001	Dec 15, 1988	Mar	CAHN
>A> BX	+ SUN PHARM INDS	324MG	A089338	001	Feb 11, 1987	Mar	CAHN

QUINIDINE SULFATE

TABLET;ORAL
QUINIDINE SULFATE

>D> AB	MUTUAL PHARM	200MG	A081030	001	Apr 14, 1989	Mar	CAHN
>D> AB		300MG	A081031	001	Apr 14, 1989	Mar	CAHN
>A> AB	SUN PHARM INDS	200MG	A081030	001	Apr 14, 1989	Mar	CAHN
>A> AB		300MG	A081031	001	Apr 14, 1989	Mar	CAHN

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL
RALOXIFENE HYDROCHLORIDE

>A> AB	AMNEAL PHARMS	60MG	A208206	001	Apr 08, 2016	Mar	NEWA
>A> AB	GLENMARK PHARMS LTD	60MG	A204491	001	Mar 22, 2016	Mar	NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
ZANTAC

AP	+ IGI LABS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan	CAHN
	ZANTAC IN PLASTIC CONTAINER						
	@ IGI LABS INC	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Jan	CAHN
	@	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Jan	CAHN

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

>D> AA	CARACO	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Mar	CAHN
>A> AA	NOSTRUM LABS INC	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Mar	CAHN

RASAGILINE MESYLATE

TABLET;ORAL
RASAGILINE MESYLATE

AB	ORCHID HLTHCARE	EQ 0.5MG BASE	A201970	001	Mar 15, 2016	Feb	NEWA
AB		EQ 1MG BASE	A201970	002	Mar 15, 2016	Feb	NEWA

RESERPINE

TABLET; ORAL

RESERPINE

@	HIKMA INTL PHARMS	0.1MG	A080975	001		Feb	CAHN
@		0.25MG	A080975	002		Feb	CAHN
@		1MG	A080975	003		Feb	CAHN

RETAPAMULIN

OINTMENT; TOPICAL

ALTABAX

+	AQUA PHARMS LLC	1%	N022055	001	Apr 12, 2007	Jan	CAHN
---	-----------------	----	---------	-----	--------------	-----	------

RIFAMPIN

INJECTABLE; INJECTION

RIFAMPIN

AP	HIKMA PHARMS	600MG/VIAL	A205039	001	Mar 03, 2016	Feb	NEWA
AP	WATSON PHARMS INC	600MG/VIAL	A206736	001	Jan 19, 2016	Jan	NEWA

RILUZOLE

TABLET; ORAL

RILUZOLE

>A>	AB	ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016	Mar	NEWA
-----	----	----------------	------	---------	-----	--------------	-----	------

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

AB	ALLERGAN PHARMS INTL	5MG	N020835	002	Apr 14, 2000	Jan	CAHN
AB		30MG	N020835	001	Mar 27, 1998	Jan	CAHN
AB	+	35MG	N020835	003	May 25, 2002	Jan	CAHN
	@	75MG	N020835	004	Apr 16, 2007	Jan	CAHN
AB	+	150MG	N020835	005	Apr 22, 2008	Jan	CAHN

TABLET, DELAYED RELEASE; ORAL

ATELVIA

AB	+	ALLERGAN PHARMS INTL	35MG	N022560	001	Oct 08, 2010	Jan	CAHN
----	---	----------------------	------	---------	-----	--------------	-----	------

RIVASTIGMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

RIVASTIGMINE

AB	ALVOGEN MALTA	4.6MG/24HR	A204403	001	Sep 03, 2015	Jan	CAHN
AB		9.5MG/24HR	A204403	002	Sep 03, 2015	Jan	CAHN
AB		13.3MG/24HR	A204403	003	Aug 31, 2015	Jan	CAHN

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

EXELON

AB	+	NOVARTIS	EQ 6MG BASE	N020823	006	Apr 21, 2000	Jan	CRLD
		RIVASTIGMINE TARTRATE						
>A>	AB	AUROBINDO PHARMA LTD	EQ 1.5MG BASE	A204572	001	Mar 25, 2016	Mar	NEWA
>A>	AB		EQ 3MG BASE	A204572	002	Mar 25, 2016	Mar	NEWA
>A>	AB		EQ 4.5MG BASE	A204572	003	Mar 25, 2016	Mar	NEWA
>A>	AB		EQ 6MG BASE	A204572	004	Mar 25, 2016	Mar	NEWA

RIZATRIPTAN BENZOATE

TABLET; ORAL

RIZATRIPTAN BENZOATE

AB	ALKEM LABS LTD	EQ 5MG BASE	A203269	001	Feb 18, 2016	Feb	NEWA
AB		EQ 10MG BASE	A203269	002	Feb 18, 2016	Feb	NEWA
AB	NOSTRUM LABS INC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Jan	CAHN
AB		EQ 10MG BASE	A202047	002	Dec 31, 2012	Jan	CAHN

ROPIVACAINE HYDROCHLORIDE

>D> INJECTABLE; INJECTION

>D> NAROPIN

>D>	AP	FRESENIUS KABI USA	2MG/ML	N020533	001	Sep 24, 1996	Mar	CDFR
>D>	AP		5MG/ML	N020533	003	Sep 24, 1996	Mar	CDFR
>D>	AP		7.5MG/ML	N020533	004	Sep 24, 1996	Mar	CDFR

ROPIVACAINE HYDROCHLORIDE

>A>	AP	AKORN INC	5MG/ML	A203955	001	Apr 11, 2016	Mar	NEWA
>D>	AP	HOSPIRA	2MG/ML	A090194	001	Sep 23, 2014	Mar	CDFR
>D>	AP		5MG/ML	A090194	002	Sep 23, 2014	Mar	CDFR
>D>	AP		7.5MG/ML	A090194	003	Sep 23, 2014	Mar	CDFR

>D>	INJECTABLE; INJECTION								
>D>	ROPIVACAINE HYDROCHLORIDE								
>D>	AP	10MG/ML		A090194	004	Sep 23, 2014	Mar	CDFR	
>D>	AP	NAVINTA LLC	5MG/ML	A078601	002	Jul 17, 2014	Mar	CDFR	
>D>	AP		10MG/ML	A078601	003	Jul 17, 2014	Mar	CDFR	
>D>	AP	SAGENT STRIDES	2MG/ML	A090318	001	Sep 23, 2014	Mar	CDFR	
>D>	AP		5MG/ML	A090318	002	Sep 23, 2014	Mar	CDFR	
>D>	AP		7.5MG/ML	A090318	003	Sep 23, 2014	Mar	CDFR	
>D>	AP		10MG/ML	A090318	004	Sep 23, 2014	Mar	CDFR	
>A>	SOLUTION; INJECTION								
>A>	NAROPIN								
>A>	AP	FRESENIUS KABI USA	20MG/10ML (2MG/ML)	N020533	001	Sep 24, 1996	Mar	CDFR	
>A>	AP		40MG/20ML (2MG/ML)	N020533	002	Sep 24, 1996	Mar	NEWA	
>A>			100MG/20ML (5MG/ML)	N020533	003	Sep 24, 1996	Mar	CDFR	
>A>	AP		100MG/10ML (10MG/ML)	N020533	005	Sep 24, 1996	Mar	NEWA	
>A>	AP		150MG/20ML (7.5MG/ML)	N020533	004	Sep 24, 1996	Mar	CDFR	
>A>	AP		150MG/30ML (5MG/ML)	N020533	008	Sep 24, 1996	Mar	NEWA	
>A>			200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Mar	NEWA	
>A>	AP	+	200MG/20ML (10MG/ML)	N020533	011	Sep 24, 1996	Mar	NEWA	
>A>			400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996	Mar	NEWA	
>A>			500MG/100ML (5MG/ML)	N020533	009	Sep 24, 1996	Mar	NEWA	
>A>			1GM/200ML (5MG/ML)	N020533	010	Sep 24, 1996	Mar	NEWA	
>A>	ROPIVACAINE HYDROCHLORIDE								
>A>	AP	HOSPIRA	20MG/10ML (2MG/ML)	A090194	001	Sep 23, 2014	Mar	CDFR	
>A>	AP		40MG/20ML (2MG/ML)	A090194	005	Sep 23, 2014	Mar	NEWA	
>A>	AP		100MG/10ML (10MG/ML)	A090194	004	Sep 23, 2014	Mar	CDFR	
>A>	AP		150MG/30ML (5MG/ML)	A090194	002	Sep 23, 2014	Mar	CDFR	
>A>	AP		150MG/20ML (7.5MG/ML)	A090194	003	Sep 23, 2014	Mar	CDFR	
>A>	AP		200MG/20ML (10MG/ML)	A090194	006	Sep 23, 2014	Mar	NEWA	
>A>	AP	NAVINTA LLC	150MG/30ML (5MG/ML)	A078601	002	Jul 17, 2014	Mar	CDFR	
>A>	AP		200MG/20ML (10MG/ML)	A078601	003	Jul 17, 2014	Mar	CDFR	
>A>	AP	SAGENT STRIDES	40MG/20ML (2MG/ML)	A090318	001	Sep 23, 2014	Mar	CDFR	
>A>	AP		150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014	Mar	CDFR	
>A>	AP		150MG/20ML (7.5MG/ML)	A090318	003	Sep 23, 2014	Mar	CDFR	
>A>	AP		200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014	Mar	CDFR	

SILDENAFIL CITRATE

TABLET; ORAL

SILDENAFIL CITRATE

@	TEVA	EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb	DISC	
		EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb	NEWA	
@		EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb	DISC	
		EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb	NEWA	
@		EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb	DISC	
		EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb	NEWA	

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

@	SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Feb	DISC	
@		10MG	A076285	002	Dec 20, 2006	Feb	DISC	
@		20MG	A076285	003	Dec 20, 2006	Feb	DISC	
@		40MG	A076285	004	Dec 20, 2006	Feb	DISC	
@		80MG	A076285	005	Jun 23, 2006	Feb	DISC	

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; IV (INFUSION)

AMMONUL

AP	+	MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Feb	CFTG	
			SODIUM PHENYLACETATE AND SODIUM BENZOATE						
AP		AILEX PHARMS PVT LTD	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Feb	NEWA	

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE

		HOSPIRA INC	0.5MEQ/ML	A202981	001	Mar 04, 2016	Feb	NEWA	
--	--	-------------	-----------	---------	-----	--------------	-----	------	--

SODIUM FLUORIDE F-18INJECTABLE;INTRAVENOUS
SODIUM FLUORIDE F-18

AP ZEVACOR PHARMA INC 10-200mCi/ML A203592 001 Aug 18, 2015 Feb CAHN

SODIUM IODIDE I-131CAPSULE;ORAL
SODIUM IODIDE I 131

>A> JUBILANT DRAXIMAGE 0.009-0.1mCi N021305 006 May 19, 2005 Mar CMS1
 >A> @ 2-200mCi N021305 004 Nov 18, 2004 Mar CMS1
 SODIUM IODIDE I-131
 >D> JUBILANT DRAXIMAGE 0.009-0.1mCi N021305 006 May 19, 2005 Mar CMS1
 >D> @ 2-200mCi N021305 004 Nov 18, 2004 Mar CMS1

SODIUM PHENYLBUTYRATEPOWDER;ORAL
BUPHENYL

>A> AB + HORIZON PHARMA INC 3GM/TEASPOONFUL N020573 001 Apr 30, 1996 Mar CAHN
 >D> AB + HYPERION THERAPS INC 3GM/TEASPOONFUL N020573 001 Apr 30, 1996 Mar CAHN
 TABLET;ORAL
 BUPHENYL
 >A> AB + HORIZON PHARMA USA 500MG N020572 001 May 13, 1996 Mar CAHN
 >D> AB + HYPERION THERAPS INC 500MG N020572 001 May 13, 1996 Mar CAHN

SODIUM POLYSTYRENE SULFONATEPOWDER;ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

AA BELCHER PHARMS LLC 454GM/BOT A205727 001 Feb 23, 2016 Feb NEWA
 AA INVATECH PHARMA 454GM/BOT A206815 001 Feb 18, 2016 Feb NEWA

SOTALOL HYDROCHLORIDETABLET;ORAL
SOTALOL HYDROCHLORIDE

>D> AB1 IMPAX PHARMS 80MG A075663 001 Nov 07, 2000 Mar DISC
 >A> @ 80MG A075663 001 Nov 07, 2000 Mar DISC
 >D> AB1 120MG A075663 002 Nov 07, 2000 Mar DISC
 >A> @ 120MG A075663 002 Nov 07, 2000 Mar DISC
 >D> AB1 160MG A075663 003 Nov 07, 2000 Mar DISC
 >A> @ 160MG A075663 003 Nov 07, 2000 Mar DISC
 >D> AB1 240MG A075663 004 Nov 07, 2000 Mar DISC
 >A> @ 240MG A075663 004 Nov 07, 2000 Mar DISC
 >D> @ MUTUAL PHARM 80MG A076576 001 Apr 08, 2004 Mar CAHN
 >D> @ 120MG A076576 002 Apr 08, 2004 Mar CAHN
 >D> @ 160MG A076576 003 Apr 08, 2004 Mar CAHN
 >A> @ SUN PHARM INDS 80MG A076576 001 Apr 08, 2004 Mar CAHN
 >A> @ 120MG A076576 002 Apr 08, 2004 Mar CAHN
 >A> @ 160MG A076576 003 Apr 08, 2004 Mar CAHN

SPIRONOLACTONETABLET;ORAL
SPIRONOLACTONE

>D> AB MUTUAL PHARM 25MG A089424 001 Jul 23, 1986 Mar CAHN
 >D> AB 50MG A089424 002 Aug 11, 1999 Mar CAHN
 >D> AB 100MG A089424 003 Aug 11, 1999 Mar CAHN
 >A> AB SUN PHARM INDS 25MG A089424 001 Jul 23, 1986 Mar CAHN
 >A> AB 50MG A089424 002 Aug 11, 1999 Mar CAHN
 >A> AB 100MG A089424 003 Aug 11, 1999 Mar CAHN

SUCRALFATETABLET;ORAL
SUCRALFATE

AB MYLAN IRELAND LTD 1GM A074415 001 Jun 08, 1998 Jan CAHN

SUGAMMADEX SODIUMSOLUTION;INTRAVENOUS
BRIDION

ORGANON SUB MERCK EQ 200MG BASE/2ML (EQ 100MG
 BASE/ML)
 + EQ 500MG BASE/5ML (EQ 100MG
 BASE/ML)

N022225 002 Dec 15, 2015 Jan CPOT
 N022225 001 Dec 15, 2015 Jan CPOT

SULFAMETHOXAZOLE

TABLET; ORAL

SULFAMETHOXAZOLE

@ AUROLIFE PHARMA LLC 500MG

A 085844 001

Feb CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>D> AB MUTUAL PHARM 800MG;160MG

A 071017 001 Aug 25, 1986 Mar CAHN

>A> AB SUN PHARM INDS 800MG;160MG

A 071017 001 Aug 25, 1986 Mar CAHN

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

@ AUROLIFE PHARMA LLC 500MG

A 085628 001

Feb CAHN

SULINDAC

TABLET; ORAL

SULINDAC

>D> AB MUTUAL PHARM 150MG

A 072050 001 Apr 17, 1991 Mar CAHN

>D> AB 200MG

A 072051 001 Apr 17, 1991 Mar CAHN

>A> AB SUN PHARM INDS 150MG

A 072050 001 Apr 17, 1991 Mar CAHN

>A> AB 200MG

A 072051 001 Apr 17, 1991 Mar CAHN

SUMATRIPTAN

SPRAY; NASAL

IMITREX

AB + GLAXOSMITHKLINE 5MG/SPRAY

N 020626 001 Aug 26, 1997 Feb CFTG

AB + 20MG/SPRAY

N 020626 003 Aug 26, 1997 Feb CFTG

SUMATRIPTAN

AB LANNETT 5MG/SPRAY

A 204841 001 Feb 19, 2016 Feb NEWA

AB 20MG/SPRAY

A 204841 002 Feb 19, 2016 Feb NEWA

SUMATRIPTAN SUCCINATE

POWDER; INHALATION

ONZETRA XSAIL

+ AVANIR PHARMS EQ 11MG BASE

N 206099 001 Jan 27, 2016 Jan NEWA

SOLUTION; SUBCUTANEOUS

ZEMBRACE SYMTOUCH

DR REDDYS LABS LTD EQ 3MG BASE/0.5ML (EQ 3MG
BASE/0.5ML)

N 208223 001 Jan 28, 2016 Jan NEWA

TAMOXIFEN CITRATE

SOLUTION; ORAL

SOLTAMOX

MIDATECH PHARMA US EQ 10MG BASE/5ML

N 021807 001 Oct 29, 2005 Jan CAHN

TABLET; ORAL

TAMOXIFEN CITRATE

@ ACTAVIS LABS FL INC EQ 10MG BASE

A 076179 001 Feb 20, 2003 Jan DISC

@ EQ 20MG BASE

A 076179 002 Feb 20, 2003 Jan DISC

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INTRAVENOUS

ULTRA-TECHNEKOW FM

+ MALLINKRODT NUCLEAR 1-19 CI/GENERATOR

N 017243 003 Feb 18, 2014 Jan CAHN

@ 0.25-3 CI/GENERATOR

N 017243 002 Jan CAHN

TEGASEROD MALEATE

TABLET; ORAL

ZELNORM

@ US WORLDMEDS LLC EQ 2MG BASE

N 021200 001 Jul 24, 2002 Jan CAHN

@ EQ 6MG BASE

N 021200 002 Jul 24, 2002 Jan CAHN

>D> TELITHROMYCIN

>D> TABLET; ORAL

>D> KETEK

>D> SANOFI AVENTIS US 300MG

N 021144 002 Feb 09, 2005 Mar DISC

>A> @ 300MG

N 021144 002 Feb 09, 2005 Mar DISC

>D> + 400MG

N 021144 001 Apr 01, 2004 Mar DISC

>A> @ 400MG

N 021144 001 Apr 01, 2004 Mar DISC

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

>D>	AB	MUTUAL PHARM	7.5MG	A078581	001	Sep 08, 2009	Mar	CAHN
>D>		@	15MG	A071174	001	Jul 10, 1986	Mar	CAHN
>D>	AB		22.5MG	A071175	002	Sep 14, 2009	Mar	CAHN
>D>		@	30MG	A071175	001	Jul 10, 1986	Mar	CAHN
>A>	AB	SUN PHARM INDS	7.5MG	A078581	001	Sep 08, 2009	Mar	CAHN
>A>		@	15MG	A071174	001	Jul 10, 1986	Mar	CAHN
>A>	AB		22.5MG	A071175	002	Sep 14, 2009	Mar	CAHN
>A>		@	30MG	A071175	001	Jul 10, 1986	Mar	CAHN

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

>A>	AB	IDT AUSTRALIA LTD	5MG	A206413	001	Apr 12, 2016	Mar	NEWA
>A>	AB		20MG	A206413	002	Apr 12, 2016	Mar	NEWA
>A>	AB		100MG	A206413	003	Apr 12, 2016	Mar	NEWA
>A>	AB		140MG	A206413	004	Apr 12, 2016	Mar	NEWA
>A>	AB		180MG	A206413	005	Apr 12, 2016	Mar	NEWA
>A>	AB		250MG	A206413	006	Apr 12, 2016	Mar	NEWA
	AB	KREMERS URBAN PHARMS	5MG	A203898	001	Feb 10, 2016	Jan	NEWA
	AB		20MG	A203898	002	Feb 10, 2016	Jan	NEWA
	AB		100MG	A203898	003	Feb 10, 2016	Jan	NEWA
	AB		140MG	A203898	004	Feb 10, 2016	Jan	NEWA
	AB		180MG	A203898	005	Feb 10, 2016	Jan	NEWA
	AB		250MG	A203898	006	Feb 10, 2016	Jan	NEWA
>A>	AB	LANNETT HOLDINGS INC	5MG	A202750	001	Mar 23, 2016	Mar	NEWA
>A>	AB		20MG	A202750	002	Mar 23, 2016	Mar	NEWA
>A>	AB		100MG	A202750	003	Mar 23, 2016	Mar	NEWA
>A>	AB		140MG	A202750	004	Mar 23, 2016	Mar	NEWA
>A>	AB		180MG	A202750	005	Mar 23, 2016	Mar	NEWA
>A>	AB		250MG	A202750	006	Mar 23, 2016	Mar	NEWA

TERBUTALINE SULFATE

TABLET;ORAL

TERBUTALINE SULFATE

>D>	AB	IMPAX LABS	2.5MG	A075877	001	Jun 26, 2001	Mar	DISC
>A>		@	2.5MG	A075877	001	Jun 26, 2001	Mar	DISC
>D>	AB	+	5MG	A075877	002	Jun 26, 2001	Mar	DISC
>A>		@	5MG	A075877	002	Jun 26, 2001	Mar	DISC
>D>	AB	LANNETT	2.5MG	A077152	001	Mar 25, 2005	Mar	CTEC
>A>			2.5MG	A077152	001	Mar 25, 2005	Mar	CTEC
>D>	AB		5MG	A077152	002	Mar 25, 2005	Mar	CTEC
>A>			5MG	A077152	002	Mar 25, 2005	Mar	CTEC

TESTOSTERONE

FILM, EXTENDED RELEASE;TRANSDERMAL

ANDRODERM

>D>	+	ACTAVIS LABS UT INC	2MG/24HR	N020489	003	Oct 20, 2011	Mar	CAHN
>D>		@	2.5MG/24HR	N020489	001	Sep 29, 1995	Mar	CAHN
>D>	+		4MG/24HR	N020489	004	Oct 20, 2011	Mar	CAHN
>D>		@	5MG/24HR	N020489	002	May 02, 1997	Mar	CAHN
>A>	+	ALLERGAN SALES LLC	2MG/24HR	N020489	003	Oct 20, 2011	Mar	CAHN
>A>		@	2.5MG/24HR	N020489	001	Sep 29, 1995	Mar	CAHN
>A>	+		4MG/24HR	N020489	004	Oct 20, 2011	Mar	CAHN
>A>		@	5MG/24HR	N020489	002	May 02, 1997	Mar	CAHN

PELLET;IMPLANTATION

TESTOPEL

>D>	+	ACTIENT PHARMS	75MG	A080911	001		Mar	CAHN
>A>	+	AUXILIUM PHARMS INC	75MG	A080911	001		Mar	CAHN

TABLET, EXTENDED RELEASE;BUCCAL

STRIANT

>A>	+	AUXILIUM PHARMS INC	30MG	N021543	001	Jun 19, 2003	Mar	CAHN
>D>	+	AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003	Mar	CAHN

TETRABENAZINE

TABLET; ORAL

TETRABENAZINE

AB	HETERO LABS LTD V	12.5MG	A204574	001	Feb 03, 2016	Jan	NEWA
AB		25MG	A204574	002	Feb 03, 2016	Jan	NEWA

TETRACAINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

TETRACAINE HYDROCHLORIDE

+	ALCON RES LTD	0.5%	N208135	001	Feb 29, 2016	Feb	NEWA
---	---------------	------	---------	-----	--------------	-----	------

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

>D>	ACTIENT PHARMS	200MG	A087943	001	Aug 22, 1983	Mar	CAHN
>D>		300MG	A087944	001	Aug 22, 1983	Mar	CAHN
>D>	+	400MG	A081034	001	Feb 28, 1992	Mar	CAHN
>A>	AUXILIUM PHARMS INC	200MG	A087943	001	Aug 22, 1983	Mar	CAHN
>A>		300MG	A087944	001	Aug 22, 1983	Mar	CAHN
>A>	+	400MG	A081034	001	Feb 28, 1992	Mar	CAHN

SOLUTION, ELIXIR; ORAL

ELIXOPHYLLIN

+	NOSTRUM LABS INC	80MG/15ML	A085186	001		Jan	CAHN
---	------------------	-----------	---------	-----	--	-----	------

TABLET, EXTENDED RELEASE; ORAL

THEOCHRON

AB	NOSTRUM LABS INC	100MG	A088320	001	Feb 21, 1985	Jan	CAHN
AB		200MG	A088321	001	Feb 21, 1985	Jan	CAHN
	@	300MG	A087400	002	Jan 11, 1983	Jan	CAHN

THEOPHYLLINE

AB	MYLAN IRELAND LTD	400MG	A040560	003	Apr 21, 2006	Jan	CAHN
AB	+	600MG	A040560	002	Apr 21, 2006	Jan	CAHN

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

>D>	AB	MUTUAL PHARM	10MG	A089953	004	Aug 01, 1986	Mar	CAHN
>D>		@	15MG	A088461	001	Nov 18, 1983	Mar	CAHN
>D>	AB		25MG	A089953	003	Aug 01, 1986	Mar	CAHN
>D>	AB		50MG	A089953	002	Aug 01, 1986	Mar	CAHN
>D>	AB		100MG	A089953	001	Oct 07, 1988	Mar	CAHN
>A>	AB	SUN PHARM INDS	10MG	A089953	004	Aug 01, 1986	Mar	CAHN
>A>		@	15MG	A088461	001	Nov 18, 1983	Mar	CAHN
>A>	AB		25MG	A089953	003	Aug 01, 1986	Mar	CAHN
>A>	AB		50MG	A089953	002	Aug 01, 1986	Mar	CAHN
>A>	AB		100MG	A089953	001	Oct 07, 1988	Mar	CAHN

THIOTHIXENE

CAPSULE; ORAL

THIOTHIXENE

>D>	AB	SANDOZ	1MG	A071610	001	Jun 24, 1987	Mar	DISC
>A>		@	1MG	A071610	001	Jun 24, 1987	Mar	DISC
>D>	AB		2MG	A071570	001	Jun 24, 1987	Mar	DISC
>A>		@	2MG	A071570	001	Jun 24, 1987	Mar	DISC
>D>	AB		5MG	A071529	001	Jun 24, 1987	Mar	DISC
>A>		@	5MG	A071529	001	Jun 24, 1987	Mar	DISC
>D>	AB		10MG	A071530	001	Jun 24, 1987	Mar	DISC
>A>		@	10MG	A071530	001	Jun 24, 1987	Mar	DISC

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE; ORAL

XELJANZ XR

+	PFIZER INC	EQ 11MG BASE	N208246	001	Feb 23, 2016	Feb	NEWA
---	------------	--------------	---------	-----	--------------	-----	------

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

>D>	@	MUTUAL PHARM	100MG	A071357	001	Jul 16, 1987	Mar	CAHN
>D>	@		250MG	A071358	001	Jul 16, 1987	Mar	CAHN
>D>	@		500MG	A071359	001	Jul 16, 1987	Mar	CAHN
>A>	@	SUN PHARM INDS	100MG	A071357	001	Jul 16, 1987	Mar	CAHN
>A>	@		250MG	A071358	001	Jul 16, 1987	Mar	CAHN

TABLET;ORAL									
TOLAZAMIDE									
>A>	@	500MG		A071359	001	Jul 16, 1987	Mar	CAHN	
<u>TOLMETIN SODIUM</u>									
CAPSULE;ORAL									
TOLMETIN SODIUM									
>D>	@	MUTUAL PHARM	EQ 400MG BASE	A073311	001	Nov 27, 1991	Mar	CAHN	
>A>	@	SUN PHARM INDS	EQ 400MG BASE	A073311	001	Nov 27, 1991	Mar	CAHN	
TABLET;ORAL									
TOLMETIN SODIUM									
>D>	AB	MUTUAL PHARM	EQ 200MG BASE	A073310	001	Nov 27, 1991	Mar	CAHN	
>A>	AB	SUN PHARM INDS	EQ 200MG BASE	A073310	001	Nov 27, 1991	Mar	CAHN	
<u>TOPIRAMATE</u>									
TABLET;ORAL									
TOPIRAMATE									
AB		ACTAVIS TOTOWA	25MG	A078637	001	Feb 27, 2013	Jan	CAHN	
AB			50MG	A078637	002	Feb 27, 2013	Jan	CAHN	
AB			100MG	A078637	003	Feb 27, 2013	Jan	CAHN	
AB			200MG	A078637	004	Feb 27, 2013	Jan	CAHN	
<u>TRAMADOL HYDROCHLORIDE</u>									
TABLET;ORAL									
TRAMADOL HYDROCHLORIDE									
>A>	AB	ACI HEALTHCARE LTD	50MG	A202075	001	Nov 28, 2011	Mar	CAHN	
>D>	AB	ALLIED PHARMA INC	50MG	A202075	001	Nov 28, 2011	Mar	CAHN	
>D>	AB	MUTUAL PHARM	50MG	A076100	001	Jun 20, 2002	Mar	CAHN	
>A>	AB	SUN PHARM INDS	50MG	A076100	001	Jun 20, 2002	Mar	CAHN	
TABLET, EXTENDED RELEASE;ORAL									
ULTRAM ER									
>D>	AB1	+ VALEANT INTL	100MG	N021692	001	Sep 08, 2005	Mar	CAHN	
>D>	AB1		200MG	N021692	002	Sep 08, 2005	Mar	CAHN	
>D>	AB1		300MG	N021692	003	Sep 08, 2005	Mar	CAHN	
>A>	AB1	+ VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005	Mar	CAHN	
>A>	AB1		200MG	N021692	002	Sep 08, 2005	Mar	CAHN	
>A>	AB1		300MG	N021692	003	Sep 08, 2005	Mar	CAHN	
<u>TRANEXAMIC ACID</u>									
INJECTABLE;INJECTION									
TRANEXAMIC ACID									
AP		AUROBINDO PHARMA LTD	100MG/ML	A205035	001	Jan 14, 2016	Jan	NEWA	
AP		NORTH CREEK PHARMS	100MG/ML	A202755	001	Feb 25, 2016	Feb	NEWA	
<u>TRAZODONE HYDROCHLORIDE</u>									
TABLET;ORAL									
TRAZODONE HYDROCHLORIDE									
>D>	AB	@ AUROLIFE PHARMA LLC	50MG	A072484	001	Apr 30, 1990	Feb	CAHN	
>D>	AB	MUTUAL PHARM	50MG	A073137	002	Mar 24, 1993	Mar	CAHN	
>D>	AB		100MG	A073137	001	Mar 24, 1993	Mar	CAHN	
>D>	AB		150MG	A073137	003	Dec 22, 1995	Mar	CAHN	
>A>	AB	SUN PHARM INDS	50MG	A073137	002	Mar 24, 1993	Mar	CAHN	
>A>	AB		100MG	A073137	001	Mar 24, 1993	Mar	CAHN	
>A>	AB		150MG	A073137	003	Dec 22, 1995	Mar	CAHN	
<u>TRETINOIN</u>									
CREAM;TOPICAL									
TRETINOIN									
AB		ELAN PHARMA INTL LTD	0.025%	A075264	001	Dec 24, 1998	Feb	CAHN	
AB1			0.05%	A075265	001	Dec 24, 1998	Feb	CAHN	
AB			0.1%	A075213	001	Dec 24, 1998	Feb	CAHN	
GEL;TOPICAL									
TRETINOIN									
AB		ELAN PHARMA INTL LTD	0.01%	A075589	001	Jun 11, 2002	Feb	CAHN	
AB			0.025%	A075529	001	Feb 22, 2000	Feb	CAHN	
<u>TRIMETHOBENZAMIDE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
TRIMETHOBENZAMIDE HYDROCHLORIDE									
>D>	AB	MUTUAL PHARMA	300MG	A076570	001	Aug 28, 2003	Mar	CAHN	
>A>	AB	SUN PHARM INDS	300MG	A076570	001	Aug 28, 2003	Mar	CAHN	

TRIMETHOPRIM

TABLET;ORAL

TRIMETHOPRIM

>D>	@ MUTUAL PHARM	200MG	A070495	001	Sep 24, 1986	Mar	CAHN
>A>	@ SUN PHARM INDS	200MG	A070495	001	Sep 24, 1986	Mar	CAHN

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION;ORAL

PRIMSOL

	@ AYTU PHARMS	EQ 25MG BASE/5ML	A074374	001	Jun 23, 1995	Jan	CAHN
+		EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jan	CAHN

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS;OPHTHALMIC

RESCULA

>D>	+ R-TECH UENO LTD	0.15%	N021214	001	Aug 03, 2000	Mar	DISC
>A>	@	0.15%	N021214	001	Aug 03, 2000	Mar	DISC
>A>	@ SUCAMPO PHARMA LLC	0.15%	N021214	001	Aug 03, 2000	Mar	CAHN

URSODIOL

CAPSULE;ORAL

ACTIGALL

>D>	@ ACTAVIS LABS UT INC	150MG	N019594	001	Dec 31, 1987	Mar	CAHN
>D> AB	+	300MG	N019594	002	Dec 31, 1987	Mar	CAHN
>A>	@ ALLERGAN SALES LLC	150MG	N019594	001	Dec 31, 1987	Mar	CAHN
>A> AB	+	300MG	N019594	002	Dec 31, 1987	Mar	CAHN

VALGANCICLOVIR HYDROCHLORIDE

TABLET;ORAL

VALGANCICLOVIR HYDROCHLORIDE

>A> AB	AUROBINDO PHARMA LTD	EQ 450MG BASE	A204750	001	Mar 31, 2016	Mar	NEWA
>A> AB	HETERO LABS LTD V	EQ 450MG BASE	A205166	001	Mar 18, 2016	Mar	NEWA

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

AB	BIONPHARMA INC	250MG	A073484	001	Jun 29, 1993	Jan	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

SYRUP;ORAL

VALPROIC ACID

>A> AA	NOSTRUM LABS INC	250MG/5ML	A090517	001	May 28, 2010	Mar	CAHN
>D> AA	SUN PHARM INDS INC	250MG/5ML	A090517	001	May 28, 2010	Mar	CAHN

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

>A> AP	AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A205780	001	Mar 31, 2016	Mar	NEWA
>A> AP		EQ 1GM BASE/VIAL	A205780	002	Mar 31, 2016	Mar	NEWA
>A> AP		EQ 5GM BASE/VIAL	A205779	001	Mar 29, 2016	Mar	NEWA
>A> AP		EQ 10GM BASE/VIAL	A205779	002	Mar 29, 2016	Mar	NEWA
AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A205694	001	Jan 21, 2016	Jan	NEWA
AP		EQ 1GM BASE/VIAL	A205694	002	Jan 21, 2016	Jan	NEWA

VECURONIUM BROMIDE

INJECTABLE;INJECTION

VECURONIUM BROMIDE

AP	SAGENT PHARMS	10MG/VIAL	A078274	001	Dec 29, 2008	Jan	CAHN
AP		20MG/VIAL	A078274	002	Dec 29, 2008	Jan	CAHN

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

@ PFIZER	180MG	N019152	002	Dec 15, 1989	Feb	DISC
----------	-------	---------	-----	--------------	-----	------

VORICONAZOLE

FOR SUSPENSION;ORAL

VORICONAZOLE

>A> AB	AMNEAL PHARMS	200MG/5ML	A205034	001	Apr 13, 2016	Mar	NEWA
--------	---------------	-----------	---------	-----	--------------	-----	------

INJECTABLE;IV (INFUSION)

VORICONAZOLE

>A> AP	ALVOGEN INC	200MG/VIAL	A206398	001	Mar 23, 2016	Mar	NEWA
--------	-------------	------------	---------	-----	--------------	-----	------

TABLET;ORAL

VORICONAZOLE

AB	AUROBINDO PHARMA LTD	50MG	A206837	001	Jan 22, 2016	Jan NEWA
AB		200MG	A206837	002	Jan 22, 2016	Jan NEWA

XENON XE-133

GAS;INHALATION

XENON XE 133

	LANTHEUS MEDCL	20mCi/VIAL	N017284	002		Feb CTEC
	MALLINKRODT NUCLEAR	10mCi/VIAL	N018327	001	Mar 09, 1982	Feb CMFD
		20mCi/VIAL	N018327	002	Mar 09, 1982	Feb CMFD

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

>D>	@ MUTUAL PHARMA	5MG	A077288	001	Apr 23, 2007	Mar CAHN
>D>	@	10MG	A077288	002	Apr 23, 2007	Mar CAHN
>A>	@ SUN PHARM INDS	5MG	A077288	001	Apr 23, 2007	Mar CAHN
>A>	@	10MG	A077288	002	Apr 23, 2007	Mar CAHN

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

AB	SUNOVION PHARMS INC	25MG	N020789	003	Aug 22, 2003	Feb CAHN
AB		50MG	N020789	002	Aug 22, 2003	Feb CAHN
AB	+	100MG	N020789	001	Mar 27, 2000	Feb CAHN

ZONISAMIDE

AB	BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Jan CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan CAHN
>D>	@ MUTUAL PHARM	25MG	A077635	001	Dec 22, 2005	Mar CAHN
>D>	@	50MG	A077635	002	Dec 22, 2005	Mar CAHN
>D>	@	100MG	A077635	003	Dec 22, 2005	Mar CAHN
>A>	@ SUN PHARM INDS	25MG	A077635	001	Dec 22, 2005	Mar CAHN
>A>	@	50MG	A077635	002	Dec 22, 2005	Mar CAHN
>A>	@	100MG	A077635	003	Dec 22, 2005	Mar CAHN

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

EXCEDRIN (MIGRAINE)

+ GLAXOSMITHKLINE CONS 250MG;250MG;65MG N020802 001 Jan 14, 1998 Feb CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

BIONPHARMA INC 5MG

N022429 001 Jul 23, 2009 Jan CAHN

+ 10MG N022429 004 Jul 23, 2009 Jan CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BIONPHARMA INC 5MG

N022429 003 Jul 23, 2009 Jan CAHN

+ 10MG N022429 002 Jul 23, 2009 Jan CAHN

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

NOSTRUM LABS INC 5MG/5ML

A091327 001 Oct 17, 2011 Mar CAHN

>D> SUN PHARM INDS INC 5MG/5ML A091327 001 Oct 17, 2011 Mar CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

NOSTRUM LABS INC 5MG/5ML

A091327 002 Oct 17, 2011 Mar CAHN

>D> SUN PHARM INDS INC 5MG/5ML A091327 002 Oct 17, 2011 Mar CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

NOVEL LABS INC 5MG

A206793 001 Mar 08, 2016 Feb NEWA

10MG A206793 002 Mar 08, 2016 Feb NEWA

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

CHLORPHENIRAMINE MALEATE

@ AUROLIFE PHARMA LLC 12MG

A070797 001 Aug 12, 1988 Feb CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BIONPHARMA INC 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT

A090397 001 Nov 22, 2010 Jan CAHN

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

APOTEX TECHNOLOGIES 0.05MG/SPRAY

A208150 001 Feb 29, 2016 Feb NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

BIONPHARMA INC EQ 200MG FREE ACID AND POTASSIUM SALT

A078682 001 Mar 24, 2009 Jan CAHN

MIDOL LIQUID GELS

+ BIONPHARMA INC 200MG

N021472 001 Oct 18, 2002 Jan CAHN

TABLET;ORAL

IBUPROFEN

@ MUTUAL PHARM 200MG

A070493 001 Dec 24, 1985 Mar CAHN

>A> @ SUN PHARM INDS 200MG A070493 001 Dec 24, 1985 Mar CAHN

LEVONORGESTREL

TABLET;ORAL

HER STYLE

NOVAST LABS LTD 1.5MG

A207976 001 Mar 11, 2016 Feb NEWA

LEVONORGESTREL

>A> GLENMARK PHARMS LTD 1.5MG

A207044 001 Mar 25, 2016 Mar NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

BIONPHARMA INC 1MG

N021855 001 Aug 04, 2005 Jan CAHN

+ 2MG N021855 002 Aug 04, 2005 Jan CAHN

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL
MONISTAT 3 COMBINATION PACK

>A>	+	MEDETECH PRODUCTS	2%,200MG	N020670	002	Apr 16, 1996	Mar CMS1
		MONISTAT-3 COMBINATION PACK					
>D>	+	MEDETECH PRODUCTS	2%,200MG	N020670	002	Apr 16, 1996	Mar CMS1

NAPROXEN SODIUM

CAPSULE;ORAL
NAPROXEN SODIUM

>D>	+	BANNER LIFE SCIENCES	EQ 200MG BASE	N021920	001	Feb 17, 2006	Mar CAHN
>A>	+	BIONPHARMA INC	EQ 200MG BASE	N021920	001	Feb 17, 2006	Mar CAHN

TABLET;ORAL

NAPROXEN SODIUM

>A>		AUROBINDO PHARMA LTD	EQ 200MG BASE	A205497	001	Mar 18, 2016	Mar NEWA
-----	--	----------------------	---------------	---------	-----	--------------	----------

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL
NICOTINE POLACRILEX

ACTAVIS LABS NY INC EQ 4MG BASE

A204833	001	Feb 26, 2016	Feb NEWA
---------	-----	--------------	----------

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL FOR WOMEN

+ ALLERGAN SALES LLC 3.9MG/24HR

N202211	001	Jan 25, 2013	Jan CAHN
---------	-----	--------------	----------

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

>A>		MISSION PHARMACAL CO	65MG/ML	A206211	001	Mar 24, 2016	Mar NEWA
-----	--	----------------------	---------	---------	-----	--------------	----------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 03 MARCH 2016

NO MARCH 2016 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MARCH 2016 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001 >A>	9242986	Dec 08, 2029	DS DP			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	8747894	May 08, 2032	DP U-1373			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	8747894	May 08, 2032	DP U-1373			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8809305	Dec 23, 2022	U-1078			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001					ODE	Dec 11, 2022
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AVANAFIL - STENDRA</u>						
N 202276 001 >A>	6656935	Apr 27, 2025	DS DP U-155			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVANAFIL - STENDRA</u>						
N 202276 002 >A>	6656935	Apr 27, 2025	DS DP U-155			
<u>AVANAFIL - STENDRA</u>						
N 202276 003 >A>	6656935	Apr 27, 2025	DS DP U-155			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001 >A>	9265725	Dec 08, 2027	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	9259428	Jun 13, 2023	U-644			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9169238	Feb 04, 2030	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9169238	Feb 04, 2030	DP			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	9192616	Aug 02, 2026	U-1229			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9265831	Jan 28, 2031	DP			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001					NDF	Feb 05, 2019
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	9241918	Mar 16, 2025	DP U-1814			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9216183	Jan 15, 2023	U-1487			
	9226931	Jan 15, 2023	U-1799			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	Feb 18, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-1815		NCE	Feb 18, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815		NCE	Feb 18, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-1815		NCE	Feb 18, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-1815		NCE	Feb 18, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	Feb 18, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	Feb 18, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9192576	Apr 30, 2032	DP U-976			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	9259421	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	9248123	Jan 13, 2032	U-1808			
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	>A> 9295687	Jul 10, 2035	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001					I-722 I-723	Jan 21, 2019 Jan 21, 2019
<u>CEFIXIME - SUPRAX</u>						
N 202091 001	9233112	Dec 14, 2028	DP U-1676			
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	9233068	Dec 11, 2029	DP		NP	Dec 10, 2018
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	>A> 5814639	Sep 29, 2015	DS DP			
	>A> 5814639*PED	Mar 29, 2016				
	>A> 6703396	Mar 09, 2021	DS DP			
	>A> 6703396*PED	Sep 09, 2021				
	7803788	Feb 02, 2022	U-257			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001					ODE	Nov 10, 2022
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					>A> ODE	Mar 11, 2023
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					>A> ODE	Mar 11, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	9248191	Aug 27, 2024	U-1479			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9233077	Jun 17, 2034	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9233077	Jun 17, 2034	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001					D-161 D-162 I-726 I-727	Feb 05, 2019 Feb 05, 2019 Feb 05, 2019 Feb 05, 2019
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002					D-161 D-162 I-726 I-727	Feb 05, 2019 Feb 05, 2019 Feb 05, 2019 Feb 05, 2019
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001					D-154	Jan 20, 2019
<u>DAPSONE - ACZONE</u>						
N 207154 001	5863560 6060085 6620435 9161926	Sep 11, 2016 Sep 11, 2016 Sep 11, 2016 Nov 18, 2033	DP U-124 DP DP		NS	Feb 24, 2019
<u>DEFERASIROX - JADENU</u>						
N 206910 001	>A> 9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 002	>A> 9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 003	>A> 9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001					>A> NCE	Mar 30, 2021
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	>A> 9283178	Oct 20, 2020	U-1205			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818 001	8450287	Dec 19, 2027	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9233103 9238029	Mar 05, 2032 Jan 17, 2026	U-1805 DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	9233103 9238029	Mar 05, 2032 Jan 17, 2026	U-1805 DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	6238994	May 17, 2019	DP			
	6238994*PED	Nov 17, 2019				
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6462058*PED	Dec 15, 2020				
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
	7399485	May 26, 2018	DP			
	7399485*PED	Nov 26, 2018				
	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				
	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023	DP			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9238029	Jan 17, 2026	DP			
	9241910	Mar 10, 2029	DP			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9220784	Oct 17, 2027	U-1488			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001 >A>	9242986	Dec 08, 2029	DS DP			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001 >A>	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002 >A>	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	9241946	Apr 05, 2022	U-1063			
<u>ELBASVIR; GRAZOPREXIL - ZEPATIER</u>						
N 208261 001	7973040	Jul 24, 2029	DS DP U-1813		NCE	Jan 28, 2021
	8871759	May 04, 2031	DS DP U-1813			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	8551957	Oct 19, 2029	DP U-1651		>A> M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	8551957	Oct 19, 2029	DP U-1651		>A> M-174	Mar 18, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	7407955	May 02, 2025	DS DP			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	7407955	May 02, 2025	DS DP			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - ODEFSEY</u>						
N 208351 001	>A> 5814639	Sep 29, 2015	DS DP		>A> NCE	Nov 05, 2020
	>A> 5814639*PED	Mar 29, 2016				
	>A> 5914331	Jul 02, 2017	DS			
	>A> 5914331*PED	Jan 02, 2018				
	>A> 6642245	Nov 04, 2020		U-257		
	>A> 6642245*PED	May 04, 2021				
	>A> 6703396	Mar 09, 2021	DS DP			
	>A> 6703396*PED	Sep 09, 2021				
	>A> 6838464	Feb 26, 2021	DS DP			
	>A> 7067522	Dec 20, 2019	DS DP			
	>A> 7125879	Aug 09, 2022	DS DP	U-257		
	>A> 7390791	May 07, 2022	DS DP			
	>A> 7803788	Feb 02, 2022		U-257		
	>A> 8080551	Apr 11, 2023	DS DP			
	>A> 8101629	Aug 09, 2022	DP			
	>A> 8754065	Aug 15, 2032	DS DP	U-257		
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	>A> 5914331	Jul 02, 2017	DS			
	>A> 5914331*PED	Jan 02, 2018				
	>A> 6043230	Jul 25, 2017		U-248		
	>A> 6043230	Jul 25, 2017		U-541		
	>A> 6043230	Jul 25, 2017		U-1170		
	>A> 6043230	Jul 25, 2017		U-1259		
	>A> 6043230*PED	Jan 25, 2018				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	>A> 5814639	Sep 29, 2015	DS DP			
	>A> 5814639*PED	Mar 29, 2016				
	>A> 5914331	Jun 02, 2017	DS			
	>A> 5914331*PED	Dec 02, 2017				
	>A> 5922695	Jul 25, 2017	DS	U-248		
	>A> 5922695	Jul 25, 2017	DS	U-541		
	>A> 5922695	Jul 25, 2017	DS	U-1170		
	>A> 5922695	Jul 25, 2017	DS	U-1259		
	>A> 5935946	Jul 25, 2017	DS DP	U-248		
	>A> 5935946	Jul 25, 2017	DS DP	U-541		
	>A> 5935946	Jul 25, 2017	DS DP	U-1170		
	>A> 5935946	Jul 25, 2017	DS DP	U-1259		
	>A> 5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP	U-248		
	>A> 5977089	Jul 25, 2017	DS DP	U-541		
	>A> 5977089	Jul 25, 2017	DS DP	U-1170		
	>A> 5977089	Jul 25, 2017	DS DP	U-1259		
	>A> 5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017		U-248		
	>A> 6043230	Jul 25, 2017		U-541		
	>A> 6043230	Jul 25, 2017		U-1170		
	>A> 6043230	Jul 25, 2017		U-1259		
	>A> 6043230*PED	Jan 25, 2018				
	>A> 6642245	Nov 04, 2020		U-248		
	>A> 6642245	Nov 04, 2020		U-541		
	>A> 6642245	Nov 04, 2020		U-1170		
	>A> 6642245	Nov 04, 2020		U-1259		
	>A> 6642245*PED	May 04, 2021				
	>A> 6703396	Mar 09, 2021	DS DP			
	>A> 6703396*PED	Sep 09, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	>A> 5814639	Sep 29, 2015	DS DP			
	>A> 5814639*PED	Mar 29, 2016				
	>A> 5914331	Jun 02, 2017	DS			
	>A> 5914331*PED	Dec 02, 2017				
	>A> 5922695	Jul 25, 2017	DS	U-248		
	>A> 5922695	Jul 25, 2017	DS	U-541		
	>A> 5922695	Jul 25, 2017	DS	U-1170		
	>A> 5922695	Jul 25, 2017	DS	U-1259		
	>A> 5935946	Jul 25, 2017	DS DP	U-248		
	>A> 5935946	Jul 25, 2017	DS DP	U-541		
	>A> 5935946	Jul 25, 2017	DS DP	U-1170		
	>A> 5935946	Jul 25, 2017	DS DP	U-1259		
	>A> 5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP	U-248		
	>A> 5977089	Jul 25, 2017	DS DP	U-541		
	>A> 5977089	Jul 25, 2017	DS DP	U-1170		
	>A> 5977089	Jul 25, 2017	DS DP	U-1259		
	>A> 5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017		U-248		
	>A> 6043230	Jul 25, 2017		U-541		
	>A> 6043230	Jul 25, 2017		U-1170		
	>A> 6043230	Jul 25, 2017		U-1259		
	>A> 6043230*PED	Jan 25, 2018				
	>A> 6642245	Nov 04, 2020		U-248		
	>A> 6642245	Nov 04, 2020		U-541		
	>A> 6642245	Nov 04, 2020		U-1170		
	>A> 6642245	Nov 04, 2020		U-1259		
	>A> 6642245*PED	May 04, 2021				
	>A> 6703396	Mar 09, 2021	DS DP			
	>A> 6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	>A> 5814639	Sep 29, 2015	DS DP			
	>A> 5814639*PED	Mar 29, 2016				
	>A> 5914331	Jun 02, 2017	DS			
	>A> 5914331*PED	Dec 02, 2017				
	>A> 5922695	Jul 25, 2017	DS	U-248		
	>A> 5922695	Jul 25, 2017	DS	U-541		
	>A> 5922695	Jul 25, 2017	DS	U-1170		
	>A> 5922695	Jul 25, 2017	DS	U-1259		
	>A> 5935946	Jul 25, 2017	DS DP	U-248		
	>A> 5935946	Jul 25, 2017	DS DP	U-541		
	>A> 5935946	Jul 25, 2017	DS DP	U-1170		
	>A> 5935946	Jul 25, 2017	DS DP	U-1259		
	>A> 5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP	U-248		
	>A> 5977089	Jul 25, 2017	DS DP	U-541		
	>A> 5977089	Jul 25, 2017	DS DP	U-1170		
	>A> 5977089	Jul 25, 2017	DS DP	U-1259		
	>A> 5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017		U-248		
	>A> 6043230	Jul 25, 2017		U-541		
	>A> 6043230	Jul 25, 2017		U-1170		
	>A> 6043230	Jul 25, 2017		U-1259		
	>A> 6043230*PED	Jan 25, 2018				
	>A> 6642245	Nov 04, 2020		U-248		
	>A> 6642245	Nov 04, 2020		U-541		
	>A> 6642245	Nov 04, 2020		U-1170		
	>A> 6642245	Nov 04, 2020		U-1259		
	>A> 6642245*PED	May 04, 2021				
	>A> 6703396	Mar 09, 2021	DS DP			
	>A> 6703396*PED	Sep 09, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	9238108	Jan 22, 2027	DP			
	>A> 9259539	Feb 01, 2026	DP			
	>A> 9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	9238108	Jan 22, 2027	DP			
	>A> 9259539	Feb 01, 2026	DP			
	>A> 9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9119876	Mar 13, 2035	DP			
	>A> 9295657	Mar 13, 2035	U-1829			
	>A> 9295657	Mar 13, 2035	U-1830			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	>A> 9295657	Mar 13, 2035	U-1829			
<u>EPINEPHRINE HYDROCHLORIDE - EPINEPHRINE</u>						
N 205029 001	>A> 9283197	Aug 15, 2034	DP U-1828			
	>A> 9283197	Aug 15, 2034	DP U-1829			
	>A> 9283197	Aug 15, 2034	DP U-1830			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6469182	Jun 16, 2019	U-1096		I-721	Jan 28, 2019
	6469182	Jun 16, 2019	U-1812		ODE	Jan 28, 2023
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	9220698	Mar 10, 2031	U-1781			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	9238076	Apr 15, 2024	DP U-412			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	9238076	Apr 15, 2024	DP U-412			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788 001	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	9241935	Jan 25, 2027	DP			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002					D-155	Feb 01, 2019
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	>A> 8329680	Jan 09, 2021	U-596		>A> I-725	Feb 19, 2019
	>A> 8329680	Jan 09, 2021	U-1826			
	>A> 8329680*PED	Jul 09, 2021				
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006	>A> 5980864	Nov 09, 2021	DS DP U-1119			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Jul 28, 2018	DS DP U-1378			
	9254278	Mar 09, 2032	U-1816			
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	>A> 6582678	Apr 24, 2018	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	>A> 6582678	Apr 24, 2018	DP			
	6878721	Feb 25, 2025	DS DP U-1773			
<u>GRANISETRON - SANCUSO</u>						
N 022198 001	7608282	Jan 22, 2025	DP U-1011			
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183 001					NP	Nov 06, 2018
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	>A> 9265760	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	>A> 9265760	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	>A> 9265760	Jul 25, 2033	U-1810			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	>A> 9265760	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	>A> 9265760	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	>A> 9265760	Jul 25, 2033	U-1810			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001					>A> I-729	Mar 04, 2019
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 001					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 002					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	7544799	Jul 16, 2018	DS DP		Y	
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	7544799	Jul 16, 2018	DS DP		Y	
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	6878721	Feb 25, 2025	DS DP U-1168			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	>A> 9265893	Sep 23, 2032	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	>A> 9265893	Sep 23, 2032	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N 021536 002	>A> 9265893	Sep 23, 2032	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9233211	Mar 02, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9233211	Mar 02, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9233211	Mar 02, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN HUMAN - HUMULIN R</u>						
N 018780 004	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001 >A>	9283193	Sep 14, 2026	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002 >A>	9283193	Sep 14, 2026	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003 >A>	9283193	Sep 14, 2026	DP			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001					ODE	Oct 22, 2022
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	9216969	Nov 08, 2026	DS DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	9233117	Mar 13, 2034	U-1631			
	9233118	Mar 13, 2034	U-1631			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	9216167	May 28, 2024	U-1800			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIIDRIA</u>						
N 205388 001	9278101	Jul 30, 2023	U-1518			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001 >A>	9284342	Sep 13, 2030	DS DP U-1470		D-158 D-159 D-160	Feb 12, 2019 Feb 12, 2019 Feb 12, 2019
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029		U-1801		
	8283369	Nov 26, 2028		U-1802		
	8283369	Nov 26, 2028		U-1804		
	8357713	Nov 26, 2028	DP	U-1801		
	8357713	Nov 26, 2028	DP	U-1802		
	8357713	Nov 26, 2028	DP	U-1803		
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029		U-1803		
	9216179	Aug 02, 2030		U-1806		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001 >A>	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001 >A>	9283282	Oct 28, 2018	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001 >A>	9283282	Oct 28, 2018	DS DP			
<u>LINAGLIPTIN - TRAJENTA</u>						
N 201280 001	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	7407955	May 02, 2025	DS DP			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	9265893	Sep 23, 2032	DP			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2020	DS DP	U-1317		
	9265758	Mar 07, 2025			U-1316	
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2020	DS DP	U-1317		
	9265758	Mar 07, 2025			U-1316	
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2020	DS DP	U-1317		
	9265758	Mar 07, 2025			U-1316	
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2020	DS DP	U-1317		
	9265758	Mar 07, 2025			U-1316	
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2020	DS DP	U-1317		
	9265758	Mar 07, 2025			U-1316	
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2020	DS DP	U-1317		
	9265758	Mar 07, 2025			U-1316	
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	9199977	Sep 06, 2033	DS DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001 >A>	9259423	May 23, 2031			U-1822	
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002 >A>	9259423	May 23, 2031			U-1822	
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003 >A>	9259423	May 23, 2031			U-1822	
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004 >A>	9259423	May 23, 2031			U-1822	
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005 >A>	9259423	May 23, 2031			U-1822	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	9265762	May 29, 2027	DP U-1820			
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	>A> 8410077	Mar 13, 2029	DP		>A> ODE	Mar 10, 2023
	>A> 9200088	Mar 13, 2029	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 001	9233184	Aug 01, 2027	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 002	9233184	Aug 01, 2027	DP			
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 001					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 002					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	7326708	Nov 24, 2026	DS DP U-1227			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	>A> 8999386	Aug 14, 2033	DP		>A> NP	Dec 04, 2018
	>A> 9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	>A> 8999386	Aug 14, 2033	DP		>A> NP	Dec 04, 2018
	>A> 9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	>A> 8999386	Aug 14, 2033	DP		>A> NP	Dec 04, 2018
	>A> 9295642	Aug 14, 2033	DP U-1827			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	>A> 9278105	May 12, 2031	U-282			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9248229	Mar 12, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 001 >A>	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 002 >A>	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 003 >A>	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 004 >A>	7955619	Aug 12, 2028	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	9238108	Jan 22, 2027	DP			
>A>	9278182	Feb 01, 2026	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 001	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 002	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 003	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003 >A>	9265911	Jan 06, 2031	DP U-1824			
>A>	9265911*PED	Jul 06, 2031				
>A>	9279794	Feb 19, 2034	DP U-1823			
>A>	9279794*PED	Aug 19, 2034				
>A>	9295802	Jan 06, 2031	DP U-1226			
>A>	9295802*PED	Jul 06, 2031				
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001				>A> M-173		Mar 18, 2019
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056 001	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
	6428810	Nov 03, 2019	DP U-1817			
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056 002	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	5840737	Jul 15, 2016	U-588			
	6489346	Jul 15, 2016	DP U-588			Y
	6645988	Jul 15, 2016	DP			Y
	6699885	Jul 15, 2016	U-588			Y
	6780882	Jul 15, 2016	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	7399772	Jul 15, 2016	U-588			
	RE45198	Jul 15, 2016	U-588			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	5840737	Jul 15, 2016	U-623			
	5840737	Jul 15, 2016	U-624			
	6489346	Jul 15, 2016	DP U-623	Y		
	6489346	Jul 15, 2016	DP U-624	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	U-623	Y		
	6699885	Jul 15, 2016	U-624	Y		
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
	RE45198	Jul 15, 2016	U-623			
	RE45198	Jul 15, 2016	U-624			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 001	7399772	Jul 15, 2016	U-588			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 002	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001					ODE	Nov 13, 2022
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002					ODE	Nov 13, 2022
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	>A> 9259388	Nov 06, 2029	U-1644			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024	DP			
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PROPOFOL - PROPOFOL</u>						
A 205307	001				PC	Feb 24, 2016
<u>RIVAROXABAN - XARELTO</u>						
N 022406	001	7157456	Dec 11, 2020	DS DP U-1301		
		7157456	Dec 11, 2020	DS DP U-1302		
<u>RIVAROXABAN - XARELTO</u>						
N 022406	002	7157456	Dec 11, 2020	DS DP U-1301		
		7157456	Dec 11, 2020	DS DP U-1302		
<u>RIVAROXABAN - XARELTO</u>						
N 022406	003	7157456	Dec 11, 2020	DS DP U-1301		
		7157456	Dec 11, 2020	DS DP U-1302		
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366	002	6858618	Dec 17, 2021	U-618		
		6858618	Dec 17, 2021	U-1032		
		6858618	Dec 17, 2021	U-1807		
		6858618*PED	Jun 17, 2022			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366	003	6858618	Dec 17, 2021	U-618		
		6858618	Dec 17, 2021	U-1032		
		6858618	Dec 17, 2021	U-1807		
		6858618*PED	Jun 17, 2022			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366	004	6858618	Dec 17, 2021	U-618		
		6858618	Dec 17, 2021	U-1032		
		6858618	Dec 17, 2021	U-1807		
		6858618*PED	Jun 17, 2022			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065	001	9216178	Nov 01, 2032	DP		
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065	002	7612073	Nov 17, 2024	U-1010		
		7612073*PED	May 17, 2025			
		9216178	Nov 01, 2032	DP		
		RE43797	Nov 17, 2024	U-1590		
		RE43797*PED	May 17, 2025			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	001	7205302	Apr 04, 2023	DS DP U-1797	ODE	Dec 21, 2022
		8791122	Aug 01, 2030	DS DP		
		9173881	Aug 12, 2029	U-1798		
	>A>	9284280	Jun 25, 2030	U-1831		
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	002	7205302	Apr 04, 2023	DS DP U-1797	ODE	Dec 21, 2022
		8791122	Aug 01, 2030	DS DP		
		9173881	Aug 12, 2029	U-1798		
	>A>	9284280	Jun 25, 2030	U-1831		
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	003	7205302	Apr 04, 2023	DS DP U-1797	ODE	Dec 21, 2022
		8791122	Aug 01, 2030	DS DP		
		9173881	Aug 12, 2029	U-1798		
	>A>	9284280	Jun 25, 2030	U-1831		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
>A>	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
>A>	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
>A>	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
>A>	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
>A>	9284280	Jun 25, 2030	U-1831			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 001	9095509	Dec 06, 2030	DP			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 002	9095509	Dec 06, 2030	DP			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001					M-171	Feb 26, 2019
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	7326708	Nov 24, 2026	DS DP U-802			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	>A> 9284342	Sep 13, 2030	DS DP U-1470			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	7265099	Aug 07, 2020	U-1795		>A> NCE	Dec 15, 2020
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	7265099	Aug 07, 2020	U-1795		>A> NCE	Dec 15, 2020
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSOPHERES - LUMASON</u>						
N 203684 001					>A> I-728	Mar 31, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	9272137	Sep 07, 2027	DP			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	6715485	Mar 03, 2020	DP			
	7975690	Aug 18, 2025	DP	U-1809		
	8047202	Jul 02, 2023	DP			
	8327844	Oct 03, 2023		U-1809		
	8550073	Oct 22, 2029	DP			
	8555877	Mar 03, 2020	DP			
	8590530	Sep 15, 2025	DP	U-1809		
	8875704	Apr 07, 2028	DP	U-1809		
	8899229	Aug 18, 2030	DP			
	8978647	Dec 06, 2030	DP			
	9108015	Sep 15, 2025	DP			
	9119932	Apr 23, 2024	DP			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001 >A>	5789379	Apr 14, 2020	DS DP	U-1320		
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9125816	Aug 30, 2020		U-490		
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020		U-490		
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9125816	Aug 30, 2020		U-490		
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020		U-490		
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	9125816	Aug 30, 2020		U-490		
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020		U-490		
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	6503894	Aug 30, 2020		U-1103		
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020		U-1103		
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020		U-1103		
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020		U-1103		
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020		U-1103		
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020		U-1103		
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020		U-1103		
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020		U-1103		
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020		U-1103		
	9132089*PED	Mar 02, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	>A> 9295675	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	>A> 9295675	Feb 11, 2034	DP U-1531			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	9254328	Mar 13, 2026	DP			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001	6770660	Jun 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002	6770660	Jun 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003	6770660	Jun 01, 2023	U-1444			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	>A> 6956027	Mar 25, 2023	DS		NCE	Nov 06, 2017
	>A> 6956041	Dec 08, 2020	DP			
	>A> 7091208	Dec 08, 2020	U-247			
	>A> 7265221	Dec 08, 2020	DS			
	>A> 7301023	May 23, 2022	DS			
	>A> RE41783	Dec 08, 2020	DS			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	>A> 9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	>A> 9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9278901	May 24, 2024	U-1475		D-156 D-157	Jan 28, 2019 Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9278901	May 24, 2024	U-1475		D-156 D-157	Jan 28, 2019 Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9278901	May 24, 2024	U-1475		D-156 D-157	Jan 28, 2019 Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9278901	May 24, 2024	U-1475		D-156 D-157	Jan 28, 2019 Jan 28, 2019
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	9283233	Apr 13, 2030	U-1821			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001					M-172	Feb 24, 2019
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001					ODE	Dec 11, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	>A> 9278961	Dec 15, 2028	U-1825			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	9227946	Jun 15, 2027	U-1668			
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 001				>A> PC		Sep 18, 2016
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 002				>A> PC		Sep 18, 2016
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	>A> 9265720	May 13, 2030	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	>A> 9265720	May 13, 2030	U-674			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 36th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>